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ABSTRACT
Cardiac fibrosis poses a central challenge in preventing heart failure for patients
who have suffered a cardiac injury such as myocardial infarction or aortic valve stenosis.
This chronic condition is characterized by a reduction in contractile function through
combined hypertrophy and excessive scar formation, and although currently prescribed
therapeutics targeting hypertrophy have shown improvements in patient outcomes,
pathological fibrosis remains a leading cause of reduced cardiac function for patients
long-term. Cardiac fibroblasts play a key role in regulating scar formation during heart
failure progression, and interacting biochemical and biomechanical cues within the
myocardium guide the activation of fibroblasts and expression of extracellular matrix
proteins. While targeted experimental studies of fibroblast activation have elucidated the
roles of individual pathways in fibroblast activation, intracellular crosstalk between
mechanotransduction and chemotransduction pathways from multiple biochemical cues
has largely confounded efforts to control overall cell behavior within the myocardial
environment.
Computational networks of intracellular signaling can account for complex
interactions between signaling pathways and provide a promising approach for
identifying influential mechanisms mediating cell behavior. The overarching goal of this
dissertation is to improve our understanding of complex signaling in fibroblasts by
investigating the role of mechano-chemo interactions in cardiac fibroblast-mediated
fibrosis using a combination of experimental studies and systems-level computational
models. Firstly, using an in vitro screen of cardiac fibroblast-secreted proteins in response
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to combinations of biochemical stimuli and mechanical tension, we found that tension
modulated cell sensitivity towards biochemical stimuli, thereby altering cell behavior
based on the mechanical context. Secondly, using a curated model of fibroblast
intracellular signaling, we expanded model topology to include robust
mechanotransduction pathways, improved accuracy of model predictions compared to
independent experimental studies, and identified mechanically dependent mechanismsof-action and mechano-adaptive drug candidates in a post-infarction scenario. Lastly,
using an inferred network of fibroblast transcriptional regulation and model fitting to
patient-specific data, we showed the utility of model-based approaches in identifying
influential pathways underlying fibrotic protein expression during aortic valve stenosis
and predicting patient-specific responses to pharmacological intervention. Our work
suggests that computational-based approaches can generate insight into influential
mechanisms among complex systems, and such tools may be promising for further
therapeutic development and precision medicine.
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CHAPTER 1
INTRODUCTION
1.1. Study Significance
Cardiac fibrosis remains a major barrier towards the treatment and prevention of
heart failure. For the roughly 2.2% of Americans suffering from heart failure 1, excessive
accumulation of extracellular matrix (ECM) contributes to increased myocardial stiffness,
loss of contractile function, and increased risk of mortality to as high as 75% 2. Scar
formation can result from multiple underlying causes including myocardial infarction
(MI), aortic valve stenosis (AVS), and hypertension, and while current therapies for these
conditions generally improve outcomes in patient populations through the reduction of
myocyte hypertrophy3,4, no drug is currently approved by the FDA for the treatment of
cardiac fibrosis. Moreover, although excessive fibrosis can reduce function, reparative
scar formation is also at times necessary to retain structural integrity following a cardiac
injury such as MI. Therefore, ideal pharmacologic therapies for treating fibrosis should
reduce scar formation in a targeted manner both spatially and temporally.
Cardiac fibroblasts act as key mediators of fibrosis by controlling the balance of
ECM formation and degradation, with cells assuming a contractile phenotype and
synthesizing matrix proteins and proteases in response to both biochemical and
mechanical cues5,6. Because local mechanics vary spatially within the myocardium (e.g
infarcted versus remote tissue during MI), controlling fibroblast behavior based on local
mechanical and biochemical cues has the potential to improve patient outcomes by
producing matrix only where it is needed. However, decades of previous research has
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identified numerous intracellular signaling mechanisms that transduce fibroblast
responses to individual stimuli, and these pathways often overlap and interact with one
another via a series of crosstalk and feedback mechanisms, thus complicating efforts to
understand fibroblast behavior within the diverse biochemical and biomechanical
environment of the myocardium.
We hypothesized that integrating fibroblast biomechanical and biochemical
signaling pathways into a suite of computational tools will enable predictions of novel
mechanisms underlying cardiac fibrosis, and the studies presented in this dissertation
integrate in vitro assessment of fibroblast mechano-chemo interactions with in silico
modeling of cell signaling and transcriptional regulation to better understand the extent of
crosstalk between environmental stimuli, the mechanisms-of-action that mediate fibrotic
protein expression, and potential applications of computational networks towards the
discovery of targeted anti-fibrotic therapeutics.
1.2. Specific Aims
Aim 1: Test the hypothesis that interactions between mechanical loading and
canonical biochemical cues mediate fibrotic behavior in cardiac fibroblasts.
Primary mouse cardiac fibroblasts were subjected to six biochemical
cytokines with or without the presence of cyclic mechanical tension. Cell
morphology and activation via smooth muscle actin were measured via
immunofluorescence microscopy to assess fibroblast phenotypes, and cell
secretion of collagens, matrix metalloproteinases, and matricellular proteins were
assessed via high-throughput protein assays. Statistical tests for both the presence
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of interactions between biochemical and mechanical stimuli and their
contributions towards fibrosis-related protein secretion were conducted, finding
that mechanical strain could alter cell sensitivities towards individual biochemical
stimuli to influence protein expression.
Aim 2: Refine and employ an existing, manually-curated computational model of
fibroblast signaling to accurately predict fibrotic activity against available signaling
datasets.
Using a model of fibroblast intracellular signaling, we expanded this
model to include new mechanotransduction studies and mechanisms of mechanochemo crosstalk. A manual search of new mechanotransduction literature was
conducted to identify and incorporate new intracellular species into an expanded
model. We compared model predictions to secreted ECM levels reported from
previous in vitro and animal studies to test the hypothesis that this model will
accurately predict fibrotic activity for both biochemical and mechanical stimuli,
using both qualitative and semi-quantitative comparisons. We additionally
conducted network perturbation analyses to identify influential mechanisms-ofaction under variable mechanical contexts, and we performed comprehensive drug
screening to identify drug candidates leading to mechano-adaptive fibrotic
behavior.
Aim 3: Develop a new, data-driven model of fibroblast transcriptional regulation
to identify influential regulators of fibrosis.
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We employed an established gene regulatory network inference technique
to model interactions between transcription factors and fibrotic gene expression.
A series of topological analyses and simulations were used to test the hypothesis
that select transcription factors act as “hubs” to mediate mechano-chemo
interactions in cardiac remodeling. Combination of this network with the previous
fibroblast signaling and subsequent parameter estimation using existing data of
signaling inputs and fibrotic outputs additionally improved the accuracy of
patient-specific predictions in the context of aortic valve stenosis, and network
perturbation analyses and virtual drug screens were used for influential pathway
identification and stratification of patient responses to simulated drugs.
1.3. Study Impact
The combination high-throughput mechanical testing and computational modeling
of cell signaling and transcription discussed investigated here improves our
understanding of fundamental biological processes governing cardiac fibrosis. This
strategy provides several key innovations over previous studies: (1) a robust dataset
highlighting key mechano-chemo interactions that mediate fibroblast secretion including
scenarios in which stretch sensitizes or desentizes fibroblasts towards biochemical
stimulation, (2) the integration of a robust mechanotransduction topology into a
mechanistic model for accurate prediction of fibrosis-related gene expression and
identification of context-dependent regulators of cell behavior, and (3) inference of a new
transcriptional model and fitting to patient-specific myofibroblast data for identifying
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transcriptional points of control for fibrosis and stratifying patient responses to changes in
plasma biomarkers.
The results of these studies suggest that model-based strategies can accurately
predict fibroblast behavior across many pathological scenarios, and that computational
approached can generate insight into potential heart failure treatments for a variety of
previous conditions. Because our models can be modified for patient-specific conditions,
our work has the potential to advance precision medicine within cardiovascular medicine
by predicting patient responses to current and potential treatments. Additionally, these
tools have the potential to fast-track therapeutic discovery through the use of
comprehensive drug screens and to improve rates of attrition during drug development by
accounting for many signaling processes simultaneously.
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CHAPTER 2
LITERATURE REVIEW
2.1. Cardiac fibrosis in heart failure
Congestive heart failure represents a significant and persistent burden to global
and national health as a subset of cardiovascular disease (CVD). Heart failure provides a
significant contribution to the overall health and economic burden caused by CVD, with a
prevalence of 2.2% of the U.S. population over 20 years old and almost 80,000 deaths
attributed to this disease in 2016, resulting in over $30 billion in healthcare costs 1,2. This
disease, stemming from an inability of the heart to pump enough blood for oxygen and
nutrient distribution to the body, can result from several initial cardiac pathologies such
as myocardial infarction (MI), hypertension, valvular diseases, and muscular diseases
such as dilated or inflammatory cardiomyopathy. The resulting patient prognoses have
been bleak overall; of the patients who develop heart failure, community and national
studies have found 5-year mortality rates to be as high as 75% 3,4.
Although underlying causes can vary, two major modes of pathogenesis are
frequently responsible for the losses in cardiac function associated with heart failure:
hypertrophy and fibrosis. Hypertrophy, or enlargement of cardiomyocytes, can act as a
compensatory mechanism in response to the underlying conditions above resulting in
thickening of the myocardium and loss of contractile function. Fibrosis, or accumulation
of collagenous scar tissue, can additionally result in stiffening of the myocardium and
loss in pump function due to decreased contractility and impaired electrical conduction 5.
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Taken together, these mechanisms form a detrimental combination that reduces heart
function, and both must be addressed to improve patient survival and quality of life.
2.1.1. Current standards of care for prevention and treatment
Pharmacologic therapies have been the gold standard of care for heart failure
patients for several decades, as several major classes of drugs have been developed to
antagonize neuro-hormonal pathways and ultimately reduce hypertrophic responses in the
myocardium. Several of the most commonly prescribed drugs for heart failure include
angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs),
beta blockers, and neprilysin inhibitors, although other classes such as diuretics are also
frequently prescribed to reduce symptoms of congestion. ACE inhibitors, a class of reninangiotensin antagonists that block the conversion of angiotensin I to the bioactive
vasoconstrictor angiotensin II (AngII), are recommended by both the American College
of Cardiology and the European Society of Cardiology as a first-line treatment for heart
failure6,7, and clinical trials have shown reductions in heart size, hospital admission for
heart failure, and mortality rates overall compared to placebo 8–10. For patients who may
not tolerate ACE inhibitors, ARBs are recommended as an alternative vasodilator for the
ability to competitively block angiotensin II type 1 receptors in smooth muscle cells, and
individual ARBs have been shown in randomized clinical trials to provide a comparable
benefit for patients11,12. Beta blockers are also recommended in combination with either
ACE inhibitor or ARB treatment; these β-adrenergic receptor inhibitors act in parallel
with AngII inhibitors by blocking binding of adrenaline and norepinephrine and have
shown improvements in event-free survival in randomized clinical trials 13,14. Recently,
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the combination of the ARB valsartan and neprilysin inhibitor sacubitril has provided
promising improvements for the outcomes of heart failure patients, as several clinical
trials have demonstrated improvements in clinical endpoints and quality of life over the
ACE inhibitor enalapril15–17.
While the use of the above therapeutics has largely improved patient care over the
past three decades, it is important to note that many patients do not respond to these lines
of treatment as reported in the randomized clinical trials above. These therapeutics
largely treat vasoconstricting processes that contribute to hypertension, thereby reducing
cardiac load and antagonizing enlargement of the myocardium. But in many cases,
residual hypertrophy or fibrosis still causes an overall reduction in heart function, leading
to hospital admission, reduced quality of life, and a high risk of mortality for patients. As
a late-stage intervention, implantable medical devices such as left ventricular assist
devices or bi-ventricular assist devices can be used to relieve additional cardiac load 7, but
these interventions are generally intended as a bridge-to-transplant and drastically reduce
patient mobility and quality of life. To improve patient outcomes without resorting to
these interventions, it is essential to develop new therapeutics that target cardiac fibrosis
in addition to hypertrophy. Furthermore, no FDA-approved drugs targeting cardiac
fibrosis currently exist, further highlighting the critical gap in care for heart failure
patients. Therefore, understanding the mechanisms-of-action behind cardiac fibrosis can
directly impact patient outcomes by informing new therapeutic development.
2.1.2. Role of scar formation in cardiac function

9

Myocardial fibrosis is characterized by the excessive accumulation of
extracellular matrix (ECM) components compared to degradation by matrix proteases.
The processes of ECM deposition and degradation are typically balanced in healthy
myocardium, where a resident population of quiescent cardiac fibroblasts maintain a
network of ECM that fills the interstitial space between cardiomyocytes 18,19. This matrix,
primarily composed of collagens I and III, serves both as a scaffold for cardiomyocytes
and other interstitial cells and acts as an integral component of normal function by
resisting myocyte contraction and maintaining structural integrity. Low levels of both
collagens and proteolytic enzymes, notably matrix metalloproteinases (MMPs), are
synthesized in order to continually renew and reinforce interstitial ECM 20,21. This
continuous production forms a tightly controlled balance between degradation of old
ECM and deposition of new ECM to maintain optimal structural integrity and resistance
to cardiomyocyte contraction.
Upon injury such as MI or hypertension-induced pressure overload, the balance in
ECM turnover is disrupted by multiple changes in the local biochemical and mechanical
environment, and excessive accumulation in fibrillar collagens can cause severe
reductions in heart function. While the underlying injury may alter the location,
architecture, or magnitude of collagen accumulation, greater amounts of collagen are
frequently deposited in interstitial and perivascular regions of the myocardium, which in
turn increase tissue stiffness, impair diastolic performance, and reduce ejection fraction 22–
24

. Querejeta and colleagues observed this relationship between fibrosis and cardiac

function in a study of heart failure patients with or without hypertension, wherein

10

histological analyses from endomyocardial biopsies revealed substantial increases in
interstitial collagen for hypertensive patients, and serum levels of procollagen I carboxyterminal propeptides (PICP) strongly correlated with patient ejection fractions, suggesting
a connection between collagen synthesis markers and clinical outcomes 22. In support of
these findings, Schelbert and colleagues found that nonischemic patients with higher
extracellular volume fraction, used as a measure of interstitial scar formation and
measured via cardiovascular magnetic resonance, experienced significantly higher end
diastolic volumes, end systolic volumes, and lower ejection fractions compared to
patients with lower extracellular volume fractions, as well as higher incidences of
hospitalization for heart failure and death23.
Excessive scar formation after MI has also been related to declines in cardiac
function; while development of an organized scar at the infarct site is needed to maintain
structural integrity after sudden ischemia and loss of cardiomyocytes, the accumulation of
scar remote to the infarct zone (i.e. posterior and interior left ventricular walls) can also
decrease contractile function25. It should be stressed, however, that cardiac fibrosis is not
inherently detrimental to cardiac function. After an injury in which myocardial tissue is
lost such as MI, scar tissue is essential to replace necrotic tissue to prevent continued scar
expansion, compaction, and possible cardiac rupture26,27. However, limiting fibrosis
where and when it is not needed is essential towards preventing the development of heart
failure and improving prognoses for current patients28.
2.1.3. Underlying causes and mechanisms of cardiac fibrosis
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As noted above, detrimental cardiac fibrosis can result from several different
underlying pathologies, including chronic hypertension, MI, aortic valvular stenosis
(AVS), aging-related processes, and various forms of cardiomyopathy. This review
focuses on fibrosis related to MI and AVS due to their relevance in terms of
biomechanics and experimental studies described in subsequent chapters, but
mechanisms of fibrosis related to these additional underlying causes remain important
facets of research and have been reviewed elsewhere 29,30.
2.1.3.1. Myocardial infarction. With approximately 800,000 Americans suffering
a MI per year1, this disease represents a substantial proportion of patients experiencing
maladaptive remodeling related to fibrosis. Infarcts are caused by an occlusion in a
coronary artery (often the left coronary, left circumflex, or left anterior descending
arteries), causing immediate ischemia and necrosis of the downstream myocardium.
Within minutes, a dynamic wound healing process commences to replace necrotic tissue
with collagenous scar. During an immediate inflammatory phase lasting within one week
from the initial occlusion, neutrophils and macrophages infiltrate the infarct zone and
release a variety of proteolytic enzymes such as MMPs and cathepsins to clear necrotic
tissue and signal for the proliferation and migration of cardiac fibroblasts via secretion of
a variety of biochemical cytokines31. In the following weeks post-MI, resident cardiac
fibroblasts begin to undergo proliferation and transition to an activated phenotype
commonly referred to as myofibroblast activation. These contractile cells begin to
synthesize ECM proteins including procollagens, fibronectin, laminin, as well as
matricellular proteins such as periostin, osteopontin, tenascins, and thrombospondins
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which serve as new matrix to withstand hemodynamic forces in place of normal
myocardium27,32.
While scar formation is resolved in many cases via apoptosis and removal of
fibroblasts19, excessive scar formation can result from sustained environmental cues such
as increased local stiffness or chronic influxes of inflammatory and neurohormonal
factors. This over-accumulation of collagenous scar at the infarct site, as well as the
deposition of ECM in remote areas due to increased biochemical factors, can serve to
increase stiffness levels beyond homeostatic levels resulting in contraction-related
dysfunction as discussed above. Over time, infarct scar tissue can also undergo additional
remodeling with changes in collagen orientation, thickness, and area, potentially resulting
in infarct expansion and increased risk of complications such as cardiac rupture 33.
2.1.3.2. Aortic valvular stenosis. AVS is generally characterized by an inability of
the aortic valve leaflets to adequately open and is also highly associated with heart failure
diagnoses, due in part to fibrosis of the aortic valve itself and of the left ventricle 34. Under
homeostatic conditions, aortic valve leaflets maintain a unique 3-layered architecture
consisting of the fibrosa layer composed of fibrillar collagen, the spongiosa layer
composed of proteoglycans, and the ventricularis layer composed of elastin 35,36. During
stenosis of the valve, resident valvular interstitial cells (VICs), which typically secrete
low levels of ECM components to maintain tissue homeostasis, assume a myofibroblast
phenotype similar to that of cardiac fibroblasts, leading to overaccumulation of matrix in
the valve. These cells can also assume an osteogenic phenotype associated with
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calcification of the valve and increased alkaline phosphatase activity 36, and both fibrotic
and osteogenic processes severely reduce valve opening and blood flow.
Due to a reduction in valve function, pressure overload is induced in the left
ventricle, acting as a pathologic signal that stimulates a secondary phase of interstitial
fibrosis via cardiac fibroblasts37 and further increases the risk of heart failure. This
secondary fibrosis has been associated with declines in diastolic and systolic function in
patients as evaluated by Milano and colleagues 24, and stresses the importance of
ventricular wall fibrosis even in valvular diseases. One of the most effective treatments
for AVS has been valvular replacement with a biomechanical valve, and transcatheter
aortic valve replacements (TAVR) have had a profound effect on improving outcomes for
AVS patients while reducing surgery-related risks 38. However, Azevedo and colleagues
found that even for patients after valve replacement surgery, the degree of ventricular
fibrosis was significantly correlated to reductions in ejection fraction at patient follow-up
and predictive of overall survival39. Thus, preventing cardiac fibrosis caused by
underlying diseases such as AVS remains a challenge for improving patient prognoses
even following surgical intervention.
2.1.5. Anti-fibrotic therapies: previous trials and challenges
Given the importance of fibrosis in determining heart failure development in
patients, many previous efforts have focused on developing therapies that target specific
fibrotic processes in previous animal and human trials. These therapies range in their
mechanisms-of-action, from inhibition of known pro-fibrotic pathways such as reninangiotensin signaling and transforming growth factor-β (TGFβ) signaling 40, inhibition of
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inflammatory cytokines41, and inhibition of MMP or tissue inhibitor of MMP (TIMP)
expression or activity42. However, many of these therapies have produced mixed results,
with clinical trials showing little improvement in key endpoints and animal trials showing
increased risk of adverse effects related to tissue remodeling.
Two such clinical trials specifically surveyed cardiac remodeling post-MI, using
either an inhibitor of interleukin 1 (VCU-ART trial) or a broad spectrum MMP inhibitor
(PREMIER trial) to attenuate fibrosis-related declines in heart function 43,44. Neither study
found significant differences in clinical endpoints including the left ventricular end
systolic and diastolic volume indices and left ventricular ejection fractions. In the VCUART trial, Abbate and colleagues reported improvements in plasma levels of C reactive
protein with interleukin 1 (IL-1) inhibition and an overall improvement in heart failurefree survival when pooled with a previous pilot study, but limitations in study size and
relatively small effect size raise questions as to whether this effect can be generalized to a
wider population. Furthermore, these trials did not report evidence linking the respective
therapies to scar formation, and so it is still unclear whether these candidate treatments
provide benefit in preventing maladaptive fibrosis.
Although preclinical animal studies of specific anti-fibrotic therapies have
produced encouraging results for late cardiac remodeling after initial injury, increased
risk of early dysfunction with treatment highlight the need for therapies that control scar
formation in a spatially and temporally targeted manner, particularly in post-MI
remodeling. Ikeuchi and colleagues investigated an anti-TGFβ gene therapy in mice
following left coronary ligation and found that anti-TGFβ treated mice showed lower
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collagen volume fraction levels and myocyte hypertrophy as well as improved clinical
outcomes such as non-infarct wall thickness, left ventricular end systolic and diastolic
diameters at 28 d compared to sham mice45. However, the same population also
experienced a greater degree of wall thinning 9 h post-MI with anti-TGFβ treatment,
which was accompanied by heightened neutrophil invasion, inflammatory cytokine
expression, and rate of mortality at 24 h, which the authors suggest was caused by
suppression of an early adaptive response resulting in reparative scar formation. This
finding was later supported by Frantz and colleagues46 and demonstrates the temporal
nature of fibrosis, in which early scar formation can prevent further dysfunction but late
fibrosis can reduce contractility, as well as the spatial nature of fibrosis, in which the
infarct zone requires a robust scar formation for continued function while excess scar
deposition in remote zones can lead to dysfunction. Additional studies altering both
signaling pathways and matrix-related proteins in a global manner have revealed similar
challenges in temporal and spatial control. Ichihara and colleagues found that although
inhibition of the angiotensin II type 2 receptor was able to prevent pressure overloadinduced fibrosis in mice47, the same treatment in mice subjected to MI caused marked
reductions in survival at 1 week which were accompanied by decreases in infarctlocalized collagen, fibronectin, and ventricular wall thickness 48. The Lindsey group has
conducted several studies inhibiting specific MMPs in post-MI mouse models, finding
that pharmacological inhibition of MMP9 and MMP12 further reduced end systolic and
diastolic volumes as well as ejection fractions compared to saline-treated controls, with
anti-MMP9 treatment increasing leukocyte infiltration and both treatment reducing
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apoptosis at 1 week post-MI49,50. Interestingly, a knockout mouse model of TIMP3 also
increased complications related to early ventricular wall thinning, with TIMP3 -/- mice
demonstrating lower hydroxyproline content, procollagen synthesis, and TGFβ
expression 2 d post-MI as well as a 4-fold increase in cardiac rupture compared to wildtype mice51. While this transgenic anti-TIMP model cannot be directly compared with the
pharmacological anti-MMP treatments above, the increases in similar early complications
after MI for seemingly opposite modes of treatment suggest that global inhibition of one
single pathway or mechanism may produce counterintuitive effects towards overall tissue
remodeling. Moreover, the studies discussed above share common challenges in spatial
and temporal control of scar formation, suggesting that while treating excessive fibrosis
via single pathway perturbations can improve long-term outcomes, scar formation is also
needed to maintain structural integrity at sites of injury. In order to address this challenge,
discovering mechanisms-of-action that adapt to environmental contexts in both spatial
and temporal manners could tailor fibrosis for maximum benefit.
2.2. Cardiac fibroblast signaling in post-injury fibrosis
Cardiac fibroblasts play a central role in mediating ECM synthesis and
degradation in response to injury (see Sections 2.1.3.1 and 2.1.3.2 above for descriptions
of fibroblast roles in MI and AVS). These cells make up 15-25% of non-myocyte cells in
the myocardium52,53 and act as “sentinel cells” by responding to changes in the local
environment via secretion of collagens, proteases, protease inhibitors, proteoglycans, and
collagen cross-linking agents54. These changes in the cardiac environment are diverse
upon injury, with influxes of biochemical cues such as growth factors, neurohormonal
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factors, and inflammatory cytokines acting as signaling components as well as changes in
the biomechanical environment including cyclic tension and tissue stiffening 55–57. A
growing body of research has explored cardiac fibroblast responses to these biochemical
and mechanical categories of signaling, and the following subsections highlight several of
the major factors involved in cardiac fibroblast activation and behavior within
biochemical and biomechanical categories as well as studies showing their involvement
in regulating cardiac fibrosis.
2.2.1. Fibroblast chemotransduction
A wide variety of biochemical agonists have been shown to influence fibrotic
remodeling in the injured heart at both tissue and cellular scales 55,58. While it is unclear
just how many signals regulate fibroblast activation and ECM-related secretion, several
major categories of biochemical cues have been well-established as mediators of cardiac
fibrosis. Inflammatory cytokines such as tumor necrosis factor-α (TNFα), IL-1, and
interleukin 6 (IL-6) are upregulated immediately after injury as a stress response 41,59 and
act to suppress fibroblast activation and upregulate MMP secretion for the removal of
necrotic tissue. Growth factors such as TGFβ and platelet-derived growth factor (PDGF)
are later secreted by neutrophils and macrophages as part of both an anti-inflammatory
response as well as a pro-fibrotic response via upregulation of proliferation and matrix
synthesis60,61. Hormonal agonists such as AngII, norepinephrine (NE), natriuretic
peptides (NPs), and endothelin-1 (ET-1), which act as modulators of vascular
hypertrophy as described above, also modulate fibroblast behavior including ECMrelated gene expression62–64. These categories have diverse effects on fibroblast behavior
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as demonstrated both in vitro and in animal studies, and studies highlighting the
importance of each category are discussed in depth below.
2.2.1.1. Inflammatory cytokine signaling. As one of the hallmarks of the
immediate response to cardiac injury, inflammatory cytokines are upregulated in the
myocardium as early as 3 h after coronary arterial ligation 65 as well as in the subendothelium during AVS progression34. These cytokines are generally thought to be
secreted by cardiomyocytes as an immediate response to ischemia and oxidative stress
during MI59, as well as by T-lymphocytes and macrophages in response to endothelial
disruption in early aortic lesions66,67. Although a wide variety of factors make up the
entire inflammatory response, this section will focus specifically on IL-1, IL-6, and TNFα
for their widely documented influence in cardiac remodeling.
These cytokines have a largely anti-fibrotic effect in cardiac fibroblasts and VICs
by downregulating collagen secretion and upregulating the secretion and activation of
MMPs to degrade existing matrix67. In vitro investigations of the effect of IL-1, IL-6, and
TNFα on cardiac fibroblasts showed that all three cytokines decreased collagen synthesis
as measured by [H3]proline incorporation, and IL-1/TNFα treatments increased total
MMP activity68. Later experimental evidence focusing on TNFα corroborates these
findings, as Porter and colleagues found that cardiac fibroblasts stimulated with TNFα
showed both upregulated protein expression and activity of MMP9, and Awad and
colleagues found that TNFα upregulates the expression of multiple MMPs as well as total
collagenase activity69,70. Aguado and colleagues recently showed evidence of VIC
deactivation with IL-1 and TNFα stimulation with cells transitioning from patient-
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specific sera to either IL-1 or TNFα decreasing αSMA-positive staining compared to
control serum, suggesting that these cytokines exert similar effects within the context of
AVS71.
Studies utilizing transgenic mouse models have further demonstrated the antifibrotic effects of these cytokines. Dziemidowicz and colleagues recently observed that in
a mouse model of chronic β-adrenergic stimulation to induce pressure overload, IL-6 -/mice displayed significantly increased intramyocardial fibrosis compared to wild-type
mice, suggesting an antagonistic effect of IL-6 on scar formation 72. Sun and colleagues
found that following left anterior descending ligation to mimic MI, TNFα -/- mice
displayed lower MMP2 and MMP9 activity compared to wild-type mice, although lower
collagen deposition in remote regions at 28 d indicates that MMP activity alone may not
fully account for overall scar formation73. Taken together, these studies suggest a highly
influential role of early inflammatory signaling in fibroblast phenotypes, and variable
results in vivo suggest further complexities in translating these signals to scar tissue, such
as context-dependent mechanisms-of-action or possible compensatory mechanisms by
leukocytes.
2.2.1.2. Growth factor signaling. A variety of growth factors also localize to
myocardial and valvular tissue during post-injury remodeling, including TGFβ, PDGF,
fibroblast growth factor (FGF), and insulin-like growth factor (IGF) among others. These
agents are typically secreted by macrophages after early inflammation, and several
groups have suggested that these factors serve to resolve inflammation and stimulate
matrix remodeling through collagen production and cell proliferation 61. In the post-MI
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environment, TGFβ and PDGF have been shown to reach peak mRNA expression later
than inflammatory cues, with TGFβ1 reaching peak levels at 4 d and remain upregulated
for 8 weeks, and PDGFβ reaching peak levels at 7-14 d following MI25,60,74,75. Similarly,
TGFβ1 has been detected in human calcified aortic valves both in sites of calcification
and noncalcified ECM, demonstrating a later influx of growth factor-related signals 76.
TGFβ and PDGF have become well-known mediators of fibroblast activation and
fibrosis both locally post-MI and systemically 60,61,77. TGFβ has been particularly wellstudied for its ability to stimulate fibroblast and VIC contraction, αSMA stress fiber
formation, and collagen synthesis in vitro, and has been extensively reviewed
elsewhere78–82. Preclinical studies of PDGF suggest a similar role as a pro-fibrotic
stimulant, as transgenic mice overexpressing PDGF-α and -β isoforms developed
interstitial scar formation and cardiac hypertrophy 77, and post-MI mice treated with antiPDGF receptor antibodies displayed attenuated interstitial fibrosis compared to sham
mice60. Butt and colleagues further observed a proliferative effect of PDGF stimulation
on cardiac fibroblasts even compared to TGFβ, which mirrors the proliferation of
fibroblasts preceding scar formation in vivo and implicates PDGF as an influencer of the
synthetic phenotype78. It should be noted that fibroblast responses to these factors are not
completely pro-fibrotic; Tan and colleagues found that PDGF upregulated collagenase
mRNA expression in human fibroblasts, both independently in the case of PDGF-BB as
well as in synergy with serum as in the case of PDGF-AA83. Therefore, caution must be
taken when accounting for these factors in overall fibroblast behavior in vivo, particularly
when making quantitative predictions of ECM turnover.
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2.2.1.3. Hormonal factor signaling. In addition to mediating blood pressure via
vasoconstriction, several hormonal factors have also been implicated as mediators of
cardiac fibroblast behavior and scar formation. These hormones are upregulated
relatively late during post-MI remodeling, in which factors such as AngII, NP, and ET-1
are upregulated at the infarct site roughly 5-7 d after injury and remain upregulated for as
long as 2 months84–86. Additional detection of ACE, bioactive AngII, and angiotensin
receptors in human aortic valve lesions suggests that upregulated hormonal agonists also
play a role in AVS progression87.
Decades of mechanistic studies investigating AngII in fibroblasts have identified
several mechanisms by which AngII induces fibroblast activation and ECM deposition.
These mechanisms include the activation of mitogen activated protein kinase (MAPK)
pathways and upregulation of proliferation88–90, the activation of NADPH oxidase and
nuclear factor-κB for downstream expression of collagen I, fibronectin, CTGF, and
upregulation of interstitial fibrosis91, the activation of TNF receptor signaling pathways 92,
and expression of latent TGFβ as part of an autocrine feedback loop 89,93,94. Further studies
utilizing current pharmacological therapies such as ARBs show that cardiac fibrosis can
be attenuated by inhibiting AngII-dependent signaling specifically in fibroblasts 62,95.
Similarly, ET-1 has been shown to promote cardiac fibroblast activation as evidenced by
increased αSMA protein expression and [H3]proline incorporation64. Although ET-1
signaling has not been widely studied in in vivo models of post-injury fibrosis, the ET
antagonist bosentan was shown to reduce right ventricular procollagen I expression and
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total collagen content in rats subjected to hypoxic conditions, supporting the role of ET-1
as an additional hormonal agonist of cardiac fibrosis 96.
NPs represent another family of hormonal factors and are upregulated in parallel
with AngII and associated with heart failure risk, AVS severity, and post-TAVR
outcomes97–99; however, NPs appear to act as suppressors of fibroblast activation. For
example, Watson and colleagues found that treating human cardiac fibroblasts with
exogenous B-type NP in combination with TGFβ reduces αSMA protein expression
compared to cells treated with TGFβ alone80. Burke and colleagues’ investigation of both
A-type NP and the neprilysin inhibitor sacubitril in cardiac fibroblasts and a pressure
overload mouse model provides additional evidence of NPs as negative regulators 62. In
the group’s in vitro studies, cardiac fibroblasts subjected to TGFβ and increasing doses of
exogenous A-type NP showed reduced gene expression of αSMA, periostin, and collagen
I compared to TGFβ treatments alone, and additional treatments with sacubitril further
suppressed gene expression associated with fibroblast activation and proliferation via
upregulation of cyclic GMP. Similarly, treatment of pressure overload-induced mice with
valsartan and sacubitril, which increases the bioavailability of NPs due to neprilysin
inhibition, attenuated both the recruitment of myofibroblasts, as evidenced by PDGFRand vimentin-positive cells, as well as epicardial, interstitial, and perivascular scar
formation compared to valsartan alone. This synergy of valsartan and neprilysin
inhibitors was also demonstrated in both cardiac fibroblast-specific collagen synthesis
and post-MI fibrosis by von Leuder and colleagues 95, and provides convincing evidence
that NPs act as a unique negative mediator of fibroblast activation and collagen synthesis.
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Taken together, these studies suggest that while fibroblasts may not respond uniformly to
all hormonal agonists, the late upregulation of hormonal factors play an essential role in
cardiac remodeling among the additional categories of biochemical cues discussed above.
2.2.2. Fibroblast mechanotransduction
Over the past several decades, a large number of studies have investigated how
fibroblasts synthesize and build extracellular matrix proteins in response to mechanical
stimuli. By subjecting cells to a variety of mechanical cues and examining the expression
of matrix components at the genetic and protein levels, the mechanobiology field has
gained valuable insight into how cells respond to normal and pathological environments.
Fibroblasts have been examined under a variety of mechanical stimuli involved in the
injured myocardium including tension, compression, and shear, although the variety of
experimental conditions used across the literature has yielded a variety of results 100. Two
well-studied biomechanical factors in the injured myocardium across multiple initial
pathologies are tensile loading and tissue stiffening. The below sections focus on
fibroblasts that have been subjected to these mechanical stimuli and trends in ECMrelated protein synthesis.
2.2.2.1. Fibroblast responses to cyclic tension. Tensile loading has been
considered one of the principal forms of mechanical stimulation in the infarcted heart,
with local myocardium experiencing cyclic tension within hours after MI. Compared to
healthy myocardium, which undergoes compressive loading with normal cardiomyocyte
contraction, the post-MI left ventricle has been shown to extend in the circumferential
and longitudinal directions in porcine and rat models 101–103. This stretching is likely due
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to the sudden necrosis of cardiomyocytes and inability to contract, after which
subsequent blood flow causes tensile loading dependent on the orientation of collagen
fibers within the myocardium101. This overall process results in tensile strain levels of
approximately 5-10% after 1-4 weeks27, resulting in activation of a variety of
mechanotransduction signaling pathways in fibroblasts for altered proliferation,
migration, and matrix turnover104.
While cyclic tension has widely been shown to induce collagen expression and
secretion using in vitro culture systems, the exact relationships between tension and
changes in matrix-related expression remain unclear. Compiling data from a variety of
studies measuring the gene expression and secretion of collagens I and III in response to
tensile load indicates that no one single factor is completely responsible for mediating
cellular behavior105–126. Rather, a multitude of variables contribute to the extracellular
matrix expression in each experiment, including cell source, tensile directionality,
frequency, duration, and several additional environmental factors. As multiple variables
are altered from study to study, the data results in a scattering of values, even within
similar strain amplitudes (Figure 1.1 A-B). No one factor alone can entirely account for
the variation in matrix expression, although parameters including strain amplitude,
frequency, and directionality all contribute to fibroblast behavior individually 100.
2.2.2.2. Fibroblast responses to substrate stiffness. Changes in the mechanical
environment surrounding fibroblasts can also result from changes in material properties
arising from ECM turnover and fiber remodeling. Healthy myocardium has been shown
to have an elastic modulus of 10-25 kPa as measured by atomic force microscopy 127,
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representing an intermediate levels of stiffness compared to softer tissues such as brain
and harder tissues such as bone56. Under pathological conditions, however, changes in
tissue composition can increase stiffness levels perceived by fibroblastic cells. Following
MI, the infarcted zone becomes stiffer with the accumulation of scar tissue, resulting in
an average elastic modulus of 55 kPa127. Similarly, increased calcification and scar
formation following AVS decreases elasticity and increases stiffness of valvular tissue
during AVS, resulting in upregulated myofibroblast activation 128.
Perceived changes in substrate stiffness can influence fibroblast responses
including proliferation, migration, cell spreading, and protein synthesis. Previous studies
have used acrylamide hydrogels, PDMS substrates, collagen scaffolds, and other culture
environments of tunable stiffness to assess the expression of signaling intermediates and
matrix proteins116,129–132. These studies have found that increased substrate stiffness can
induce various cell types to upregulate synthesis of matrix proteins by inducing
cytoskeletal tension and activating tension-dependent signaling pathways. For example,
Herum and colleagues recently found that cardiac fibroblasts alter a host of ECM-related
genes with culture on increasingly stiff substrates, including genes for collagens I and III,
tenascin-c, periostin, osteopontin, thrombospondin 1, and secreted protein acidic and rich
in cysteine (SPARC)131. Conversely, the Anseth group demonstrated that reductions in
stiffness can rescue VICs from an activated phenotype133,134. By using a photodegradable
hydrogel system to reduce the elastic modulus for cultures from 32 kPa to 7 kPa, Wang
and colleagues found that cells displayed reduced αSMA stress fibers, proliferation, and
connective tissue growth factor associated with a quiescent phenotype 134. Taken together,
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Figure 1.1. Collagen I and III expression at both the mRNA and protein levels vary greatly in response
to mechanical strain in vitro across a variety of fibroblast types (A/B) and strain environments (C/D). In
general, most studies have reported increased production in stretched fibroblasts, though the response is
clearly not consistent across studies and seems to depend on many factors, including strain magnitude,
strain frequency, matrix adhesion type, chemical environment, and others. Reproduced from Rogers et
al.100

these findings across studies suggest that pathologically stiff environments induce
fibroblast activation consistent with that observed in post-injury myocardium.
2.2.2.3. Mechano-chemo interactions. The myocardial extracellular environment
contains a multitude of biochemical signals after an injury, and fibroblasts are constantly
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stimulated by a dynamic mixture of signaling molecules, growth factors, hormones and
other stimuli. Even in vitro, cell culture media are filled with a rich biochemical milieu.
When combined with mechanical stimuli, these factors can alter cellular responses to
mechanical loading, and a number of studies have examined these combinatory effects,
typically focusing on growth serum or transforming growth factor β (TGFβ) (both of
which are known to increase collagen expression independently of mechanical stimulus).
As a simple example of this interaction, the presence of serum, which contains a
number of growth factors, has been shown to amplify the production of collagen by
neonatal cardiac fibroblasts after 48 hours of cyclic tension 135. Other studies demonstrate
conflicting evidence, however, as Husse and colleagues found a decrease in collagen
mRNA expression for adult cardiac fibroblasts with increasing serum concentration and
mechanical tension126. The combination of the specific factor TGFβ and mechanical
tension can also act synergistically, increasing collagen expression beyond that of either
factor alone. Other studies have also observed interaction effects on expression in
neonatal cardiac fibroblasts, anterior cruciate ligament fibroblasts, and dermal
fibroblasts115,124,135,136. While the rationale for this trend is not definitively known, a
diversity of interaction possibilities should not be surprising given the multiple signaling
pathways downstream of both mechano- and chemo-stimulation and the many
intersections of these pathways.
Studies investigating individual biochemical and mechanical signals have
identified evidence of crosstalk between modes of signaling, both through common
intermediate pathways as well as through secondary activation of one or more additional
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pathways. Examples of common intermediates include angiotensin II type 1 receptors,
which have been shown to mediate cardiac fibroblast gene expression in response to both
increased stiffness and interstitial fluid flow137,138, and phosphoinositide 3-kinase/Akt
signaling, which in addition to regulating TGFβ and TNFα signal transduction 139–141 has
been shown to function downstream of β1-integrin signaling to regulate fibroblast
apoptosis142. Several groups have observed the secondary activation of biochemical
signaling mechanisms initiated by biomechanical signaling and vice versa. The Hinz
group has investigated the activation of TGFβ by fibroblasts in response to mechanical
stimuli for example finding that fibroblast-generated forces can release latent TGFβ from
the surrounding ECM via β-integrins, thereby inducing a positive feedback loop for
further activation143,144. Conversely, canonical transient receptor potential (TRPC)
channels have been appreciated for their role as stretch-activated ion channels in
promoting cardiac fibroblast activation104, but Davis and colleagues observed that the
TRPC6 channel was required for TGFβ-induced activation of fibroblasts 145. TRPC6-/cells displayed attenuated αSMA fiber incorporation and gel contraction in dermal
fibroblasts with TGFβ treatment as well as significantly smaller scar size and higher rates
of ventricular rupture in a post-MI mouse model, demonstrating an additional
mechanism-of-action beyond canonical signaling via Smad signaling. While these studies
demonstrate the complexity of fibroblast signaling, in which pathway crosstalk and
feedback play a significant role, the full extent of these interacting pathways remains
unclear, and further studies investigating the extent and dynamics between pathways are
needed.
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2.2.3. Challenges in regulating cardiac fibroblast behavior
While an increasing amount of experimental research has discovered many of the
mechanisms governing fibroblast behavior, the complexity of this underlying signaling
network can complicate efforts to control fibroblast behavior in a targeted manner. For
therapeutic applications such as preventing the overaccumulation of cardiac scar tissue,
perturbing a single pathway may not produce the intended overarching effect due in part
to additional competing cues, potentially confounding results in large animal models or
clinical trials. This challenge is further complicated by spatial and temporal differences in
the cellular microenvironment. Spatial differences in mechanical cues such as cyclic
tension and tissue stiffness observed in the post-MI environment act as local mediators of
fibroblast activation compared to remote myocardium, and so it is expected that global
pharmacological treatments such as ACE inhibitors would exert differential responses on
infarct- and remote-localized fibroblasts. Indeed, Ramirez and colleagues observed that in
a post-MI mouse model, pharmacological treatments with valsartan (an ARB) and
aliskiren (a renin inhibitor) primarily affected cardiac gene expression of ECM-related
proteins in remote regions, with minimal changes in infarcted myocardium 146.
A nuanced understanding how fibroblasts respond to biochemical and mechanical
cues is essential for developing targeted anti-fibrotic therapies, and several groups have
suggested that computational approaches can address the above challenges by predicting
influential mechanisms-of-action and cellular behavior while accounting for complex
conditions and non-linear network dynamics57,147. Systems-wide computational models
have shown promise in prediction and therapeutic discovery for both cardiac systems as
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well as other biological systems, and these approaches are further discussed in the
following section.
2.3. Systems modeling of cardiac pathologies
The field of systems biology has gained significant traction over the past decade
for its alternative paradigm for generating insight into biological systems. Computational
models of molecular and cellular systems using mechanistic models, statistical models,
and artificial intelligence approaches have been valuable in drug discovery and regulatory
approval, both from academic and industry perspectives148. While models using all of
these approaches can be useful for discovering new relationships governing disease
progression149, ordinary differential equation-based cell signaling network models have
been particularly exciting for their ability to provide a mechanistic basis for disease
progression while accounting for complex system dynamics. These networks have been
used to discover influential pathways and druggable targets across a variety of diseases,
including a variety of cancers150–152, lymphocyte development153, and drug-induced
cardiotoxicity154. Using a system of ordinary differential equations to approximate
changes in activation of signaling proteins, cellular responses to both individual stimuli
and combinations of stimuli can be predicted across in vivo time scales, providing a basis
for targeted experimental validation of new mechanisms-of-action or treatments with
therapeutic potential. This computational approach has also been applied to
cardiovascular biological systems and has provided insight into mechanisms underlying
cardiac hypertrophy, arrhythmias, inflammation, and fibrosis. Several cardiac-specific
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network models are highlighted in Section 2.3.1 below, and remaining challenges in
modeling cardiac fibrosis computationally are discussed in Section 2.3.2.
2.3.1. Cardiovascular cell signaling networks
Cell signaling networks have been used to describe the roles of multiple cell types
within cardiovascular pathologies. In particular, many groups have found success in
approximating cell behavior using fully mechanistic networks, i.e. a system of differential
equations derived from mass-action kinetics to represent biochemical reactions involved
in the network155. This strategy has been used to study cardiomyocyte signaling for a
relatively long period of time; Saucerman and colleagues published one of the first
models of cardiomyocyte β-adrenergic signaling in 2003, and the authors used this model
to identify phospholamban and L-type calcium channels as influential regulators of
isoproterenol-induced calcium signaling156. The group also predicted an alternative
therapeutic strategy to treat heart failure by improving isoproterenol-mediated cyclic
AMP induction without increasing basal levels for adverse hypertrophic effects,
demonstrating the applicability of cell signaling networks towards drug discovery for
hypertrophy-related heart failure. Zhao and colleagues expanded on this model to account
for phosphodiesterase (PDE) mediated degradation of cyclic AMP, adding a subsystem of
equations denoting biophysical interactions between four phosphodiesterase isoenzymes
and cyclic AMP/GMP157. The authors predicted that partial compensation between
PDE2/4 occurs upon inhibition of either isozyme, forming a novel, influential synergy
that inhibits cyclic AMP accumulation during heart failure development. The authors also
show that cyclic GMP potentiates cyclic AMP accumulation via suppression of PDE3,
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overturning previous hypotheses about PDE regulation and suggesting that suppression of
β-adrenergic signaling by cyclic GMP may be mediated by an alternative mechanism.
These studies highlight the value of mechanistic systems in explaining mechanisms
governing heart failure progression by accounting for complex behavior that are difficult
to elucidate experimentally, and similar networks have been used to study calcium
signaling for excitation-contraction coupling158,159. It should be noted that while relatively
few fibroblast-specific mechanistic models exist in the literature currently, these existing
models and generalized signaling pathway models have also provided insight into
fibroblast mechanotransduction and chemotransduction. For example, Schroer and
colleagues developed a model of fibroblast signal transduction by integrating TGFβ,
fibroblast growth factor (FGF), and β-integrin pathways to predict the expression of
αSMA160, demonstrating that focal adhesion kinase dampens fibroblast sensitivity to
TGFβ stimulation and that extracellular regulated kinase (ERK) largely inhibits αSMA
expression.
While fully mechanistic networks can be advantageous for accurate prediction of
signaling dynamics, this approach becomes challenging to scale up due to an incomplete
knowledge of individual reaction parameters. When it is desirable to include a larger
number of environmental stimuli, as with the post-injury cardiac environment, individual
rate law parameters must be either known or estimated from robust, time-resolved
datasets for a larger number of reactions and may not be feasible experimentally 149,155.
Furthermore, most previous experimental literature employed to identify network
topology identifies qualitative relationships between signaling species (i.e. ‘reactant A
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activates product B’ or ‘reactant A inhibits product B’), and so direct extrapolation of
previous literature to a continuous, quantitative biochemical model is often limited. In
order to overcome these challenges in capturing larger scopes with signaling networks,
several groups have developed methods for creating logic-based ordinary differential
equation models by transforming Boolean logic relationships between signaling species
into a system of normalized Hill differential equations 161,162. While these models may not
always capture quantitative characteristics of mechanistic models, these approaches
bridge the gap between discrete reaction logic and dynamical models without requiring
full knowledge of kinetic parameters.
These models have additionally been shown to accurately predict cellular
responses to pathological stimuli and therapeutic interventions in cardiovascular systems,
including fibroblasts, cardiomyocytes, and macrophage-specific changes in behavior. The
Saucerman group in particular has applied logic-based ordinary differential equations to
cardiac cell signaling by developing large-scale signaling networks for cardiomyocyte
chemotransduction and mechanotransduction as well as fibroblast chemo-/mechanotransduction163–165. Additional groups have also used this approach to describe other
cardiovascular systems, such a model published by Irons and Humphrey describing
chemo-/mechano-transduction in vascular smooth muscle cells and adventitial fibroblasts
during hypertension166 and a recent model developed by Wang and colleagues describing
pulmonary arterial adventitial fibroblast signaling 167. Excitingly, these networks are
capable of simulating crosstalk between various signaling pathways that may not be
possible with fully mechanistic models of limited scope. Ryall and colleagues found that

34

based on their model of cardiomyocyte chemotransduction, the proto-oncongene Ras
acted as a central hub for signaling related to cell area by integrating upstream signaling
from multiple agonists and maintaining activation of downstream signaling, even with
knockdown of any individual biochemical input 163. Zeigler and colleagues demonstrated
sizable cross-talk between TGFβ and biomechanical signaling in a model of cardiac
fibroblast signaling, as both model predictions and experimental validation found that the
TGFβ1 receptor is necessary for mechanically-induced αSMA expression and contraction
of collagen gels165. By incorporating multiple signaling inputs at once, logic-based
signaling networks can predict cell responses to complex environmental conditions with
direct translational applications. Using their model of cardiac fibroblast signaling for
example, Zeigler and colleagues recently simulated cellular responses to time courses of
post-MI biochemical stimuli mimicking the inflammatory, reparative, and maturation
phases of wound healing168. The authors found that different intracellular signaling
species mediate collagen I and III expression during early, intermediate, and late phases
of wound healing, thus informing potential time courses for treating MI patients with
anti-fibrotic therapeutics.
An exciting translational application of logic-based signaling networks is the
ability to conduct comprehensive drug screens in silico by predicting cell responses to
knockdowns of individual or combinations of signaling species, which act as analogs for
pharmacological perturbations. Tan and colleagues conducted one such drug screen using
a model of cardiomyocyte mechanotransduction, finding that several perturbations in
combination with angiotensin receptor blockers could provide therapeutic benefit above
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the use of angiotensin receptor blockers alone, such as those inhibiting ET-1 receptors or
integrins164. Applications of this computational approach to specific pathological
scenarios can provide a basis for further experimental studies and ultimately improve the
efficiency of drug discovery by accounting for many connected signaling pathways
simultaneously.
2.3.2. Remaining challenges in model-informed therapeutic development
Network models of cell signaling have created a wealth of opportunities to
accelerate drug discovery across multiple disease areas by pointing investigators towards
influential mechanisms-of-action within a large-scale system. While several groups have
made progress in tailoring these models for cardiac fibrosis as discussed above, several
challenges remain in using this approach to predict pathological fibrosis in a spatially
resolved manner.
As discussed in Section 2.2, fibroblast-mediated ECM synthesis is informed by a
diverse range of biochemical and biomechanical cues, and in order to predict fibroblast
behavior in response to these stimuli simultaneously, a robust understanding of the
signaling pathways underlying both types of stimuli is essential. While previous
computational studies of fibroblast signaling have incorporated both chemotransduction
and mechanotransduction pathways to predict ECM turnover by fibroblasts, the model
topologies have often relied on a subset of mechanotransduction pathways such as
integrin-focal adhesion kinase signaling, thereby predicting cell behavior without full
knowledge of the system. Moreover, recent in vitro studies have discovered additional
surface sensors of biomechanical forces with implications for cardiac fibroblast signaling,

36

such as the mechanosensitive ion channels Piezo 1/2 or the transcriptional co-activator
Yes Associated Protein 1104. Because preceding fibroblast signaling networks do not
account for these newly discovered signaling species, implementing these species and
related signaling crosstalk may provide further insight into fibroblast responses to
changes in local biomechanical cues.
An additional challenge remaining for predicting fibrosis is predicting changes
across multiple layers of regulation. In addition to the intracellular signaling interactions
studied in previous network models, regulation of cell behavior can occur in at the
transcriptional level via expression of additional transcription factors which initiate or
block transcription of target genes. Previous studies have shown that these transcriptional
mediators play an essential role in controlling responses to environmental signals, such as
the SOX9 transcription factor during cardiac fibroblast-mediated fibrosis after ischemic
injury169,170. Additionally, a variety of computational methods have been developed to
derive transcriptional networks from large-scale transcriptomic data, making the
prediction of transcriptional regulation in biological systems viable 171. Integrating
networks of transcriptional regulation with cell signaling models has been shown to
generate more nuanced insight into disease states than gene expression or signaling
information alone, with one such model identifying influential transcription factors
associated and sensitive targets of anti-cancer drugs in multiple subtypes of breast
cancer172. By combining signal transduction and transcriptional regulation, these
composite networks can improve predictive capabilities for complex disease states, and
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such integrated strategies could prove advantageous for predicting cardiac cell behavior
underlying cardiac fibrosis.
One additional challenge to be addressed in model-informed drug discovery stems
from a need to treat disease progression in a patient-specific manner. As discussed in
Section 2.1.1, current pharmacological treatments for post-injury heart failure progression
do not improve outcomes for a substantial proportion of patients, and similar rates of
ineffectiveness persist for drugs across many pathological conditions 173. While traditional
clinical trials have shown overall improvements in patient populations with these
treatments compared to placebo or previous standards of care, a shift towards precision
medicine, in which patient-specific features are used to inform decisions about treatment,
can improve outcomes for a greater proportion of patients. Systems-level models are
uniquely positioned to address this need by integrating patient-specific data with
mechanistic knowledge of a biological system, ultimately predicting cell- and tissue-level
responses on a patient-by-patient basis. Such methods have been used successfully in
various computational models of cancer and lysosomal disorders among other
diseases174,175. This approach has not yet been extensively applied towards treating
cardiac fibrosis, however, and integrating patient populations into models of cardiac cell
signaling and transcription could enable a more comprehensive understanding of
maladaptive fibrosis and create predictive tools for optimizing outcomes for individual
patients. While solving each of the challenges above will ultimately require long-term
efforts in model development and use, building on current models of cardiac fibroblast
signaling with these goals in mind will enable further insight into the mechanisms
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underlying cardiac fibrosis and generate new hypotheses towards treating fibrosis in a
targeted manner.
2.4. Introduction to dissertation aims
The following chapters of this dissertation will focus on investigating mechanochemo interactions in cardiac fibroblast-mediated fibrosis through experimental and
computational studies. As discussed in Section 2.2.3, interactions between biomechanical
and biochemical stimuli after cardiac injury frequently guide overall fibroblast behavior
and complicate efforts to prevent maladaptive fibrosis. While previous experimental
studies have elucidated relationships between individual cues, systems-level experimental
and computational approaches can be used to account for a larger scope of interactions
consistent with the in vivo microenvironment. By combining a high-throughput
mechanical and biochemical testing of cardiac fibroblasts with computational models of
fibroblast signaling and transcriptional regulation, this work aims to further understand
the extent of interactions between mechanical and biochemical signal transduction, the
mechanisms integrating these signals, and potential pharmacological avenues for treating
pathological fibrosis in patients.
In Chapter 3, a high-throughput bioreactor was used to subject cardiac fibroblasts
to mechanical tension in combination with several fibrosis-related biochemical agonists,
testing the hypothesis that interactions between mechanical loading and canonical
agonists mediate fibrotic behavior. In Chapter 4, a manually curated computational model
of cardiac fibroblast signaling was expanded to include new mechanotransduction
signaling mechanisms, and global sensitivity analyses, targeted validation against current
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literature, and comprehensive drug screens were used to demonstrate the model’s ability
to predict context-dependent changes in ECM expression. In Chapter 5, a new network of
fibroblast transcriptional regulation was inferred from patient-specific transcriptomic
data, and this network was integrated into the above model of cardiac fibroblast signaling
to predict changes in gene expression on a patient-by-patient basis. Taken together, this
work suggests that cardiac fibroblast responses to the local biochemical environment are
highly context-specific, and the integration of multiple pathways using large-scale
modeling approaches can be a powerful approach for identifying influencers of networkwide behavior and druggable targets across mechanical contexts and patient conditions.
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CHAPTER 3
AIM 1: TEST THE HYPOTHESIS THAT INTERACTIONS BETWEEN
MECHANICAL LOADING AND CANONICAL BIOCHEMICAL CUES MEDIATE
FIBROTIC BEHAVIOR IN CARDIAC FIBROBLASTS
3.1. Introduction
Myocardial infarction (MI) affects a significant proportion of the US population,
with approximately 8 million adults diagnosed from 2011-2014 1. Although short-term
outcomes have improved with the widespread adoption of percutaneous coronary
intervention and reduced response times 2, maladaptive scar tissue formation in the
myocardium can lead to serious post-MI complications such as cardiac rupture, infarct
expansion, or heart failure. These complications are dependent on a balance between
tissue formation by the synthesis of extracellular matrix (ECM) and tissue degradation by
a variety of proteases including matrix metalloproteinases (MMPs). While ECM
synthesis is desirable at the infarct site for maintaining the structural integrity necessary
to prevent cardiac rupture, excessive matrix accumulation can reduce systolic and
diastolic function by increasing wall stiffness and decreasing wall conductivity, resulting
in progression to heart failure 3. Thus, controlling local ECM turnover is an essential
component in promoting healthy scar formation post-MI.
Cardiac fibroblasts mediate the fibrotic response to injury by assuming an
activated phenotype and synthesizing both matrix proteins and proteases, thereby
controlling the balance in matrix turnover to form collagenous scar tissue 4. Fibroblasts
are highly responsive to post-infarct biochemical cues consisting of pro-inflammatory
cytokines, growth factors, and hormonal agents that stimulate fibroblasts to degrade or
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deposit ECM. A growing body of research has also shown that fibroblast functionality is
dependent on local mechanical cues; MI-induced loss of cardiomyocytes results in
increased circumferential stretch at the infarct 5,6, which stimulates fibroblast activation
through several mechano-sensing mechanisms 7. While biochemical and mechanical
signaling pathways have been studied individually in cardiac fibroblasts, few studies have
examined the interplay between biochemical and mechanical signaling. Previous studies
have shown that cytokine-stretch combinations can alter fibroblast activation beyond
either cytokine or stretch treatment alone 8,9, but several questions remain regarding the
role of stretch within the context of biochemical signaling, such as the relative
contribution of stretch towards fibrosis compared to biochemical agonists and the ability
of stretch to regulate biochemical signaling.
In this study, we address these questions by assessing the effects of six different
biochemical agonists on cardiac fibroblast behavior in different mechanical contexts.
Using a multi-well cell stretching device, we subjected adult mouse cardiac fibroblast
(mCF)-seeded fibrin gels to multiple doses of each agonist under static conditions or
cyclic stretch. By measuring the secretion of 13 fibrosis-regulating proteins across all
mechano-chemo combinations, we examined how stretch contributes to overall fibrotic
activity when combined with each agonist as well as how stretch alters agonist-mediated
protein secretion. We found that stretch contributed to overall fibrotic activity when
added to individual agonists by either amplifying agonist-mediated downregulation or
suppressing agonist-mediated upregulation of several matrix metalloproteinases. We
further analyzed these data to identify cases in which stretch alters fibroblast sensitivity
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towards biochemical agonists and found that stretch sensitized fibroblasts towards
agonists that downregulate protease expression and dampened the effects of agonist
stimulation on protease upregulation. This systems-level study provides a resource of
fibroblast protein expression in response to interacting environmental stimuli and
highlights the complexity of intracellular signaling pathways in determining fibroblast
phenotypes within the post-MI environment.
3.2. Results
mCF-seeded fibrin gels secrete matrix-regulating proteins across several orders of
magnitude
In order to subject fibroblasts to biochemical stimuli and mechanical stretch, we
used a multi-well stretching device in which deformable culture wells transmit uniaxial
tension to 3-dimensional cell-seeded fibrin constructs suspended by opposite sets of
vertical polydimethylsiloxane (PDMS) posts (Figure 3.1A-B, see Materials and Methods
for full description). When subjected to uniaxial stretch within the culture wells,
constructs experienced tensile strain primarily in the axial direction with non-zero strains
in the transverse direction, mimicking increases in tissue strain in the circumferentiallongitudinal plane measured in rat and porcine models following coronary ligation 5,10.
mCFs maintained viability over a 96-h treatment period (Figure A-2) and aligned
preferably towards the direction of stretch across all experimental groups (Figure A-3),
which parallels previous studies that show preferential cell orientation towards both static
boundary conditions and applied strain 11,12.
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Figure 3.1. Generation and treatment of cardiac fibroblast-seeded constructs. (A) Schematic of
multi-well membrane modified with PDMS posts. Red surfaces represent silicone culture surfaces, with
the addition and culture of cell-seeded fibrin resulting in anisotropic constructs that can be uniaxially
stretched (cutout). (B) Brightfield (BF) and immunofluorescent staining for DAPI and αSMA for
fibroblast-seeded gels after treatment. (C) Combinations of low dose (LD) and high dose (HD)
biochemical agonists used in combination with cyclic stretch on fibroblast-seeded constructs.

We used this culture platform to treat mCFs with either one of six biochemical
agonists alone, cyclic stretch alone, or combinations of agonist treatments and stretch
over a 96-h period to facilitate measurable protein secretion (Figure 3.1C). Using a
multiplexed immunoassay for simultaneous, quantitative detection of soluble proteins, we
measured secreted levels of 13 secreted proteins associated with cardiac fibrosis in
agonist-/stretch-treated samples (see Materials and Methods for full description). Across
all experimental groups, protein secretion varied across several orders of magnitude, from
μM levels of collagen I-associated peptides to pM levels of several proteases and
inhibitors (Figure 3.2A). Interestingly, mCFs consistently expressed several species that
have not been widely associated with fibroblast-specific protein expression, namely
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Figure 3.2. Cardiac fibroblasts express fibrosis-regulating proteins across orders of magnitude in
response to biochemical and mechanical perturbations. (A) Cell count-normalized protein
concentrations for un-stretched controls and all perturbations (i.e. stretched, agonist-treated, or stretched
and agonist-treated). (B) Coefficients of variation (CV) for protein concentrations across all conditions.

MMP12, TIMP4, and THBS4 13. Additionally, select proteins exhibit greater variance
across experimental groups than others as evidenced by coefficients of variation (Figure
3.2B), even within similar functional categories (e.g. MMP2/MMP9), which may be
indicative of proteins with higher general sensitivity vs. robustness against stimulation.
Biochemical stimuli differentially modulate secretion profiles of proteases and
matricellular proteins
We examined the relationships between biochemical cues and fibrosis-related
protein secretion by comparing the effects of biochemical agonists with un-stretched
controls on proteins secretion. Consistent with analyte coefficients of variation across all
experimental groups, matricellular proteins POSTN and OPN and MMPs 1, 8, 9 and 12
were highly sensitive to biochemical simulation with variable expression across all
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Figure 3.3. Biochemical agonists and mechano-chemo combinations alter profiles of fibroblast
secretion of matrix-related proteins. All values represent log2(fold-change) comparing each agonist
treatment to designated controls. (A-C) Dot plots representing changes in secretion with individual
agonists (A), changes in secretion with cyclic stretch (B), either alone (left column) or in combination
with agonists, and changes in secretion with agonist-stretch in comparison to stretch-only samples (C).
All statistical comparisons against respective controls were made using two-way ANOVA with
Dunnett’s post-hoc tests.

treatment groups (Figure 3.3A). Other species were robust to changes with biochemical
cues resulting in minor trends with stimulation by TNFα and PDGF, including protease
inhibitors, collagen I-associated peptides and MMPs 2 and 3. Across both sets of
treatment doses, inflammatory cytokines IL-1β and TNFα uniquely regulated protein
secretion compared to other agonist types, with high doses of both agonists particularly
upregulating MMP9 secretion compared to unstretched controls (p=5.1E-4 and 3.9E-10
for IL-1β and TNFα respectively). Trending and significant increases in MMP1, MMP12,
and collagen I-associated peptide levels additionally suggest that mCFs shift in balance
towards the secretion of anti-fibrotic proteins in response to these inflammatory stimuli
(p-values shown in Figure A-5A).
Cyclic stretch combines with biochemical stimuli to dictate overall protein secretion
Although the importance of mechanotransduction in cardiac fibrosis has gained
attention recently, it is still unclear how this signaling axis integrates with complex
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biochemical signaling during cardiac remodeling. We first examined cyclic stretch as an
individual stimulus compared to un-stretched controls and found that stretched mCF
cultures upregulated collagen I-associated peptide levels and showed trending increases
in POSTN and MMPs 1, 8, and 12 compared to un-stretched controls (Figure 3.3B, left
column, p-values shown in Figure A-5B), indicating that stretch alone did not produce
definitively pro-fibrotic behavior. We then examined the role of stretch in conjunction
with biochemical signaling by comparing secreted protein levels for cultures subjected to
agonist-stretch combinations to un-stretched controls. Like static cultures, matricellular
proteins and MMPs 1, 8, 9 and 12 were the most variably secreted across agonists (Figure
3.3B, right heatmap), although inflammatory cytokines showed notably weaker
upregulation of MMPs 1, 9, and collagen I-associated peptides under stretch compared to
static conditions.
In order to understand how mechanical stretch contributes to overall fibroblastmediated remodeling, we quantified differences between the effects of agonist treatments
alone (i.e. agonist-only treatments vs. un-stretched controls) and agonist-stretch
combinations (i.e. combinations vs. un-stretched controls, see Materials and Methods for
full description). We categorized these differences in overall protein secretion into three
groups: (1) stretch can have an additive effect by enhancing secretion levels beyond those
of agonist stimulation alone (Figure 3.4A with example in 3.4D), (2) stretch can have a
subtractive effect by suppressing changes in secretion with agonist treatment (Figure 3.4B
with example in 3.4E), and (3) stretch can have an inverting effect by overriding the
effect of agonist stimulation alone, thus changing the overall effect from upregulation to
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Figure 3.4. Cyclic tension differentially alters the effects of biochemical stimulation on fibroblast
protein secretion. (A-C) Effects of agonist-stretch combinations on overall protein secretion. Xcoordinates represent the effect of agonist treatments alone relative to un-stretched controls, and ycoordinates represent the effect of agonist-stretch combinations relative to un-stretched controls.
Shaded areas indicate secreted proteins that show an additive effect compared to agonist treatment
alone (A), a subtractive effect (B), or an inverting effect from downregulation to upregulation and vice
versa (C). (D-F) Representative plots demonstrating effects of agonist-stretch combinations compared
to agonist treatment alone. Values for all groups are normalized to mean levels of un-stretched controls,
solid lines represent median levels, dashed lines represent mean levels, and whiskers represent 1.5(IQR)
levels. (G-I) Stretch effect magnitudes for cases of additive effect (G), subtractive effects (H), or
inverting effects (I). Magnitudes are expressed in log2(fold-change), and Student’s t-tests with
Bonferroni correction for multiple comparisons are used for all comparisons against un-stretched
controls. Asterisks represent level of confidence in interactions: * p< 0.2; ** p< 0.1; *** p< 0.05.
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downregulation or vice versa (Figure 3.4C with example in 3.4F). From this analysis, we
found that stretch showed trending or significant additive effects on agonist stimulation
for 11 agonist-secreted protein pairs and showed trending or significant antagonistic
effects for 8 pairs.
Within the additive effect group, stretch showed the most evidence of further
upregulating MMP12 (Figure 3.4G), with increases in expression in conjunction with IL1β (p=0.013 for agonist/stretch combination versus un-stretched controls), TNFα
(p=0.023), NE (p=0.055), and AngII stimulation (p=0.12). Secreted levels of OPN were
also further increased by stretch when combined with low-dose TGF-β1 and AngII
treatments, resulting in approximately 3-fold increases relative to un-stretched controls
(p=0.050 and 0.11, respectively). Stretch also showed synergistic trends in a suppressive
manner; when combined with TNFα, TGF-β1, and NE treatments, stretch further
decreased the expression of MMP2, leading to over 2-fold reductions in protease levels
compared to un-stretched controls (p=0.10, 0.16, and 0.18, respectively). By quantifying
differences between agonist-only effects and combination effects across all agonistsecreted protein pairs, we found that the addition of stretch exerts the largest changes in
expression for MMP12, with multiple agonist/stretch combinations increasing secreted
levels approximately 2-fold above agonist-only counterparts (Figure 3.4G).
Stretch demonstrated subtractive effects on protein secretion by suppressing the
secretion of matrix metalloproteinases that were upregulated by agonist treatments alone
(Figure 3.4B). MMP9 upregulation by several agonists was especially suppressed by
stretch, as both IL-1β and TNFα significantly reduced expression in combination with
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Figure 3.5. Cyclic tension alters cardiac fibroblast sensitivity to biochemical agonists. (A-C)
Changes in agonist effect on protein secretion for fibroblasts in static or strained cultures. X-coordinates
represent effects of agonist treatments relative to un-stretched controls, and y-coordinates represent
effects of agonist-stretch combinations relative to samples subjected to stretch only. Shaded areas
indicate secreted proteins that show sensitization towards agonists (A), desensitization (B), or
sensitivity reversal from upregulation to downregulation (C). (D-F) Representative plots demonstrating
stretch-mediated changes in sensitivity of fibroblasts to agonist treatment. Values for un-stretched
groups (gray) are normalized to mean levels of un-stretched controls, and values for stretched groups
(colors) are normalized to mean levels of stretch-only groups. (G-I) Sensitivity magnitudes for cases of
sensitization (G), desensitization (H), or sensitivity reversal (I). Magnitudes are expressed in log2(foldchange), and Student’s t-tests with Bonferroni correction for multiple comparisons are used for all
comparisons against respective controls. Asterisks represent level of confidence in interactions: * p<
0.2; ** p< 0.1; *** p< 0.05.
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stretch compared to treatment with either cytokine alone (Figure 3.4H). However, stretch
also demonstrated antagonism towards the secretion of collagen I-associated peptides and
protease inhibitor PAI1, as upregulated secretion of these species by IL-1β or TNFα were
suppressed to near-control levels. Several agonist-secreted protein pairs also trended
towards an inverting effect in which agonist/stretch combinations upregulated the
expression of proteins that were downregulated by agonists alone (Figure 3.4C), such as
TGF-β1-mediated secretion of MMP12 (Figure 4F). Although not meeting our criteria for
statistical significance, these cases could also prove important in determining the full
effect of stretch on cardiac remodeling, and further studies are necessary to explore these
trends.
Cyclic stretch modulates fibroblast sensitivity to biochemical stimulation
In order to quantify the ability of stretch to regulate biochemical signaling, we
adapted the analysis discussed above to compare the effects of agonist treatments in a
static context (i.e. agonist-only treatments vs. un-stretched controls) and in a stretched
context (i.e. agonist/stretch combinations vs. stretch-only treatments). We categorized
changes between contexts into three groups: (1) stretch can sensitize fibroblasts towards
biochemical stimuli by enhancing the effect of agonist treatment under stretch (Figure
3.5A, with example in 3.5D), (2) stretch can desensitize fibroblasts by suppressing the
effect of agonist stimulation (Figure 3.5B, with example in 3.5E), and (3) stretch can
reverse fibroblast behavior completely by causing agonists to downregulate secretion
compared to upregulation in a static environment, or vice versa (Figure 3.5C, with
example in 3.5F). We found that stretch showed trending or significant evidence of
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Figure 3.6. Cyclic stretch modulates
overall secretion of matrix-related
proteins. (A) Sensitivity of individual
secreted proteins to all biochemical agonists
in both stretch contexts. Levels for each
output were calculated as the sum of
log2(fold-change) values with each agonist
relative to control as a representation of
overall response of each output towards all
agonists. (B) Influence of individual agonists
across all secreted proteins in both stretch
contexts. Values for respective analyses are
ranked by un-stretched levels for each
species. Levels for each agonist were
calculated as the sum of log2(fold-change)
values of each output relative to control as a
representation of overall effect of each
agonist towards all outputs.

agonist sensitization for 12 agonist-secreted protein pairs and showed similar evidence of
agonist de-sensitization for 12 pairs compared to the same treatments under static
conditions. None of the reversals were statistically significant.
Within the sensitizing group, stretch primarily acted to amplify agonist-mediated
suppression, mediating further suppression of MMP8 levels by TNFα (p=0.044 for
agonist/stretch combination versus stretched-only samples) and PDGF (p=0.059).
Multiple agonists also exhibited amplified suppression of POSTN secretion with stretch,

68

with TNFα, PDGF, and IL-1β all showing trending or significant suppression in a
stretched context (p=0.020, 0.034, and 0.16 respectively). Interestingly, AngII appeared
to further suppress MMP1, MMP12, and OPN under stretch, with MMP1 levels
decreasing to almost 25% of those for stretch-only samples (Figure 3.5D). Of these
trends, secreted outputs MMP8 and POSTN appeared to have the highest degrees of
sensitization, as TNFα and IL-1β reduced expression of these proteins by approximately
2.5-fold more under stretch than under static conditions (Figure 3.5G).
Fibroblasts also showed decreases in sensitivity towards select agonist treatments
under stretch (Figure 3.5B); in particular, expression of MMP9 and OPN, both of which
were upregulated in response to multiple agonists in static conditions, were not
significantly altered by the same agonists under stretch (Figure 3.5E). Interestingly,
secretion of PINP and PAI1 also showed significant desensitization towards low-dose
TNFα stimulation under stretch, although magnitudes of these changes were less than
those for TNFα-mediated MMP9 secretion (Figure 3.5H).
We additionally found that several agonist-secreted protein pairs demonstrated a
reversal in sensitivity in which agonists that upregulated protein expression in static
conditions downregulated expression under stretch (Figure 3.5C). Similarly to our
findings of overriding effects described above, these cases did not meet our criteria for
statistical significance. However, this type of behavior appears to be consistent for
MMP1, MMP8, and POSTN expression (Figure 3.5I), with TNFα stimulation reducing
MMP1 expression to roughly 40% of stretch-only levels (Figure 3.5F). Further studies
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validating these trends are necessary to fully understand the ability of stretch to reverse
the effects of biochemical stimulation.
Cyclic stretch differentially regulates global fibroblast sensitivity to cytokine stimulation
We lastly assessed the sensitivity of each secreted protein to all biochemical
agonists in either static or stretched conditions to identify global trends in mechanochemo interactions. Using a summed fold-change metric for total sensitivity, we found
that matricellular proteins OPN and POSTN as well as MMPs 1, 8, 9, and 12 ranked as
the most sensitive to biochemical treatment in both mechanical conditions (Figure 3.6A).
Within these outputs, OPN, MMP9, and MMP1 all showed de-sensitization towards all
agonists under stretched conditions, although total sensitivity levels still ranked highly
overall. Alternatively, both POSTN and MMP8 showed increased sensitivity to agonist
stimulation in a high-stretch environment, indicating that these species may be more
readily regulated within infarcted areas. Using a similar analysis to compare agonist
regulation across all secreted outputs, we found that stretch altered the overall influence
of TNFα, NE, and AngII on the secretion of all proteins (Figure 3.6B). While stretch
decreased the total magnitude of effects from TNFα stimulation, however, both NE and
AngII exerted greater changes in protein levels within a stretched environment, more than
doubling the influence of AngII on protein secretion.
3.3. Discussion
Study design
The contribution of fibrosis to heart failure after MI has gained attention due to its
role in chronic mechanical and electrical dysfunction. Prior studies of fibroblast behavior
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have highlighted the central role of dynamic mechanical stretch in the development of
scar tissue, and future drug therapies that account for cell responses to this mechanical
environment as well as responses to biochemical signals could improve patient outcomes.
By screening the effect of individual biochemical stimuli for their effects on fibroblastspecific matrix remodeling in the presence and absence of cyclic stretch, we sought to
generate new insight into stretch-mediated fibrosis within the complex post-infarct
environment.
In order to subject fibroblasts to biochemical stimuli and stretch while simulating
myocardial architecture and material properties, we employed a previously developed
strategy in which cells are incorporated into a fibrin matrix and seeded into culture wells
containing vertical, opposing sets of silicone posts. Fibroblasts cultured in this manner
have been shown to remodel the surrounding matrix and form aligned constructs with
comparable stiffness to myocardial levels 14–17, thus mimicking in vivo mechanical
conditions more closely than 2-dimensional mechanical testing systems which typically
utilize culture surfaces with supraphysiologic stiffnesses. It should be noted that even
upon returning to a soft substrate after culture on stiff substrates such as tissue culture
plastic, fibroblasts permanently exhibit altered adhesion and maintain an activated state
as reported by the Hinz group 18,19. We acknowledge that this fundamental issue in
mimicking in vivo conditions can confound mechanotransduction-related cell behavior,
and although mCFs assumed an activated state throughout treatment the use of soft gels
prevented further stiffness-related stimulation during treatment, and myofibroblastmediated remodeling could be examined without confounding mechanical factors.
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Relative secretion levels of matrix proteins and proteases
We first aimed to contextualize the effects of environmental cues on fibroblastmediated scar formation by comparing absolute concentrations of mCFs-secreted proteins
across and within functional categories. Collagen I-associated peptides were
predominately secreted along with MMP1, MMP2, MMP8, and TIMP1, which although
secreted at distinct stages after myocardial injury 20, point to dominant mechanisms of
ECM turnover via fibrillar collagen synthesis collagenase-mediated degradation. We also
detected relatively small, but consistent levels of MMP12, TIMP4, and THBS4, all of
which have been observed in fibroblast-specific gene expression studies but have not yet
been directly measured at the protein expression level 13,21–23. These biomarkers have
been implicated in post-infarct remodeling either through paracrine signaling toward
resolving inflammation as in the case of MMP12 24, or by modulating responses to
pressure overload as in the case of THBS4 25. Their direct link to cardiac fibroblast
secretion suggests that fibroblasts may act in a communicatory role in addition to directly
mediating matrix turnover.
Differential sensitivity of secreted proteins and influence of biochemical stmuli
We compared fibroblast-specific matrix remodeling across biochemical stimuli by
measuring matrix-related protein expression for six canonical agonists that have been
shown to individually mediate fibroblast function 26. MMPs 1, 8, 9, and 12 and
matricellular proteins OPN and POSTN were highly sensitive to agonist treatments
compared to all other measured proteins. This finding of differential sensitivity towards
stimuli is supported by targeted studies of MMP expression and activity such as that of
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Siwik and colleagues in which IL-1β treatment induced large increases in MMP9 activity
relative to MMPs 2 and 13 27. Although absolute concentration levels were small for
several proteins relative to other secreted outputs, large changes in expression suggest
that select proteases may play an essential role in mediating biochemically driven matrix
turnover.
Both inflammatory agonists used in our study exhibited a unique influence on
protease expression relative to other agonists. We observed that both IL-1β and TNFα
mediate significant increases in MMP9 levels, with TNFα additionally upregulating
MMP12 expression, which suggest that inflammatory factors primarily acted to
upregulate protease expression. These trends agree with parallel increases of
inflammatory and protease levels within the acute post-infarct phase, which form the
basis for removing necrotic tissue from the infarcted area 28–30, as well as in vivo studies
in which TNFα-/- mice displayed reduced MMP9 expression, earlier collagen deposition,
and reduced incidence of rupture post-MI compared to wild-type mice 31. Both MMP9
and MMP12 have been implicated as key mediators of cardiac fibrosis and ventricular
function post-MI, as MMP9-/- mice subjected to left coronary arterial ligation displayed
enhanced MMP levels and attenuated collagen accumulation compared to wild-type mice
32

, and Ramirez and colleagues found MMP9 -/- mice exhibited improved responses to

renin inhibitor aliskiren and angiotensin receptor inhibitor valsartan by attenuating
increases in fibrotic gene expression, collagen content, and improving overall survival 33.
Pharmacological inhibition of MMP9 and MMP12 both exacerbated left ventricular
function post-infarction 24,34, confirming the highly influential roles of both proteases and
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suggesting that MMP9-regulated tissue remodeling may be specific to the spatial and
temporal context.
Contribution of tension to overall protein secretion
Mechanical stretch has been widely shown to induce pro-fibrotic phenotypes in
cardiac fibroblasts as one component of overall mechanical stimulation 35. While
previous work has shown that tensile forces can modulate fibroblast responses when
combined with biochemical stimulation 8,9, it is still unclear how stretch contributes
towards overall remodeling compared to biochemical signaling, and whether mechanical
and biochemical signaling axes operate dependently or independently of each other. We
aimed to answer these questions by treating mCF cultures with combinations of
biochemical agonists and mechanical stretch and comparing the effects of these
combinatory treatments to those of agonist-only treatments on protein expression.
We found that cyclic stretch altered protein secretion in two primary modalities:
stretch either added to the effect of biochemical stimulation by further upregulating or
suppressing protein secretion, or stretch subtracted from biochemically-mediated effects
by suppressing expression levels to near-control levels. Stretch further increased
expression of MMP12 and OPN compared to biochemical stimulation alone whereas
secreted levels of MMP2 and MMP9 were downregulated, suggesting that stretch
reinforces pro-fibrotic activity in fibroblasts by suppressing matrix proteases and
increasing matricellular protein production. Although overall MMP levels are increased
in the post-MI inflammatory phase with macrophages and neutrophils acting as the
primary sources for secretion 13, our observed reductions in expression match a transition
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to the fibrotic phase involving the downregulation of MMPs and replacement of necrotic
myocardium with collagenous scar 20. MMP12 levels were uniquely amplified with
stretch compared to cytokine treatment alone, which could be indicative of further
negative feedback by MMP12 as knockdown studies in post-MI mice have shown both
an increase in inflammatory signals in the myocardium and a decrease in beneficial
remodeling 24,36.
Stretch-dependent sensitivity to biochemical stimulation
We additionally tested the hypothesis that stretch can not only act alongside
biochemical stimuli but also alter cellular responses to these stimuli, as previous studies
have demonstrated similar signaling mechanisms in both chemo- and mechanotransduction, such as mitogen-activated protein kinase and Akt signaling pathways
39

14,37–

. We found that stretch altered fibroblast sensitivity towards agonists by either

sensitizing cells towards agonists that suppress protease expression (e.g. MMP1, MMP8)
or by de-sensitizing cells towards agonists that upregulate expression (e.g. MMP9). These
changes in protease-related sensitivity indicate that stretch interacts with chemotransduction pathways to selectively dampen matrix protease expression. While we also
observed de-sensitization of both OPN and PINP upregulation towards biochemical
stimuli under stretch, stretch alone upregulated the expression of both proteins,
suggesting that these ECM components remained upregulated regardless of biochemical
cues in a stretched environment. These results suggest that the underlying network of
fibroblast signaling plays a large role in dictating fibroblast responses to competing cues,
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and further studies examining the intracellular signaling network are necessary to fully
understand the mechanisms of action guiding fibroblast-mediated remodeling.
Our findings suggest that cardiac fibroblasts act in a mechano-adaptive manner to
regulate matrix turnover, with mechanical stretch acting to alter matrix protease and
matricellular protein secretion both directly, acting independently of biochemical
signaling, and indirectly, acting to modify biochemical signaling. We found that TNFαmediated protein secretion showed the highest degree of mechano-adaptive behavior
compared to the other agonists tested, with stretch-mediated expression of MMP8,
MMP9, MMP12, OPN, POSTN, PINP, and PAI1. Similar findings were recently found
by Aguado and colleagues in which TNFα-mediated deactivation of cardiac fibroblasts
was amplified depending on substrate stiffness, with a higher proportion of cells reverting
towards quiescence on stiff hydrogels 40. Our evidence of stretch-mediated sensitization
and de-sensitization towards TNFα suggests that TNFα signaling mediates fibroblast
activation under dynamic mechanical conditions. Further studies are necessary to validate
these relationships between inflammation and stretch in guiding fibroblast phenotypes.
Study limitations and future directions
One limitation of this study arises from the variability that arises from the
measurement of protein expression across biological replicates. The use of separate pools
of mCFs in our comparisons allowed for genomic variability between replicates, and
although our use of a mixed-effect statistical model was able to discern agonist- and
stretch-mediated behavior, we cannot rule out additional mechano-chemo interactions
that we were unable to detect. However, the interactions that we identified in our analysis
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persisted despite this variability, thereby improving our confidence in these findings. Our
screen of mechano-chemo interactions was additionally limited to two doses of
biochemical stimulation and two mechanical states, and further dose-response studies
would further explore the extent of relationships between these stimuli. Additionally, a
number of other secreted factors were not measured in our study that have been shown to
play significant roles in matrix remodeling, including those related to matrix processing
and turnover (e.g. cathepsins, lysyl oxidase, etc.) and paracrine signaling (e.g. tenascin-c,
interleukins, thrombospondins, etc.). Further measurements would provide insight into
the contribution of fibroblast secretion towards maladaptive remodeling.
Lastly, our data suggest that fibroblast secretion relies on a complex network of
intracellular signaling, which contains interactions between transduction pathways that
dictate overall responses. Several groups have successfully identified influential
mechanisms of mechano-transduction and mechano-chemo crosstalk using computational
models of cell signaling 41–43, providing new directions towards controlling cell behavior
in a dynamic mechanical environment. For translation of these model predictions to
tissue-scale remodeling and clinical use however, proteomic datasets containing fullyquantified information for protein states (i.e. absolute active/total protein concentrations)
are critical for transforming semi-quantitative systems models into those capable of
predicting absolute changes in cell and tissue properties. The quantitative nature of this
current proteomic dataset presents opportunities for fitting systems-level models to
quantitative data and allows for quantitative predictions of fibroblast secretion, and future
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work integrating these models with proteomic datasets are necessary to predict fibroblastmediated matrix remodeling on a systems level.
We developed a screen of cardiac fibroblast protein secretion in response to
combinations of biochemical agonists and mechanical stretch to investigate how cyclic
stretch influences fibrotic activity within the context of biochemical signaling. We found
that biochemical stimuli primarily altered the expression of MMPs 1, 8, 9, 12, OPN, and
POSTN, and inflammatory agonists IL-1β and TNFα particularly promoted protease
secretion, thereby shifting the balance in matrix turnover towards degradation. The
addition of stretch to biochemical stimuli shifted fibroblast behavior towards matrix
accumulation by either further upregulating matricellular protein expression, further
downregulating protease expression, or antagonizing the upregulation of MMP9 by
inflammatory agonists. We also found that stretch mediated fibroblast sensitivity towards
biochemical stimuli by increasing sensitivity towards agonists that suppress MMP1,
MMP8, and POSTN while decreasing sensitivity towards those that upregulate MMP9,
thereby priming cells towards matrix accumulation. The screening approach employed
here allows for the identification of emergent interactions between cell stimuli and can be
used to inform targeted studies for interactions that govern matrix turnover.
3.4. Materials and Methods
Cardiac fibroblast isolation
All animal procedures were conducted in accordance with the Institutional
Animal Care and Use Committee at Clemson University. mCFs were isolated and
cultured as previously reported 44. Wild-type C57BL/6 mice (male, 10-12 weeks old, ~25
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g body weight) were sacrificed, and hearts were harvested and collected in KrebsHenseleit buffer (Sigma, St. Louis, MO). The ventricles were isolated, minced, and
digested enzymatically at 37 °C with Liberase TM (Roche, Indianapolis, IN).
Supernatants from six successive digestion periods were collected, centrifuged at 300 x g
at 4 °C, and resuspended into Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma)
containing 10% fetal bovine serum (FBS, Atlanta Biologicals, Flowery Branch, GA), 100
U/mL penicillin G, 100 μg/mL streptomycin, and 1 ng/mL amphotericin B (all Sigma).
Cells were plated in culture flasks and incubated at 37 °C and 5% CO 2 for 4 h. Fresh
culture medium was added to remove non-adherent cells, and culture medium was
replaced every 48 h thereafter. mCFs were cultured on tissue culture plastic until passage
2 before seeding in fibrin gels as described below.
Fibroblast-seeded fibrin gels
mCFs were seeded into fibrin gels using a previously reported procedure 16 and
loaded gels into silicone 16-well plates (CellScale, Waterloo, ON). Fibrin was chosen as
a scaffold material for its ability to promote de novo collagen synthesis and fibroblastmediated remodeling. Previous studies embedding human dermal fibroblasts and smooth
muscle cells in fibrin gels have demonstrated improved synthesis of collagen compared to
collagen gels, which tend to inhibit synthesis 45–47. Fibrin additionally allows for cellinitiated remodeling and compaction of the matrix for a functional assessment of cell
contractility, and cell-remodeled fibrin gels of a similar density as those used here have
been shown to have a linear modulus of 19-28 kPa 48, which is more comparable to the
stiffness of healthy myocardium (10-25 kPa) 35 than collagen gels of a similar density 48.
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Fibrin has been the focus of tissue regeneration strategies post-MI as a scaffold for cell
transplantation 49 with cell-seeded fibrin injected into the myocardium improving post-MI
function in mice 50, and thus the study of fibroblast-mediated remodeling and secretion
within this matrix could also prove useful for tissue engineering applications.
Prior to plating gels, well plates were modified to contain six PDMS posts each,
which have been shown to facilitate gel remodeling by fibroblasts 15,16,51,52. To construct
the posts, a Delrin mold was fabricated via milling with a negative pattern for sets of
three posts corresponding with axial ends of each construct. Individual post geometries
were 1 mm x 1 mm x 2 mm (l x w x h), and posts were spaced 0.75 mm apart within each
pattern. Upon fabrication of the negative mold, Sylgard 184 PDMS (Dow Corning,
Midland, MI) was mixed at a 10:1 ratio (base : curing agent), poured into the mold,
degassed via a vacuum desiccator for 10 min, and cured in a 95 °C oven for 1 h to allow
for polymerization for an elastic modulus of approximately 700 kPa as determined by
previous studies 53. Upon curing, sets of posts were removed from the mold and bonded
to 16-well plates using freshly mixed Sylgard 184 PDMS as a glue. Two sets of posts
were placed in each well and spaced 5 mm apart on opposing sides in the direction of
stretch. Well plates were then placed in a 95 °C oven for 1 h to allow for polymerization
of the PDMS glue. Prior to use, wells were additionally coated with 3.5% Pluronic F-127
(Sigma) in phosphate buffered saline (PBS, Sigma) for 8 min to prevent adhesion to the
well surfaces.
Upon well plate modification, mCFs were removed from flasks with 0.25%
Trypsin-EDTA (Gibco, Grand Island, NY) and incubated with DiI (Invitrogen, Grand
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Island, NY) to visualize cell membranes after treatment. Cells were resuspended in a
thrombin solution (0.44 U/mL bovine thrombin in DMEM with 0.5% FBS) and combined
with a fibrinogen solution (6.6 mg/mL in 20 mM HEPES-buffered saline) at a 1:1 ratio to
create a fibrin gel. Upon combining, 200 uL of fibrin gel was added to each well, and gels
were incubated at 37 °C for 30 min to allow for polymerization. DMEM containing 0.5%
FBS, 50 ug/mL L-ascorbic acid (Sigma), and 33.3 ug/mL aprotinin (Roche) was then
added to each well to prevent premature degradation of fibrin gels. Although a wellknown inhibitor of MMP activation, the expression of collagens, proMMPs, and gel
contraction compared to negative controls have been shown to remain unchanged with
added aprotinin in fibroblast- and mesenchymal stromal cell-seeded gels 54,55, suggesting
that this inhibitor allows for the measurement of protease and matrix secretion while
maintaining structural integrity of fibrin constructs. After addition of this culture
medium, gels were cultured for 48 h to allow for gel remodeling. For each replicate, 14
gels were seeded with 1x105 mCFs for compaction, viability, and immunocytochemistry
analyses, and 14 gels were seeded with 2x105 mCFs to collect sufficient protein for
secretomic analysis.
Cyclic stretch and cytokine treatment
Prepared well plates were loaded into MechanoCulture FX2 uniaxial stretching
devices (CellScale, Waterloo, ON). For stretched gels, a strain amplitude of 6.5% and
frequency of 1.0 Hz was used, which were chosen to match regional circumferential
strains measured in rats following acute cryoinfarction 5 and in pigs following permanent
coronary artery ligation 56. Axial and transverse strains for gels were validated by
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measuring gel deformation during 0.33-mm increments of stretch by the device actuator
and calculating the 11 (axial) and 22 (transverse) components of the Green strain tensor
from each set of values (Figure A-1). Gels within each stretch condition were treated with
either no agonist (control group) or one of six cytokines or growth factors: transforming
growth factor-β1 (TGF-β1, Cell Signaling Technology, Danvers, MA), angiotensin II
(AngII, Sigma), interleukin-1β (IL-1β, Cell Signaling Technology), platelet-derived
growth factor-BB (PDGF, Cell Signaling Technology), L-norepinephrine bitartrate (NE,
Sigma), and tumor necrosis factor-α (TNFα, Cell Signaling Technology). These agonists
have all been shown to influence fibrotic remodeling post-MI at both tissue and cellular
scales 57; AngII and NE, both canonical mediators of cardiac hypertrophy, have been
shown to alter fibroblast-specific remodeling, with in vivo and in vitro studies of
angiotensin receptor blockers and neprilysin inhibitors attenuating fibrosis caused by
AngII infusion 58,59. TGF-β1 and PDGF as growth factors have also become well-known
mediators of fibroblast activation and fibrosis both post-MI and systemically
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, and

inhibition of either factor has been shown to attenuate fibrosis in the infarcted
myocardium 61,63. Inflammatory agonists IL-1β and TNFα additionally alter cardiac
fibrosis as shown in clinical trials of IL-1β inhibitor anakinra and animal studies
overexpressing TNFα 64,65. While not an exhaustive study of possible fibroblast agonists,
these six agonists represent several major modes of fibroblast activation post-MI. All
concentrations were chosen from previous literature measuring fibroblast responses to
individual agonists including collagen expression 43,66–68, MMP, TIMP, and growth factor
expression 67,69, and αSMA expression or gel contraction 43 (concentrations displayed in

82

Figure 1C). All gels were treated for a total of 96 h, during which doses and medium
were replenished after 48 h.
Gel compaction analysis
Brightfield images were taken at the beginning and end of treatment using an
EVOS FL Auto microscope with a 4x Plan Fluor 0.13 NA objective (Life Technologies,
Grand Island, NY). A 4x3 grid of images were captured and combined to create a
composite image of each gel. Gel outlines were then segmented using the threshold
feature in ImageJ 70. Gel compaction was calculated as the fold change of the final gel
area from the initial gel area.
Immunocytochemistry and image analysis
Cell viability was determined via a fluorescence-based assay as described
previously 71. Gels were stained using a live/dead cell double staining kit (Sigma)
according to the manufacturer instructions, and fluorescent images were captured at the
center of each gel for calcein and propidium iodide to identify viable and dead cells,
respectively. CellProfiler software was used for quantitative image analysis 72. Viable
cells were identified from calcein images using a minimum cross entropy thresholding
method, and dead cells were identified from propidium iodide images using a manual
threshold to remove false positives due to low numbers of dead cells per image. Cell
viability for each gel was determined as the ratio of viable cells to total cells, and cell
orientation was measured for viable cells as the angle from the axis of stretch to the major
axis of each cell.
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For analysis of fibroblast activation, immunostaining and quantitative analysis
were performed as reported previously 43. Gels were fixed in 10% neutral buffered
formalin (VWR, Radnor, PA) and washed 3x in PBS. Gels were permeabilized in 0.2%
Triton-X-100 (Sigma) in PBS and washed 3x in PBS, and gels were blocked with 2%
bovine serum albumin (Sigma) at 4 °C overnight. Gels were stained with alpha smooth
muscle actin-Alexa Fluor 488 (αSMA, Invitrogen) and 4’,6-diamidino-2-phenylindole,
dihydrochloride (DAPI, Invitrogen), washing gels 3x with PBS after applying each stain.
Fluorescent images were captured at the center of each gel for DAPI, αSMA, and DiI
stains. Using CellProfiler software, individual cells were identified by DAPI and DiI
stains, and integrated αSMA intensity was measured within each identified cell. Mean
αSMA expression levels were calculated as the average integrated intensities across all
cells per image. Total cell counts for each gel were extrapolated using final gel areas
calculated in compaction analysis (Figure A-4A). From the number of identified cells in
each image, total cell counts for each gel were calculated as the product of the cell
density in each image and the final gel area.
Secreted protein measurement
During cell treatments, culture supernatants were collected at both 48 h and 96 h
after initial treatment and stored at -20 °C. Pro-collagen I amino-terminal propeptide
(PINP) and matrix metalloproteinase-1 (MMP1) content were both measured via enzymelinked immunosorbent assay as per the manufacturer’s instructions (MyBiosource, San
Diego, CA). Luminex magnetic bead assays (R&D Systems, Minneapolis, MN) were
used to measure a panel of 11 additional analytes: MMP2, 3, 8, 9, and 12, tissue
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inhibitors of matrix metalloproteinases-1 and 4 (TIMP1 and 4), osteopontin (OPN),
periostin (POSTN), thrombospondin-4 (THBS4), and plasminogen activator inhibitor-1
(PAI1). These analytes were chosen as representatives known to influence cardiac
fibrosis via matrix production, degradation, or further signaling mechanisms involving
fibroblasts or other cell types, and have been implicated as clinically-relevant soluble
markers of scar formation 73. In addition to direct synthesis of matrix proteins as
measured by PINP levels and secretion of matrix-degrading proteins as measured by
MMP levels, matricellular proteins POSTN, OPN, and THBS4 have been shown to
mediate fibrosis in pressure overload models by as in the case of OPN and THBS4 23,74,
or in fibroblast-specific ablation post-MI as in the case of POSTN 75,76, suggesting
possible sensitivity towards mechanical stress as well as prominent roles in matrix
turnover. Therefore, we included these outputs to provide a representative dataset of
mechano-chemo interactions that encompasses multiple fibrosis-related processes in
addition to the secretion of matrix proteins and proteases. Luminex assays were measured
using a MAGPIX magnetic bead reader (Luminex, Austin, TX). Absolute protein
concentrations were determined from standard curves for each analyte, and all
concentrations were normalized by total cell counts as determined above to account for
proliferation-related bias.
Agonist-stretch effect analysis
For each measured protein, contrasts between two sets of experimental groups
were assessed: (i) agonist treatments alone and controls (ΔT0), and (ii) combined agoniststretch treatments and controls (ΔTS). Contrasts for both sets were expressed as log 2(fold

85

change), and effect magnitudes were calculated as change between contrasts: 𝐸 =
|∆𝑇𝑆 − ∆𝑇 |. Effect directions were calculated as the difference between contrast
magnitudes: 𝐸 = |∆𝑇𝑆| − |∆𝑇 |. Signs of effect direction terms were used to determine
categories of combinatorial effects: a positive term denoted an additive effect of
combined treatment (i.e. stretch further increased or decreased protein secretion beyond
agonist treatment alone), and a negative term denoted a subtractive effect (i.e. stretch
suppressed the effect of agonist treatment alone). Individual contrasts that had opposite
signs (e.g. ΔT0<0 and ΔTS>0) were denoted as inverting effects.
Agonist-stretch sensitivity analysis
In a similar manner to effect analysis above, contrasts between two sets of
experimental groups were assessed: (i) agonist treatments alone and controls (ΔT 0), and
(ii) combined agonist-stretch treatments and samples subjected to stretch only (ΔT s).
Contrasts for both sets were expressed as log2(fold change), and sensitivity magnitudes
were calculated as the change between contrasts: 𝑆 = |∆𝑇 − ∆𝑇 |. Sensitivity
directions were calculated as the difference between contrast magnitudes: 𝑆 = |∆𝑇 | −
|∆𝑇 |. Signs of sensitivity direction terms were similarly used to determine categories of
sensitivity changes: a positive term denoted a sensitizing effect of stretch on agonist
treatment (i.e. stretch caused a greater response to agonist stimulation), and a negative
term denoted a de-sensitizing effect (i.e. stretch caused a dampened response to agonist
stimulation). Individual contrasts that had opposite signs (e.g. ΔT 0<0 and ΔTs >0) were
denoted as reversal effects.
Statistical analysis
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Statistical analyses were performed using the lme4 package in the R statistical
suite 77. mCFs were isolated from 8 groups of mice representing one biological replicate
each, and cells were equally divided between all experimental groups within each
replicate for N=8 replicates per experimental group. For each measured protein,
normalized concentrations were fit to a linear mixed-effect model in which biochemical
agonists and stretch states were modeled as fixed variables, and biological replicate was
modeled as a random variable. Analysis of deviance was used to assess the model
validity in comparison to a null model containing only random variables, using a type I
error rate of 0.05 for valid models. Two-factor ANOVA was used to test fixed variables,
Dunnett’s post-hoc tests were used for multiple comparisons between agonists and
respective controls, and Student’s t-tests with Bonferroni correction were used for
individual comparisons made in agonist-stretch effect and sensitivity analyses.
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CHAPTER 4
AIM 2: REFINE AND EMPLOY AN EXISTING, MANUALLY-CURATED
COMPUTATIONAL MODEL OF FIBROBLAST SIGNALING TO ACCURATELY
PREDICT FIBROTIC ACTIVITY AGAINST AVAILABLE SIGNALING DATASETS
4.1. Introduction
Controlling cardiac fibrosis remains a major challenge in developing long-term
treatments for patients suffering from myocardial infarction (MI). For a proportion of the
over 800,000 patients diagnosed per year 1, excessive hypertrophy and scar formation in
the non-infarcted myocardium can result in the development of heart failure, with
decreases in contractility, myocardial conductivity, and pump function leading to poor
rates of survival 2. Currently prescribed therapeutics for MI patients are designed to
reduce hypertrophy via several neurohormonal mechanisms including inhibition of
angiotensin II (AngII) and norepinephrine (NE) or increasing the bioavailability of
natriuretic peptides (NPs) 3, but no drugs have been approved for treating cardiac fibrosis
directly. Notably, scar formation serves a reparative function in post-MI wound healing
by replacing necrotic myocardium and preventing infarct expansion and cardiac rupture 4.
Therefore, developing therapeutics that limit excessive fibrosis to prevent the
development of heart failure while preserving beneficial scar tissue at the infarct site
would be a critical step towards improving long-term patient outcomes.
Tissue remodeling in the myocardium is a dynamic process in which the
accumulation of extracellular matrix proteins (e.g. collagens I and III, fibronectin) and
matricellular proteins are balanced by degradation via proteases such as matrix
metalloproteinases (MMPs). This balance is mediated largely by cardiac fibroblasts,
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which infiltrate the infarct site and assume an activated, synthetic phenotype to promote
matrix accumulation 5. A wide variety of biochemical factors regulate fibroblast behavior
such as AngII, transforming growth factor-β (TGFβ1), endothelin-1 (ET1), and various
inflammatory cytokines 6,7, but a growing body of research has demonstrated that
biomechanical factors such as circumferential tension and tissue stiffness are also critical
determinants of fibroblast behavior 8. Parallel transduction of biochemical and
biomechanical stimuli is integrated by fibroblasts through a complex signaling network in
which pathways interact via systems-level crosstalk and feedback mechanisms 9,10,
making prediction and control of fibroblast behavior in the post-MI environment highly
challenging.
Computational approaches for investigating cell signaling have shown promise
for discovering mechanisms-of-action underlying pathological states and drug treatments.
Previous models representing cardiac cell signaling as a network of interactions have
proven successful in generating detailed insight into cardiomyocyte contraction and
hypertrophy as well as fibroblast chemotransduction and various other biological systems
11–14

. Previous models have simulated cardiac and adventitial fibroblast activation and

pro-fibrotic activity in response to biochemical and biomechanical cues, although limited
exploration of mechanotransduction pathways in these models still leave unanswered
questions about the role of tension in regional matrix turnover 15,16. In this current study,
we expanded a model of fibroblast mechano-chemo signal transduction capable of
accurately predicting fibrosis-related protein expression in response to canonical
biochemical factors and mechanical tension. We examined the extent and dynamics of
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mechano-chemo interactions by simulating biochemical dose-response behavior under
varying levels of mechanical stimulation, finding that tension amplified, dampened, or
reversed fibroblast responses to individual biochemical cues. Comprehensive simulations
of fibroblast responses to over 23,000 combinatory drugs in low- or high-tension contexts
identified several drug combinations that adapted fibrotic activity to the local mechanical
state, demonstrating the potential of this model to act as a screening tool for targeted
therapeutics.
4.2. Results
Development of Fibroblast Mechanotransduction Network
To develop a fibroblast signaling model capable of sensing and transducing
dynamic tension, we performed a manual literature search of intracellular signaling
reactions related to fibroblast mechanotransduction and integrated our search with an
existing model of fibroblast signaling 15. Our extended model includes 9 cytokine inputs
known to mediate fibroblast activation post-MI as well as mechanical tension, which is
transduced via multiple mechanosensors including integrins, stretch-activated ion
channels, and the G-coupled protein receptor angiotensin type I receptor (AT1R) (Figure
4.1, see Figure B-1 for nodes added to the previous network). We also added several
outputs that have been recently shown to mediate myocardial remodeling, including
proMMPs 3, 8, and 12, tenascin-c (TNC), osteopontin, and thrombospondin-4

17–20

, as

well as autocrine feedback mechanisms found to regulate fibroblast activation 21–23. The
total network, consisting of 109 nodes and 174 reactions, was implemented as a logicbased ordinary differential equation (ODE) model using the open-source Netflux package
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as previously described 24 in which node activity levels and reaction weights are
normalized values between 0 and 1 (e.g. an activity of 0.5 represents 50% of maximum
activity). All model species, reaction logic, default reaction parameters, and supporting
references can be found in Supplementary File S1.
Model predictions were validated against an independent set of experimental
studies by comparing qualitative changes (i.e., increase, decrease, or no change) in node
activation to changes in protein activity measured in vitro. Parameter sweeps for halfmaximal effective concentrations (EC50) and Hill coefficients (n) identified default
reaction parameters for optimizing predictive accuracy (Figure B-2, see Materials and
Methods, Model Validation section for full description). For fibroblast-secreted outputs,
simulated responses to biochemical and mechanical stimuli correctly predicted qualitative

Figure 4.1. Schematic of expanded logic-based ordinary differential equation model of cardiac
fibroblast chemo-/mechano-transduction. Extracellular stimuli, intracellular signaling species,
transcription factors, and fibroblast-secreted outputs are represented as nodes (boxes, 109 total).
Directed edges represent activating and inhibiting reactions (arrows and T junctions respectively, 162
total) with AND logic indicated by circular nodes.
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changes in protein secretion in 81.8% (63/77) of simulations (Figure 4.2A). Additionally,
the model correctly predicted qualitative changes in activation levels of canonical
signaling intermediates for 80.5% (33/41) of simulations compared to experimental
studies (Figure 4.2B). Consistent with previous studies, the model predicted increased
expression of collagens, matricellular proteins, and protease inhibitors with exposure to
canonical agonists TGFβ1, AngII, platelet-derived growth factor (PDGF), tumor necrosis
factor-α (TNFα), and mechanical tension, and secretion of these pro-fibrotic species was
accompanied by increased MMP production. Disagreement between model predictions
and experimental studies were typically found for studies that reported either decreases or
no change in output expression with interleukin-1β (IL1), interleukin-6 (IL6), or NE
simulation. However, as described in the next section, these incorrect model predictions
could be rectified with the experimentally observed decreases under other input contexts.
Mechanical Tension Amplifies, Dampens, or Reverses Network Responses to Biochemical
Stimuli
Several previous experimental studies have established that combined
biochemical and biomechanical signals can interact to produce context-dependent
responses from fibroblasts

25–29

. But the full scope and mechanisms behind these

interactions are mostly unclear. We investigated interactions between tension and
individual biochemical stimuli computationally by simulating dose-response relationships
between biochemical inputs and all model nodes under increasing levels of tension, using
area under the curve measurements (AUC) as a metric for total change in activity. We
characterized interactions based on changes in each AUC from basal tension to increased
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levels of tension, categorizing nodes with increased AUC levels with tension as being
amplified, nodes with decreased AUC levels as being dampened, and nodes that changed
the direction of activation with tension (i.e. from net activation to net inhibition or vice
versa) as being reversed.
We found that these interactions were dependent on both the individual inputs as
well as the level of tension. Of the 9 biochemical model inputs, AngII, TGFβ1, IL1,
TNFα, PDGF, and ET1 all demonstrated sizable changes in dose-response behavior with
various levels of tension, based on a 5% change in AUC levels. Using this threshold, a
tension level of 0.5 (i.e. 50% of maximum stimulation) amplified, dampened, or reversed

Figure 4.2. Model accurately predicts qualitative changes in output expression and intermediate
activity as measured by independent in vitro studies. (A) Expression of cell-secreted outputs and
phenotypic markers (i.e. αSMA) were predicted in response to single biochemical stimuli and
mechanical tension and compared to an independent set of experimental studies found in literature (46
papers total). (B) Activation of intracellular intermediates representing major signaling pathways were
predicted in response to single stimuli and compared to independent experimental studies measuring
changes in activity (e.g. by phosphorylation, 27 papers total). All model predictions were categorized
based on a ±5% change in activity levels compared to baseline conditions.
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an average 56.7% of node AUCs towards these six inputs compared to basal levels of
tension (Figure 4.3A), and a tension level of 0.9 (i.e. 90% of maximum stimulation)
sizably altered an average 60.4% of node AUCs (Figure 4.3B). We additionally
compared network-wide changes in AUCs between levels of tension as probability
distributions, finding that tension significantly altered distributions of dose-response
behavior of these six inputs at tension levels of both 0.5 and 0.9 (Figures B-3 and B-4).
Conversely, tension altered the dose-response behavior of very few nodes with IL6, NE,
and NP stimuli, with only 7.03% of node AUCs on average changing sizably towards
these inputs for a tension level of 0.9 (Figure B-3A). We found that although tension
levels of 0.5 and 0.9 significantly altered probability distributions of changes in AUC for
these inputs (Figure B-4), the relatively small population of nodes with sizable changes
suggests that these inputs were largely unchanged with tension., In support of their
insensitivity to tension, we found that IL6, NE, and NP all displayed lower degrees of
network connectivity compared to the remaining inputs as evidenced by lower measures
of closeness centrality and higher measures of average shortest path length and
eccentricity (Figure B-3B). While our previous work has shown that these measures do
not correlate with functional measures such as sensitivity studies 15, these topological
trends point to a less-influential role of tension for inputs that are relatively less
connected to mechanotransduction pathways in the network.
Within inputs that demonstrated tension-modulated dose-response behavior, the
level of tension applied mediated different types of interactions. Moderate tension levels
(reaction weights 0.2-0.5) largely amplified the effects of inputs; of the six inputs
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Figure 4.3. Network-wide responses to biochemical stimuli are dependent on the tensional
context. (A-B) Dose-response curves were simulated under elevated levels of tension with incremental
doses of each biochemical input, and changes in area under normalized dose-response curves (ΔAUC)
were calculated for all nodes in the model in comparison to basal dose-response simulations (i.e.
tension = 0.1). Reversal cases were identified based on opposing AUC signs between basal and elevated
tension simulations, i.e. nodes that exhibited a positive AUC with basal tension and a negative AUC
with elevated tension, and vice versa. (C-E) Examples of mechano-chemo interaction categories
identified from network-wide analysis in (A) and (B). Normalized dose-response curves for procollagen
I (proCI) expression are shown following simulations with incremental doses of NE (A), TGFβ1 (B),
and IL1 (C) under static levels of tension. (F-H) Sub-networks regulating the mechano-chemo
interactions shown in (C-E) were determined by manual examination of node activity levels following
dose-response simulations using NE (F), TGFβ1 (G), and IL1 (H) stimuli under basal and elevated
levels of tension.
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demonstrating tension-mediated changes in dose-response behavior, 51.8% of node
AUCs were amplified at a tension level of 0.5 on average while 4.43% and 0.46% of
node AUCs were dampened or reversed on average, respectively (Figure 4.3A). High
levels of tension (reaction weights 0.6-0.9) largely dampened network responses to these
inputs, with 56.4% of nodes on average decreasing AUCs with the same six inputs
compared to 2.75% and 1.22% of node AUCs showing sizable amplification or reversal,
respectively (Figure 4.3B). Repeated analyses with incremental levels of tension
suggested that this change in tension-mediated behavior occurred at a tension reaction
weight of 0.6, with an average 40.3±12.1 nodes changing from amplification to
dampening at this level for these inputs compared to a reaction weight of 0.5 (Figure B3A). These changes in sensitivity were indicative of network interactions between tension
and biochemical stimuli; we observed that NE-mediated inhibition of procollagen I
expression was amplified by tension (Figure 4.3C), which can be explained by the logical
requirement for tension-induced smad3 activation for effective inhibition by cAMP
response element-binding protein (CREB) (Figure 4.3D). We also found that tensionmediated desensitization of procollagen I expression towards TGFβ1 can be explained
mechanistically by a common autocrine feedback loop integrating both tension and
TGFβ1 signals via a reactive oxygen species (ROS)-activator protein 1 (AP1) signaling
axis (Figure 4.3E-F).
Notably, 4.40% of nodes reversed the direction of dose-response curves with IL1
stimulation with a tension reaction weight of 0.6 or greater compared to baseline tension
levels, including intermediate nodes involved in TGFβ1 signaling (TGFβ1R, NOX,
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ROS), mitogen-activated protein kinase (MAPK) signaling (TRAF, ASK1, MKK3,
MKK4, ERK) as well as the expression of procollagen I (Figure 4.3G). By comparing
these reversed nodes to the network topology, we found that IL1 exerted both stimulatory
effects via activation of AP1 and suppressive effects via activation of BMP and activin
bound inhibitor (BAMBI), with suppressive behavior dominating procollagen I
expression at high IL1 levels (Figure 4.3H). While low tension levels allowed for IL1mediated activation of AP1 and downstream procollagen expression, high levels of
tension alone were sufficient to saturate AP1 levels, eliminating the stimulatory effects of
IL1 and causing high cytokine doses to inhibit expression. Our model predicts a high
degree of interaction between tension and biochemical stimuli, suggesting that the effects
of current and potential therapeutics for cardiac fibrosis may be substantially altered by
local tension.
Network Perturbation Analysis Reveals Differential Roles of Tension
While targeted experimental studies of fibroblast signaling have identified
numerous pathways mediating extracellular matrix turnover, it is still unclear whether
certain mechanisms influence cell behavior more than others and whether these
influences are altered with changes in the mechanical context. Using our systems-level
model, we calculated changes in network activity following comprehensive knockdowns
of individual nodes to functionally assess network-wide effects of perturbations. We
calculated each node’s “knockdown influence” as the summed magnitudes of all changes
in other nodes’ activities upon knockdown of that particular node, and we calculated each
node’s “knockdown sensitivity” as the summed magnitudes of all changes in that
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particular node’s activity with knockdown of all other nodes (see Materials and Methods,
Network Perturbation Analysis section for full description). We repeated simulations for
low, medium, and high levels of tension (reaction weights 0.25, 0.5, and 0.75
respectively) and selected for the top 10 scoring nodes in both influence and sensitivity,

Figure 4.4. Network perturbation analysis reveals influential pathways of fibroblast
mechanotransduction. (A-C) Changes in activity levels for top 10 sensitive nodes with simulated
knockdown of top 10 influential nodes at low (A), medium (B), and high (C) levels of tension. Nodes
were ranked based on knockdown influence (rows) and knockdown sensitivity metrics (columns), and
changes in activity levels with perturbations are compared un-perturbed (i.e. no knockdown) conditions
at each tension level. (D-E) Comparison of top-ranked sensitive and influential nodes between levels of
tension. Nodes shown reflect all unique nodes that ranked in the top 10 based on knockdown sensitivity
(D) or knockdown influence (E) between all levels of tension simulated, and colors reflect nodes that
were top-ranked starting at low tension (green), medium tension (orange), and high tension (purple).
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which indicated differentially responsive sets of nodes (Figure 4. 4A-C, see Figure B-5
for network-wide sensitivity results).
At low levels of tension, knockdowns produced only small changes in node
activities and correspondingly low influence and sensitivity values (Figure 4.4A, D, E).
This is not surprising given all node activities are relatively low at this close-to-baseline
context. In contrast, medium and high levels of tension demonstrated marked activity
changes with knockdown perturbations and exhibited common influencers and unique
sets of sensitive nodes. Under medium tension levels, knockdown of AT1R exhibited
relatively broad inhibition compared to other top influencers, decreasing activity levels of
several proMMPs, fibronectin, TNC, and members of the IL6 pathway by an average of
35.9±5.4% (Figure 4.4B). While other top influencers mediated smaller reductions in
activity across the top 10 sensitive nodes, NADPH oxidase (NOX), ROS, AP1, and c-Jun
N-terminal kinases (JNK) demonstrated an increased capacity to mediate proMMP2,
proMMP14, and smad7 levels under medium tension. Under high tension conditions,
however, these four nodes ranked as the highest influencers network-wide, mediating
decreases in activity for members of the MAPK pathways (80.6±4.3% reduction in
activity on average), actin cytoskeleton-related signaling (68.7±22.2% average
reduction), and outputs procollagen I, procollagen III, and proMMP1 (30.9±8.9% average
reduction) (Figure 4.4C). Several members of the TGFβ1 pathway demonstrated similar
trends in regulation including latent TGFβ1, suggesting that autocrine feedback may play
a role in regulation at high tension.
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Rankings of knockdown influence and knockdown sensitivity across all tension
conditions suggest that influential mechanisms and their effects were dependent on the
tensional context (Figure 4.4D-E). While ROS, AP1, JNK, and TGFβ1-related node
knockdowns displayed an overall lower degree of influence on the network compared to
knockdown of AT1R for low- and medium-tension conditions, knockdown of these nodes
under high levels of tension mediated large changes in network-wide activity with
knockdown influence levels increasing by up to 4.9-fold compared to medium tension
(Figure 4.4D). Similarly, different sets of nodes were more sensitive towards
perturbations between tension levels, with lower knockdown sensitivity levels of
proMMPs 2, 9, and 14 and higher levels of proCI, proCIII, and proMMP1 at high tension
relative to medium tension (Figure 4.4E). These behaviors suggest that tension acts via
different pathways at different levels of stimulation, and cell behavior in a dynamic
mechanical environment may not be dictated by a single mechanism alone.
Fibroblast Signaling Network Predicts Behavior of Current Post-MI Therapeutics
Current post-MI therapeutics aim to reduce cardiac hypertrophy via inhibition or
activation of neurohormonal signaling 3, both of which also alter cardiac fibroblast
behavior and extracellular matrix turnover as a side effect. To test the hypothesis that our
model can reproduce experimentally observed effects of current post-MI drugs on
fibroblast behavior, we simulated the effects of three drug classes by modulating the
maximum activation parameters of individual nodes: (1) angiotensin receptor blockers
(ARB) were simulated via knockdown of the AT1R node, (2) neprilysin inhibitors
(NEPi), which increase the bioavailability of natriuretic peptides, were simulated via

107

overexpression of the NP node, and (3) ARB-NEPi combination drugs were simulated
via combination of (1) and (2) above (see Materials and Methods, Drug Effect
Comparisons section for full description and Table 1 for simulation parameters).
We tested whether our model could discern both individual and synergistic effects
of post-MI drugs by simulating dose-response relationships between the three drugs
above and procollagen I expression. Von Lueder and colleagues previously found that

Figure 4.5. Model-predicted effects of current post-MI drug treatments reflect experimental
evidence from independent case studies. (A) Comparison of model-predicted effect of ARB doses
with or without NEPi treatment on procollagen I expression with measurements of collagen synthesis in
cardiac fibroblasts in vitro. Doses for model predictions reflect negative modifiers of the ymax parameter
of AT1R, doses for the in vitro study reflect doses of valsartan in μM, and values reflect fold changes
compared to control conditions. (B) Comparison of model-predicted effects of ARB and ARB-NEPi
treatments on three output nodes with corresponding gene expression measurements of cardiac
fibroblasts in vitro. Values reflect fold changes compared to TGFβ1/AngII/atrial NP (T/A/A)
conditions. (C) Comparison of model-predicted effects of ARB treatment on five output nodes in
representative remote (LVC) and infarct (LVI) zones with corresponding gene expression
measurements in post-MI mouse hearts. Values reflect fold changes compared to control (non-
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valsartan primarily attenuated collagen expression in cardiac fibroblasts following
exposure to AngII, with neprilysin inhibitor LBQ657 acting in a synergistic manner with
valsartan but not altering collagen expression alone 30. Our model independently
confirmed this conclusion, as increasing levels of AT1R knockdown combined with NP
overexpression further attenuated procollagen I expression compared to AT1R
knockdown alone (Figure 4.5A). We additionally observed that NP overexpression alone
did not appreciably alter procollagen I expression while AT1R knockdown suppressed
expression to near-control levels, further supporting the authors’ conclusions of the
dominant mechanism for combinatory ARB-NEPi drugs (Figure B-6). This inability of
NEPi class treatments to independently regulate AngII signaling can be attributed to a
lack of overlap between AngII and NP pathways; AngII stimulation causes the activation
of canonical and non-canonical TGFβ1 signaling via production of latent TGFβ1, and
although NP overexpression inhibited canonical activation of smad3 by TGFβ1R, noncanonical activation and downstream procollagen expression via Akt remained
unchanged. Knockdown of AT1R inhibited both pathways of TGFβ1 signaling, thereby
reducing procollagen I levels in a dose-dependent manner.
We next assessed our model’s capability to predict the expression of multiple
gene products and potential mechanisms-of-action following perturbation by the drug
classes above. We compared model predictions of three model outputs following ARB or
ARB-NEPi treatments to a recent study by Burke and colleagues, who observed
synergistic inhibition of genes encoding alpha-smooth muscle actin (αSMA), collagen I,
and periostin by combinations of valsartan and the NEPi sacubitril 31. We found that
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model simulations predicted a similar synergistic inhibition of all three gene products in
high TGFβ1/AngII/atrial NP (T/A/A) conditions , and although simulations of ARB
treatment alone reduced output expression as concluded in the von Lueder study,
combinatory treatment in this context further reduced all three model outputs to an
average 16.6% of positive controls (Figure 4.5B). The authors additionally suggested that
sacubitril mediated on fibroblast behavior via activation of PKG and inhibition of the
small GTPase Rho, with patient-derived fibroblasts responding to sacubitril or valsartansacubitril treatment with decreased fractions of active Rho 31. Upon incorporating this
interaction into the model reaction logic, model-predicted activation levels of PKG and
Rho following NEPi and ARB-NEPi treatments confirm this mechanism-of-action by
NP-related treatments, with ARB-only treatments failing to change activity levels of both
PKG and Rho compared to TGFβ1/AngII/NP controls (Figure B-6). These comparisons
demonstrate the ability of the model topology to predict both output-level changes with
drug treatments as well as identify mechanisms-of-action compared to experimental data.
By incorporating known mechanotransduction pathways into network topology,
we expanded our model’s capability to predict responses to drug treatments in local
cardiac tissue based on differences in tension. This capability is particularly important in
the context of an infarcted left ventricle wherein fibroblasts in the infarct scar are
subjected to heightened tensile stretches compared to the fibroblasts in the remote, noninfarcted myocardium that are subjected to normal myocardial tensions 32. We
investigated this capability by simulating the expression of model outputs in response to
valsartan treatment in both low- and high-tension contexts, while setting the model
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cytokine inputs to experimentally matched post-infarct levels as previously described 13.
We compared model output expressions to a study by Ramirez and colleagues, who
observed significant differences in fibrosis-related gene expression between infarct and
remote zones and negligible effects of valsartan treatment alone using a mouse model 33.
Model predictions generally agreed with their findings, as the degree of tension sizably
altered the expression of procollagens, matricellular proteins, and connective tissue
growth factor (CTGF) relative to changes in expression with valsartan treatment (Figure
4.5C). While we observed variable degrees of error between simulated levels of
individual outputs and measured gene expression, our model accurately predicted
qualitative differences in drug response based on regional tension.
Computational Drug Screen Predicts Candidates for Mechano-Adaptive Therapy
The infarcted ventricle presents a spatially dependent need to maintain
extracellular matrix content at the infarct region while limiting scar formation in remote
regions. While targeted experimental studies involving individual or combinatory postMI drugs demonstrate efficacy either for individual cell types or bulk tissues, there is
currently no evidence of current or potential drugs showing variable effects based on
regional mechanics. Our analysis of mechano-chemo interactions above suggests that
regional mechanics can alter the effects of positive and negative perturbations, so we
investigated whether simulated drug treatments for low- and high-tension conditions
could identify drug targets that provide regional therapeutic effects post-MI.
Specifically, we sought potential drug targets that adapt matrix-related expression to the
regional tension by increasing pro-matrix expression in high tension and decreasing
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Figure 4.6. Comprehensive drug screen identifies mechano-adaptive candidates for post-MI
fibrosis. (A) Target combinations meeting preliminary threshold for mechano-adaptive behavior (i.e.
promoted negative change in matrix content in low tension and positive change in matrix content in
high tension) were scored based on rankings of matrix content changes in low- and high-tension
simulations. Boxed values represent scores of 13 candidates examined in panels (B) and (C). (B-C)
Changes in output expression predicted with mechano-adaptive candidates under tensional contexts,
expressed as changes in node activity compared to non-perturbed conditions for each level of tension.

expression in low tension. To that end, we performed a comprehensive screen of
individual and combinatory drug targets involving single node knockdown and
overexpression and dual node knockdown, overexpression, and knockdownoverexpression combinations for a total of 23,762 drug treatments.
We used a rank-based scoring strategy to score drug treatments based on changes
in output expression compared to non-perturbed conditions, calculating a matrix content
metric from individual output nodes and ranking treatments by the capacity to decrease or
increase this metric with low or high tension stimuli respectively (see Materials and
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Methods, Mechano-Adaptive Drug Screen section for full description). While no
individual drug target perturbation achieved these opposing responses (Figure B-7), we
found that 450 of 23,544 combinatory perturbations qualitatively altered matrix content
based on regional tension, and we identified a cluster of 13 perturbations that scored
highly in adapting expression of fibrosis-related outputs to regional tension (Figure 4.6A,
boxed combinations). This cluster primarily involved dual knockdown of nodes related to
the IL6 and Akt/mTOR signaling pathways, with 8 of 13 treatments targeting members of
these pathways (Figure 4.6B-C). While most of these combinations exerted relatively
minor changes in individual output levels compared to un-perturbed conditions, these
combinations primarily acted to increase expression levels of procollagens, periostin, and
PAI1 while decreasing proMMPs 1, 3, and 8 with high tension, thus aiding scar
formation in high-tension conditions only (Figure 4.6C). Additionally, seven treatments
showed evidence of increasing proMMP levels and decreasing procollagen and periostin
levels with low tension (Figure 4.6B), suggesting that inhibition of the IL6 and
Akt/mTOR pathways may simultaneously reduce pro-fibrotic matrix expression in
remote tissues with low levels of tension.
4.3. Discussion
Spatial control of myocardial fibrosis after MI has remained a challenge due in
part to simultaneous signaling from biochemical cues and regional mechanics, both of
which mediate fibroblast activation and synthesis of extracellular matrix components 34.
In the current study, we employed a computational model of fibroblast signaling to
predict the regional expression of fibrosis-related proteins by incorporating known
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signaling pathways related to canonical biochemical agonists and mechanical tension. We
found that the model correctly predicted qualitative changes in fibrotic protein expression
with a similar degree of accuracy compared to other logic-based ODE networks 16,35, and
model simulations of current therapeutics such as ARB and ARB-NEPi class drugs
accurately reproduced trends in output gene expression observed in cardiac fibroblasts
and a post-MI mouse model. Functional analyses identified influential mechano-chemo
interactions and preferential pathways of mechanotransduction such as the production of
latent TGFβ1 via a NOX-ROS-AP1 signaling axis. We additionally used the model as a
targeted screening tool by simulating fibroblast responses to drug combinations in
regions of low and high tension, and we identified 13 combinations that adapted the
expression of matrix-related proteins to the regional mechanical environment. Our results
suggest that this computational approach can aid the development of effective therapies
for pathological tissue remodeling which involves simultaneous changes to paracrine
signaling and tissue mechanics, and model predictions can generate targeted hypotheses
for controlling fibroblast behavior for further experimental investigation.
Crosstalk Between Biochemical and Biomechanical Factors in Fibroblast Signaling
Increased circumferential stretch in the post-MI infarct zone has been established
as both a direct regulator of fibroblast activation and an indirect regulator of biochemical
signaling pathways via crosstalk mechanisms 36,37. Experimentally assessing the systemwide extent and dynamics of these interactions would be exceedingly challenging due to
time and resource constraints; however, biological network models can overcome this
challenge by comprehensively simulating biochemical dose-response relationships under
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a variety of mechanical contexts. Our findings indicate that tension exerts a wide
influence on biochemical signaling in fibroblasts by either amplifying responses to
biochemical stimuli in the case of NE, dampening responses in the case of TGFβ1, and
even reversing responses in the case of IL1.
The three example cases above share a common connection in tension-mediated
expression and activation of latent TGFβ1, an autocrine feedback mechanism shown to
influence cardiac fibroblast phenotypes 10,27. We found that NE acted to antagonize latent
TGFβ1 expression via a cAMP-PKA-CREB signaling axis. Activation of CREB through
the use of phosphodiesterase inhibitors has previously been shown to antagonize fibrotic
expression of lung and cardiac fibroblasts 38,39 as well as cardiac fibrosis in a pressure
overload mouse model 40 , suggesting a potential mechano-responsiveness of this
mechanism. Simulated fibroblast responses to TGFβ1 indicated a synergistic response
under tension with latent TGFβ1 activation and output expression occurring for lower
input doses. This trend is consistent with experiments involving valvular myofibroblasts,
which exhibited earlier and greater induction of bioactive TGFβ1 and aSMA protein
levels when subjected to combined tension/TGFβ1 compared to either stimulus alone 26.
We additionally found that stimulation with IL1 produced opposite effects
depending on the level of tension, with IL1 increasing procollagen I expression for low to
medium tension levels and decreasing expression for high tension levels through
activation of BAMBI and downregulation of downstream targets of TGFβ1R. As a
positive regulator, IL1 upregulates MAPK and NFkB signaling pathways via myeloid
differentiation factor-88 (MyD88) 41, and both IL1R-/- and MyD88-/- mice display reduced
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fibrosis and progression towards heart failure in a model of acute myocarditis 42. As a
negative regulator, IL1 upregulates the expression of BAMBI to act as a decoy receptor
for TGFβ1, thereby reducing downstream signaling 43. In BAMBI-/- mice, pressure
overload worsened fibrosis compared to wild-type mice in a TGFβ1-dependent manner,
suggesting that this negative regulation is dependent on both mechanical stress and
TGFβ1 stimulation 44. IL1 has additionally been shown to reverse the myofibroblast
phenotype in valvular interstitial cells with culture on stiff substrates 45, further
suggesting that context-dependent regulation by IL1 may be a determining factor of
fibroblast phenotype. Our analysis of mechano-chemo interactions above suggests that
computational approaches can reveal context-specific mechanisms of disease progression
and reinforces the need to account for various environmental factors (such as local
biomechanics) in developing therapeutic strategies.
Influential Mechanisms Controlling Fibroblast Mechanotransduction
Fibroblasts transduce changes in their local mechanical environment using both
well-known mechanosensors such as integrins and newly-discovered mechanisms such as
piezo channels and actin-dependent translocation of YAP/TAZ 36. While these
mechanisms have all been shown to alter cell phenotypes individually, it is still unclear as
to whether individual pathways influence cell behavior over others. Network perturbation
analysis predicted that tension is primarily mediated by an autocrine feedback mechanism
in which a NOX/ROS/JNK/AP1 signaling axis stimulates latent TGFβ1 expression to
drive further NOX activation as well as procollagen expression via smad3. The secondary
activation of TGFβ1 has been demonstrated for various stimuli in fibroblasts such as
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TNFα and AngII 46,47 as well as for other cell types by influencing changes in phenotype
related to extracellular matrix deposition and angiogenesis 48–50. Inhibition of NOX2 and
NOX4 in AngII-infusion mouse models has additionally been shown to attenuate
interstitial collagen deposition, further implicating NOX/ROS signaling as a central
influencer of cardiac fibrosis 51,52. Our model prediction that this pathway primarily
influences fibrosis-related protein expression suggests that perturbation of this pathway
may induce larger reductions in cardiac fibrosis compared to others, and experimental
studies investigating this behavior could provide a basis for developing targeted antifibrotic therapies.
Fibroblast Network Model as a Screening Tool for Targeted Therapeutics
The heterogenous nature of myocardial infarctions creates a clear need for
regionally targeted therapies for tissue remodeling, with the infarct zone requiring scar
formation to provide local structural integrity and remote zones requiring scar
downregulation to prevent adverse tissue stiffening. Loss of cardiomyocytes additionally
presents different mechanical conditions between the infarct and remote zones 32, and our
model predictions above and experimental evidence suggest that myofibroblast-mediated
tissue remodeling is dependent on this mechanical context 53,54. Previous trials of antifibrotic therapies have demonstrated the need to account for local increases in
circumferential stretch in infarcted tissue. Studies inhibiting known mediators of
excessive fibrosis such as TGFβ1, osteopontin, and TIMP3 have shown increased risk of
left ventricular thinning and cardiac rupture, early complications associated with
impaired scar formation at the infarct zone 55–57 - an indication that therapies designed to
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inhibit global fibrosis are not sufficient to promote healthy scar formation where it is
needed. A further complication of post-infarct fibrotic control is the lack of evidence of
regional differences in tissue remodeling for current and potential drugs. While our
comparisons of model-predicted and experimentally tested ARB and NEPi treatments
above demonstrated the inhibitory effects of these drugs in a single context, not enough
evidence exists to determine whether these drugs produce therapeutic effects in both
remote and infarcted zones.
We investigated the ability of our model to predict regional effects of drug
treatments based on regional mechanical tension, and our computational screen of 23,762
drug treatments yielded 13 candidates that adapted expression of extracellular matrixrelated proteins to the regional tension. These candidates implicated the IL6 and
Akt/mTOR signaling pathways as well as the IL1/cAMP and MRTF/SRF pathways as
mediators of mechano-adaptive behavior. Perturbations involving the IL6 and IL1
inflammatory pathways individually have yielded mixed results clinically; while several
animal studies and clinical trials perturbing IL6 and IL1 signaling have concluded that
knockdown of these pathways suppresses cardiac fibrosis and mediates gain of function
due to MI or factors associated with MI 58–60, others have concluded that IL6 and IL1
knockdown exacerbate fibrosis post-MI or in response to MI-associated biochemical
factors 7,61,62. The results from these studies indicate that the influence of these pathways
on tissue remodeling is highly context dependent with varying responses between
treatment time courses and methods of antagonism, and our drug screen indicates that
mechanical signaling additionally modifies cellular and tissue responses to these drugs.
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While we found no clinical evidence of tissue remodeling in response to the modelpredicted drug combinations above, these results suggest that pairing of antiinflammatory treatments with those for additional signaling pathways may provide an
additional advantage in controlling regional cardiac fibrosis, and our predictions provide
testable hypotheses for further investigation. Moreover, this model-based approach
towards target discovery provides substantial value for potential drug development by
focusing efforts on drugs or drug combinations with strong mechanistic evidence of
therapeutic efficacy. This model and approach can additionally be expanded to
investigate fibrosis across multiple disease states and for individual patient conditions to
stratify patients based on predicted responses to current drugs or to identify drug
candidates for subpopulations of patients.
Study Limitations and Future Directions
One major limitation of the current study stems from the need for quantitative
predictions of fibroblast signaling processes and matrix production. While the current
model was able to make semi-quantitative predictions of cell behavior based on network
topology and normalized reaction parameters, data-driven reaction parameters are
necessary both to fully investigate mechanisms-of-action of fibrotic activity and to relate
signaling processes to experimental measures of fibrosis. Phospho-proteomic datasets
generated using methods such as reverse-phase array provide direct analogs to
intracellular protein activation or inhibition as well as the scope of measurements
required for systems-level modeling, and previous studies have demonstrated the utility
of these datasets in inferring cell signaling networks and fitting literature-curated network
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parameters 63–65. Future implementation of in vitro or clinical phospho-proteomic data
would improve the accuracy of model predictions and reveal additional mechanistic
insight into fibroblast behavior in the post-MI environment.
An additional limitation of the current model is that of scope as it relates to both
cell signaling processes as well as additional levels of regulation. While the current
model was developed based on direct experimental evidence of signaling interactions
stemming from selected biochemical and mechanical stimuli, we must acknowledge that
additional stimuli and signaling pathways play a role in cardiac fibroblast signaling, such
as interferon-γ and epidermal growth factor receptor signaling pathways 66,67. While not
meeting our requirements for inclusion (see Materials and Methods, Fibroblast Signaling
Model Development section for criteria), we expect these additional signaling
mechanisms to aid in model predictions across the diverse range of stimuli represented in
vivo. It is also important to note that a variety of biomechanical factors alter fibroblast
behavior in the post-infarct environment in addition to circumferential stretch (classified
as “mechanical tension” in the current study), such as tissue stiffening, compression, and
radial and longitudinal stretch 68. While these applied loads are sensed and transduced via
similar mechanisms as circumferential stretch, the type, magnitude, and directionality of
applied loads differentially mediate fibroblast behavior and matrix turnover 69,70, and thus
a more robust understanding of the interactions between biomechanical stimuli is needed.
Lastly, much evidence exists to suggest that many additional dimensions of regulation
mediate cardiac fibrosis including transcriptional regulation 71, remodeling of collagen
fibers 72, paracrine signaling involving inflammatory cells, immune cells and myocytes 73,
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and additional modes of cell signaling (e.g. microRNA, matrix degradation products)
74,75

. Several groups have made progress in modeling regulation within these levels in the

heart 76–78, and while incorporating all factors into a model-based approach is a nontrivial effort, a combined, multi-dimensional approach will ultimately be necessary to
fully predict tissue remodeling given the range of variables involved in post-infarct
wound healing.
Through our simulated studies of fibroblast signaling and fibrotic activity above,
we demonstrated the utility of computational models of mechano-chemo signal
transduction in identifying mechanisms-of-action governing cell behavior in complex
environments. While in vitro and in vivo evidence validating these results are crucial for
translating this mechanistic insight into clinical solutions for cardiac fibrosis, this modeldriven approach can be advantageous in focusing experimental efforts towards promising
candidates that limit scar formation to regions where it is beneficial to do so. Excitingly,
our simulations identified 13 novel drug target pairs whose modulation resulted in
desirable mechano-adaptive effects - namely, an increase in matrix accumulation within
the infarct zone (where scar material is beneficial to maintain structural integrity) and a
simultaneous decrease in matrix within the remote zone (where scar material is
detrimental to myocardial mechanical and electrical function). Given the broad
significance of the involved pathways in many different cell types, our computational
predictions also suggest that similar mechano-chemo-signaling interactions are likely
present across many cell types and tissues, potentially confounding the translation of in
vitro findings to in vivo applications where the mechanical context is strikingly different.
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Therefore, predictive models integrating both modes of signal transduction represent a
critical step towards discovering targeted therapeutics across many disease states
involving complex environmental signals. Future phospho-proteomic studies of fibroblast
signaling in combination with targeted studies of influential signaling pathways will both
enable further development of targeted treatments for cardiac remodeling and enable
therapeutic development for a range of fibrosis-related diseases.
4.4. Materials and Methods
Data and Code Availability
The code generated during this study is available at GitHub
(https://github.com/SysMechBioLab/Fibroblast_Signaling_Network_Model). The
published article includes all model and validation databases generated or analyzed
during this study.
Fibroblast Signaling Model Development
Our previously published model of cardiac fibroblast signaling was expanded
using a manual literature search of over 100 peer-reviewed studies to include newly
identified proteins and/or signaling pathways associated with fibroblast
mechanotransduction, as well as several secreted proteins newly-associated with cardiac
fibrosis. New individual proteins (model nodes) and signaling reactions (edges) were
identified from studies that concluded direct interactions between proteins altering
protein activity (e.g. by phosphorylation). New nodes and/or edges were included if at
least two independent studies contained evidence of either activation of a node or
activation of another species by a node in either cardiac or other fibroblast subtypes. As
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previously described 12,15, the final network was implemented as logic-based ordinary
differential equations in which activity levels of all nodes were modeled as a system of
Hill equations, and all activity levels and input stimuli were represented as normalized
values between 0 and 1. Logical NOT, AND, and OR gates were used for inhibitory and
complex signaling interactions by applying logical operations 1 − 𝑓(𝑥), 𝑓(𝑥)𝑓(𝑦), and
𝑓(𝑥) + 𝑓(𝑦) − 𝑓(𝑥)𝑓(𝑦) to Hill equations respectively. The system of differential
equations was constructed using the open-source Netflux package for MATLAB
(https://github.com/saucermanlab/Netflux), and all subsequent analyses were conducted
using MATLAB (Mathworks, Natwick MA). Visualizations of the full network and subnetworks were created using Cytoscape software 79.
Model Validation
Qualitative changes in select model outputs and signaling intermediates were
compared between model predictions and independent experimental studies. A set of
studies independent from model development (47 papers total) were selected based on
direct measurement of either output secretion or activity of a signaling intermediate in
response to a single input stimulus in fibroblasts. Outputs included in this set were either
collagens, matrix proteases, protease inhibitors, matricellular proteins, autocrine signaling
species, or αSMA as a marker of fibroblast activation. Intermediates included were
limited to members of canonical signaling pathways (i.e. Akt, CREB, ERK, JNK, p38,
PKC, smad3, ROS), and only intermediates with direct measurements were included in
the final set. Model predictions were performed by simulating basal conditions (all input
weights = 0.1) for 80 s, followed by simulating single input stimuli (weight = 0.8) for an
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additional 240 s in order to allow for the system to reach steady-state activity levels.
Because studies used for validation conducted in vitro experiments on tissue culture
plastic, a tension input weight of 0.4 (40% of maximum stimulation) was used for all
validation simulations. Changes in intermediate and output node activity from basal to
stimulated conditions were binned into either “increase”, “decrease”, or “no change”
categories using ± 5% change in activity levels, which has been shown previously to
distinguish qualitative changes in behavior for single-stimulus simulations 12,16. To fit
default model parameters to best describe experimental data, parameter sweeps of Hill
coefficient (n) and half-maximal effective concentration (EC50) were conducted to
maximize the accuracy of model predictions, using the percentage of correct predictions
as a metric. Maximum activation levels (Ymax) were set to a default value of 1, and time
constants (τ) were set to default values of either 0.1, 1, or 10 corresponding with species
involved in intracellular signaling reactions, ligand-receptor reactions, or transcriptiontranslation events respectively. Reaction weights (w) were set to default values of 1 with
the exception of autocrine feedback-associated reactions, which were set to default values
of 0.8 due to the lowered probability of these reactions resulting diffusion of output
proteins or sequestering by the extracellular matrix 10. Values for n and EC50 found to
maximize predictive accuracy were used with the other described parameters for all
subsequent simulations. All model species, reactions, and assigned parameters are
available at the GitHub URL above.
Mechano-Chemo Interaction Analysis
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Dose-response behaviors of biochemical stimuli were simulated for incremental
levels of the ‘tension’ input reaction to assess interactions between mechanical and
biochemical stimulations. For 0.1 increments in tension reaction weight ranging from 0.1
(10% of maximum stimulation) to 0.9 (90% of maximum stimulation), steady-state
activity levels of all nodes in the network were simulated following stimulation of each
biochemical input reaction (AngII, TGFβ1, IL6, IL1, TNFα, NE, PDGF, ET1, and NP)
for 240 s, ranging in reaction weight from 0 to 1 in 0.01 increments. The resulting doseresponse curves were normalized to steady-state activity levels for a biochemical input of
0, and the total response of each node to a biochemical stimulus was calculated as the
area under the normalized curve (AUC). Changes in AUC due to tension (ΔAUC) were
calculated for each tension level as the difference between AUCs with added tension and
with baseline tension (tension = 0.1). Sizeable mechano-chemo interactions were
identified using a threshold of ±5% in ΔAUC. ΔAUCs greater than or equal to 5% were
categorized as amplifying interactions (tension increases node response to a biochemical
stimulus), ΔAUCs less than or equal to -5% were categorized as dampening interactions
(tension decreases node response), and AUCs with opposite signs between baseline and
tension conditions and exceeded the threshold of ±5% were classified as reversal
interactions (tension causes biochemical stimulation to exert the opposite effect on node
activity). This threshold has been shown previously to distinguish qualitative changes in
activity levels with individual node perturbations 12,16, and while these studies did not use
an integrated AUC metric for comparison, our comparison of AUCs requires greater peak
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activation levels to meet the threshold, thereby imposing a stricter comparison than these
previous studies.
To compare the extent of interactions between tension levels for each input, twosample Kolmogorov-Smirnov tests were conducted for distributions of ΔAUCs,
comparing (1) distributions for tension = 0.2 vs. tension = 0.5; (2) distributions for
tension = 0.2 vs. tension = 0.9; and (3) distributions for tension = 0.5 vs. tension = 0.9.
Corrections for multiple comparisons were made using the Benjamini-Hochberg
procedure 80, and adjusted p-values are displayed in Figure B-4. As an additional measure
supporting the input-related differences in interactions found above, topological network
parameters were computed using the NetworkAnalyzer plugin for Cytoscape 81.
Network Perturbation Analysis
To identify influential signaling mechanisms across various mechanical contexts,
a series of node knockdowns were simulated for several levels of tension. For tension
reaction weights of 0.25, 0.5, and 0.75, basal conditions were simulated for 80 s (all other
input weights = 0.1) followed by knock down of individual nodes (Y max = 0.1) for 240 s.
Steady-state activity levels of all nodes were measured across knockdowns of all nodes,
and changes in activity (ΔActivity) were calculated as the difference between node
activity after knockdown and basal activity. Knockdown sensitivity of each node was
calculated as the total change in activity of the node across all knockdown simulations,
and knockdown influence of each node was calculated as the total change in activity of
all other nodes in the network upon knockdown.
Drug Effect Comparisons
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Predicted responses of the network to currently prescribed pharmacologic
therapies were compared three studies measuring cardiac fibroblast or myocardial tissue
gene expression or protein expression in vitro or in vivo 30,31,33. All drugs were simulated
by knockdown or overexpression of individual nodes: angiotensin receptor blocker
valsartan (VAL), simulated by applying a negative modifier to Y max for the AT1R node,
neprilysin inhibitors LBQ657 (LBQ) and sacubitril (SAC), simulated by applying a
positive modifier Ymax for the NP node, and angiotensin receptor neprilysin inhibitors
LCZ696 (VAL+LBQ) and sacrbitril/valsartan (VAL+SAC). All negative control
simulations were conducted using input reaction weights of 0.1, and all input reaction
weights and drug perturbation levels for in vitro studies were chosen to maximize the
dynamic range of network responses. Input reaction weights for in vivo studies were
interpolated from experimental data of cytokine levels post-MI as previously described 13
using a time point of 4 weeks post-infarction, and tension reaction weights for control
and infarct zones were set to 0.1 and 0.6, respectively. All input reaction weights and
perturbation conditions can be found in Table 4.1.
Study
30
31
33

TGFB
(w)
0.4
Int.

AngII
(w)
0.4
0.4
Int.

NP
(w)
0.6
Int.

Tension
(w)
0.3
0.3
0.1/0.6

AT1Ri
Minimum
0.01
0.5
0.5

AT1Ri
NEPi
Maximum Minimum
0.5
0.05
0.5
4
0.5
-

NEPi
Maximum
4
4
-

Table 4.1. Model parameters used for drug effect simulations. Minimum/maximum AT1R inhibitor
(AT1Ri) values represent modifiers subtracted from the Ymax parameter of the AT1R node, and
minimum/maximum neprilysin inhibitor (NEPi) values represent modifiers added to the Ymax parameter
of the NP node. Non-specified input levels were set to a default value of 0.1. Int.: interpolated from
measurements of post-MI cytokine levels in vivo.

Mechano-Adaptive Drug Screen
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A computational screen of single and double network perturbations was
conducted to identify drug targets with potential to adapt fibrotic activity to the local
mechanical environment. Biochemical input reaction weights used for all simulations
were interpolated using the method described for in vivo study comparisons at a time
point of 2 weeks post-infarction. To represent remote (low tension) and infarcted (high
tension) zones post-MI, tension reaction weights of 0.1 and 0.6 were used, respectively.
For each simulation, baseline conditions were simulated using the input reaction weights
above for 80 s, and single or double perturbations were simulated by setting Y max values
of nodes to 0.1 (knockdown) or 5 (overexpression) for 240 s. Single perturbations were
simulated for all individual nodes as both knockdown and overexpression for a total of
218 perturbations, and double perturbations were simulated for all node combinations as
double knockdown, double overexpression, or knockdown-overexpression combinations
for a total of 23,544 perturbations.
Perturbations that exhibited mechano-adaptive behavior were identified using a
rank-based score metric based on changes in activity levels for model outputs
(ΔActivity). For each perturbation and tension level, ΔActivity levels were calculated as
the difference in each node’s activity between baseline and perturbed conditions, and
changes in overall matrix content (MCC) for each perturbation and tension level were
calculated based on ΔActivity levels for all procollagens and matricellular proteins
(ΔActivityMatrix), ΔActivity levels for all MMPs (ΔActivity MMP), and ΔActivity levels for
all protease inhibitors (ΔActivityInhib): 𝑀𝐶𝐶 = ∑ ∆𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦
∆𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦

− ∆𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦

. Output nodes were categorized as follows: ΔActivity Matrix: proCI,
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proCIII, fibronectin, periostin, osteopontin; ΔActivity MMP: proMMPs 1, 2, 3, 8, 9, 12, 14;
ΔActivityInhib: TIMP1, TIMP2, PAI1. To identify perturbations that (1) qualitatively alter
matrix content in a desirable manner based on the tensional context and (2) maximize
differences in low- and high-tension expression, a two-step procedure was used to score
mechano-adaptive behavior from MCC values:
(i)

Perturbations were first filtered based on the numeric signs of MCC values
at each tension level to identify categorically desirable behavior.
Perturbations that exhibited negative MCC values (i.e. greater anti-fibrotic
activity than pro-fibrotic activity) at low tension and positive MCC values
at high tension (i.e. greater pro-fibrotic activity than anti-fibrotic activity)
were retained for subsequent steps, and all others were removed.

(ii)

Retained perturbations were then ranked based on MCC values at each
tension level. MCC values at low tension were ranked in ascending order
(i.e. low to high values), and MCC values at high tension were ranked in
descending order (i.e. high to low). The mechano-adaptive score for each
perturbation was then determined by summing each perturbation’s rank
for low and high tension and subtracting two times the sum from the
number of retained perturbations, thereby denoting highly adaptive
perturbations with high scores and less adaptive perturbations with low
scores with a minimum score of 0.
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CHAPTER 5
AIM 3: DEVELOP A NEW, DATA-DRIVEN MODEL OF FIBROBLAST
TRANSCRIPTIONAL REGULATION TO IDENTIFY INFLUENTIAL
REGULATORS OF FIBROSIS
5.1. Introduction
The development of valvular and myocardial fibrosis has proven to be a major
obstacle for the treatment of patients suffering from aortic valve stenosis (AVS). This
disease is characterized by obstruction of the aortic valve leaflets by progressive fibrosis
and calcification, reducing blood flow through the valve and leading to compensatory
cardiac hypertrophy, myocardial fibrosis, and eventually heart failure in a large
proportion of patients1. Current surgical interventions that replace the diseased valve with
a biomaterial-based valve have substantially improved outcomes for patients diagnosed
with severe AVS, and the transcatheter aortic valve replacement (TAVR) procedure has
proven to be particularly effective for patients with high surgical risk 2. While these
replacements prevent further valve and myocardial remodeling by reestablishing blood
flow, interstitial fibrosis prior to surgery is not necessarily reversed after surgery, and
investigations of patient outcomes after valve replacement have associated high
perioperative degrees of fibrosis with reductions in long-term survival and cardiac
function3–5. Therefore, preventing valve and myocardial fibrosis during initial AVS
progression by slowing the accumulation of extracellular matrix (ECM) remains crucial
for preserving heart function and preventing the late onset of heart failure.
As a mediator of ECM turnover, cardiac and valvular myofibroblasts play a key
role during AVS progression by synthesizing matrix proteins, proteases including matrix
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metalloproteinases (MMPs), and regulatory matricellular proteins to dictate overall
changes in scar formation and tissue mechanical properties6. Valvular interstitial cells
(VICs) and cardiac fibroblasts undergo activation into a myofibroblast phenotype in
response to an influx of inflammatory cytokines, growth factors, and hormonal peptides
as well as changes in local biomechanical cues including pathological stiffness and
tensile loading7,8. These extracellular cues are transduced through a complex network of
regulation in which multiple intracellular signaling pathways interact via crosstalk and
feed-forward mechanisms to dictate overall cell responses9, thus further complicating
efforts to understand how myofibroblasts respond within the AVS microenvironment.
While previous studies have shown that myofibroblasts can undergo deactivation in
response to changes in plasma biomarkers after TAVR, macrophage-secreted
inflammatory cues, and local mechanical stiffness 10–13, the complexities of myofibroblast
signal transduction among a diverse microenvironment complicates efforts to determine
mechanisms of action for therapeutic intervention.
To discover potential mechanisms of action that can be targeted to rescue
myofibroblast activation during AVS progression, we employed a computational
approach in which simulated environmental cues are transduced via a network of
signaling and transcriptional interactions to predict changes in myofibroblast protein
expression. Similar approaches have been used to model various cardiovascular and
systemic diseases and have successfully generated insight into influential mechanisms
within a broad biological scope14–17. We adapted this approach to simulate myofibroblast
responses to patient-specific plasma biomarker levels before and after TAVR by
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combining our published network of fibroblast signaling with a new, data-driven network
of myofibroblast transcriptional regulation capable of predicting the regulation of
transcription factors (TFs) associated with fibrosis-related genes. Model calibration using
patient-matched plasma biomarker and myofibroblast RNA-sequencing data allowed for
accurate predictions of ECM protein expression for pre- and post-TAVR patient
biomarker profiles, and comparisons between simulated ECM expression levels and
clinical measurements suggest strong correlations between select myofibroblast-secreted
proteins and AVS severity. Global network perturbation analysis revealed several
influential signaling axes that mediated ECM protein expression including the interleukin
6 (IL6)-glycoprotein 130 (gp130)-signal transducer and activator of transcription (STAT)
pathway as well as the transforming growth factor-β (TGFB)-reactive oxygen species
(ROS)-c-Jun N-terminal kinase (JNK) pathway. Using these influential pathways as a
basis for possible drug candidates, we screened myofibroblast responses to simulated
pathway inhibitors for patient biomarker profiles and found stratified patient responses to
inhibitors, demonstrating the ability of our approach to both prioritize therapeutic
candidates for AVS progression and to predict patient-specific responses to anti-fibrotic
therapies.
5.2. Results
Development of Myofibroblast Transcriptional Network
Using a published dataset of myofibroblast gene expression in response to preand post-TAVR patient sera, we developed a new model of myofibroblast transcriptional
regulation using established gene regulatory network inference algorithms. Upon initial
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topology inference and implementing several filtering steps to prioritize experimentallysupported and fibrosis-related interactions (Figure 5.1A), our transcriptional network
represents 10 TFs activated by intracellular signaling, 27 intermediate TFs, and 18 target
genes related to ECM turnover or autocrine feedback (Figure C-1). This network
inference strategy identified pathways mediating ECM-related genes that have been
shown to alter collagen crosslinking, degradation, and tissue elasticity in vivo but have
seen limited implementation into fibroblast signaling networks, namely cathepsin C
(CTSC), cathepsin L (CTSL), lysyl oxidase homolog 1 (LOXL1), prolyl-4-hydroxylase
(P4H), and elastin. Additionally, this data-driven approach identified several intermediate
TFs known to regulate cardiac fibrosis, including SOX9, CCND1, ATF3, and NOTCH1,
suggesting agreement between the inferred topology and previous experimental findings.
Composite Myofibroblast Network Improves Accuracy of Protein Expression Predictions
Myofibroblast activation and expression of ECM proteins during AVS relies not
only on regulatory mechanisms at the transcriptional level, but also on changes to
intracellular signaling which often involves crosstalk between multiple pathways. To
provide a predictive model that accounts for both levels of regulation simultaneously, we
integrated the inferred transcriptional network above with our published network of
fibroblast signaling, incorporating signaling reactions and TF-target interactions into a
single composite network for semi-quantitative simulation (Figure 5.1B). This composite
network, consisting of 151 nodes and 334 edges in total, predicts the expression of 27
fibrosis-related proteins (output nodes) based on 10 canonical biochemical chemokines
and mechanical tension (input nodes), thus giving a comprehensive view of
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Figure 5.1. Composite myofibroblast regulatory network accurately predicts fibrosis-related
protein expression based on patient-specific biochemical stimuli. (A) Schematic of gene regulatory
network inference and model pruning scheme resulting in a targeted myofibroblast transcriptional
network. (B) Topology of combined network consisting of a curated network of fibroblast signaling and
an inferred transcriptional network derived from myofibroblast RNA-sequencing. Biochemical and
biomechanical input nodes (orange boxes), signaling-activated TFs (yellow boxes), and fibroblastsecreted output nodes (green boxes) are connected by directed edges representing activating and
inhibiting reactions (red and blue lines respectively, 334 total) with AND logic indicated by circular
nodes. Line widths represent average reaction weight parameters estimated via genetic algorithm. (C)
Comparison of experimentally measured changes in output gene expression between pre- and postTAVR conditions (ΔExpressionTAVR) with model predicted changes in output protein activity between
pre- and post-TAVR conditions (ΔActivityTAVR). Individual comparisons made for each patient (boxes)
represent mean levels across an ensemble of estimated parameter sets, and statistical comparisons of
activity levels between pre- and post-TAVR groups were conducted via two-tailed Student’s t-tests. *
p<0.05, † p<0.05 for model predictions and experimental values. (D) Comparison of squared errors
(SE) of predicted patient ΔActivityTAVR levels between fitted model (x-axis) and a default model (yaxis). All SE values were calculated in reference to experimental ΔExpressionTAVR levels.

myofibroblast responses to environmental cues observed during AVS progression. This
network was implemented as a system of logic-based ordinary differential equations
(ODEs) as previously described18, in which normalized node activity levels are
approximated via Hill equations using normalized node and reaction parameters (see
Materials and Methods for full description).
In order to calibrate this network to the biochemical and biomechanical conditions
experienced during severe AVS and after surgical intervention, we implemented a genetic
algorithm to estimate the relative weight parameters of all network reactions based on a
published multi-omic dataset consisting of (1) proteomic profiling of serum samples for
AVS patients collected before and after TAVR procedures, and (2) RNA-sequencing of
myofibroblasts treated with each patient’s serum 10. An ensemble of parameter sets was
estimated using proteomic and transcriptomic datasets as analogs for model inputs and
outputs respectively, and the resulting fitted network emphasized downstream signaling
pathways from TGFβ, endothelin-1 (ET1), tumor necrosis factor-α (TNFα), interleukin 1
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(IL1), and IL6 as well as STAT- and nuclear factor kappa B (NFKB)-mediated
transcriptional regulation (Figure 5.1B).
We compared model predictions of myofibroblast-expressed proteins to measured
gene expression levels by simulating myofibroblast responses to each patient’s pre- or
post-TAVR serum profiles and measuring changes in output activity between pre- and
post-TAVR conditions (ΔActivityTAVR). Changes in model predicted protein expression
matched changes in gene expression in pre- and post-TAVR serum-treated
myofibroblasts (ΔExpressionTAVR), as significant decreases in simulated plasminogen
activator inhibitor-1 (PAI1) and elastin activity along with significant increases in
simulated CTSC, CTSL, P4H, periostin, and IL6 activity mirrored significant changes in
respective gene expression before and after TAVR (Figure 5.1C). Across the ensemble of
estimated parameter sets, the average mean squared error (MSE) between ΔActivity TAVR
and ΔExpressionTAVR levels all patients and model outputs was 0.0329 ± 0.0531, yielding
a similar level of error as other fitted mechanistic and logic-based networks 19,20.
We additionally assessed the accuracy of our parameter estimation strategy
against a default model without fitted reaction weight parameters (i.e. all reactions weight
parameters set to 1) by comparing ΔActivityTAVR levels for each model against the
previous ΔExpressionTAVR levels. We found that parameter estimation improved
predictive accuracy for individual outputs with respect to each patient’s serum, as fitted
model ΔActivityTAVR levels for individual patients and outputs had lower squared errors
against respective ΔExpressionTAVR levels compared to the default model (Figure 5.1D).
Moreover, comparisons of significantly altered output levels between pre- and post-
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TAVR conditions as predicted by the two models and as measured in myofibroblasts
suggests a sizeable improvement in predictive accuracy. We found that while the default
model had a classification accuracy of 43.5% in predicting truly significant and nonsignificant changes in output activity compared to gene expression data, the fitted model
improved the accuracy to 69.6%, thus predicting a higher proportion of truly significant
and non-significant changes in output levels than the default, un-fitted model.
Model-Predicted ECM Expression Correlates with Clinical Measures of AVS Severity
The relationship between cardiac fibrosis and reduced valve and heart function
during AVS is well-known, but because scar formation involves a variety of matrix
proteins, proteases, matricellular proteins, and crosslinking proteins for overall changes
in tissue architecture, linking individual secreted proteins to changes in valve and heart
function remains challenging. Our myofibroblast network can account for many of the
species involved in scar formation, so we hypothesized that comparing model-predicted
trends in myofibroblast protein expression to patient-matched clinical measurements can
identify strongly correlated proteins among a diverse protein expression profile. We
performed a systematic correlational analysis between activity levels of 23 outputs
predicted for each pre-TAVR patient serum and 13 clinical features measured prior to
surgery. We found correlation coefficient directions between model-predicted outputs
and clinical features generally matched those for pre-TAVR myofibroblast gene
expression (Figure 5.2A). Several ECM proteins and secreted cytokines demonstrated
significant negative correlations and linear regression goodness-of-fit with aortic valve
area including matricellular proteins periostin and osteopontin, collagen crosslinker P4H,
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and autocrine feedback-associated proteins latent TGFB, IL6, and ET1. These
associations suggest that high levels feedback signaling and matricellular protein
expression persist for patients with a greater degree of stenosis, although the underlying
mechanisms remain unclear.
We additionally aggregated individual ECM protein levels into a single matrix
content score (MCS) via a rank-based procedure as an analog for net matrix accumulation
for each patient (see Materials and Methods for full description). Significant negative

Figure 5.2. Model-predicted expression of fibrosis-related proteins correlates with clinical
measures of disease severity. (A) Correlational analysis of pre-TAVR output node activity levels with
clinical features measured before and after TAVR surgery and comparison between model-predicted
output expression and experimentally measured gene expression. All dots represent Pearson correlation
coefficients and respective p-values. (B) Trending and significant correlations between aggregated
matrix content score (MCS) and clinical features. Spearman correlation coefficients (r) and p-values
were used to determine statistical significance.
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correlations between pre-TAVR MCS values and pre-TAVR left ventricular end systolic
internal diameter (LVIDS) and pre- to post-TAVR changes in Kansas City
Cardiomyopathy Questionnaire score (ΔKCCQ score) as well as a trending positive
correlation with Society of Thoracic Surgeons risk score (STS score) all suggest that
predicted shifts in overall myofibroblast secretion towards ECM accumulation may be
connected to declines in ventricular function as well as negative post-surgical outcomes
(Figure 5.2B).
Network Perturbation Analysis Reveals Influential Pathways Mediating Fibrosis during
AVS
A key barrier to understanding myofibroblast activation during AVS is a lack of
insight into whether select regulatory pathways influence cell behavior over others within
the larger network. Systems-level models may be able to provide key insight into relative
pathway influences on cell behavior through comprehensive perturbation simulations to
measure network-wide signal propagation. Using our model, we performed
comprehensive knockdown simulations of individual nodes for all individual patient
serum levels, measuring changes in network activity with each knockdown (ΔActivity KD)
to assess network-wide effects in a patient-specific manner. We calculated a knockdown
influence level for each node as a metric for the total effects that one node has on all other
nodes, and we calculated a knockdown sensitivity level for each node as a metric for the
total change in activity for one node across the knockdown of all other nodes (see
Materials and Methods for full description). Selection of the top 10 scoring nodes in both
metrics for each pre- and post-TAVR serum condition showed similar trends in node
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Figure 5.3. Network perturbation analysis reveals influential pathways and differences in
myofibroblast responses across patient conditions. (A-B) Comparison of top-ranked influential and
sensitive nodes between patients and pre-/post-TAVR conditions. Nodes shown reflect all unique nodes
ranked in the top 10 based on knockdown influence (A) or knockdown sensitivity (B). Dark bars
represent knockdown influence/sensitivity levels for each pre-TAVR patient condition, and light bars
represent levels for each post-TAVR patient condition. (C) Topological representation of influential and
sensitive pathways within the myofibroblast network. Node sizes represent average knockdown
influence levels across all patient and pre-/post-TAVR conditions, node colors represent average
ΔActivityTAVR levels across all patients, and node border sizes/colors represent average knockdown
sensitivity levels across all patient and pre-/post-TAVR conditions. (D) Correlational analysis between
pre-TAVR knockdown influence levels for top-ranked nodes and ΔActivityTAVR levels for model
outputs. All dots represent Pearson correlation coefficients and respective p-values. (E) Correlational
analysis between knockdown influence levels for top-ranked nodes and predicted ΔMCS levels between
pre- and post-TAVR conditions.
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sensitivity and influence across patients, with a total of 19 nodes ranking in the top 10
knockdown influence and 17 nodes ranking in the top 10 knockdown sensitivity for at
least one patient (Figure 5.3A-B, see Figure C-2A for network-wide sensitivity analysis).
Across all patient biomarker profiles, several intracellular signaling pathways
were consistently influential with respect to network-wide activity. Among the top
biochemical inputs represented were IL6, TGFB, and ET1, and these factors were
typically propagated by gp130/STAT activation in the case of IL6 as well as by smad3,
NOX/ROS, and mitogen activated protein kinase (MAPK) activation in the case of TGFB
and ET1 signaling. (Figure 5.3C). Nodes downstream from these pathways consistently
scored highly in knockdown sensitivity, including smad7, TCF4, TP53, and NOTCH1 as
targets of IL6 signaling, and AP1, NFKB, cmyc, and MECOM as targets of TGFB/ET1
signaling. These intermediates were also predicted to sizably change from pre- to postTAVR conditions for patients, as average ΔActivity TAVR levels across all patients indicate
consistent upregulation of IL6 pathway activation after TAVR and large increases or
decreases in downstream activity for connected TFs and target output nodes depending
on individual connectivity to the IL6, TGFB, or ET1 signaling pathways (Figure 5.3C).
We next compared knockdown influence and sensitivity levels for top-ranked
nodes across patient-specific conditions to assess differences both between individual
patients and between pre-/post-TAVR conditions. We found that influential nodes
representing IL1 and TGFB signaling pathways fluctuated between the patient cohort, as
select patient sera showed large network-wide changes in activity compared to others
(Figure 5.3A) and calculated coefficients of variation across patient conditions were
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largest for IL1 and TGFB-associated nodes out of all top-ranked nodes (Figure C-2B).
While patient-specific differences in knockdown sensitivity were not as pronounced and
coefficients of variation were lower overall (Figure C-2C), overall knockdown sensitivity
levels did vary by patient, with select patients showing little sensitivity across all topranked nodes compared to others (Figure 5.3B). We also observed differences in
influence and sensitivity from pre-TAVR to post-TAVR conditions across top-ranked
nodes. Knockdown influence levels for IL6 signaling nodes increased for post-TAVR
conditions compared to pre-TAVR conditions for 7 of 8 patients, which was consistent
with increases in IL6-related activity during post-TAVR simulations and demonstrated a
greater degree of responsiveness to the IL6 pathway after surgical intervention. Select
patients also showed increased influence of TGFB signaling in post-TAVR conditions,
including levels of TGFB1R, JNK, and NFKB, suggesting that select patients may be
more susceptible to therapeutic agents inhibiting the TGFB signaling pathway than
others.
As an additional exploratory analysis of influential pathway effects on
myofibroblast secretion, we correlated pre-TAVR knockdown influence levels of topranked nodes with ΔActivityTAVR levels for all fibrosis-related outputs to assess whether
influence levels of top intermediates during severe AVS relate to changes in ECM protein
expression after surgical intervention. A total of 82 out of 437 correlations between preTAVR influence and output ΔActivityTAVR levels were significant including 27 positive
correlations and 55 negative correlations (Figure 5.3D). Influence levels of IL6associated nodes and ET1-associated nodes significantly correlated with ECM proteins
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that were highly sensitive to knockdown from our perturbation analysis. Positive
correlations with elastin, PAI1, and LOXL1 as well as negative correlations with multiple
matrix proteases, periostin, and P4H suggest that changes in the IL6 and ET1 signaling
pathways may explain changes in protease, protease inhibitor, and collagen crosslinking
protein expression observed with surgical intervention. We additionally correlated preTAVR influence levels with changes in MCS values from pre-TAVR to post-TAVR
(ΔMCS) as a metric for overall changes in myofibroblast-mediated matrix turnover, and
we found that knockdown influence of the IL1- and ET1-associated nodes positively
correlated with changes in matrix content for patients, suggesting that changes in these
signaling pathways may explain reductions in overall myofibroblast-mediated fibrosis
observed after TAVR (Figure 5.3E).
Targeted Virtual Drug Screen Predicts Stratified Patient Responses to Therapies
Our perturbation analyses above suggested that while select signaling pathways
may mediate myofibroblast protein expression over others, responses of individual
patients to pathway alteration vary widely with some patients experiencing little to no
benefit for a given therapy. This challenge is a common theme among currently
prescribed therapies for cardiovascular diseases, and computational models of biological
systems have gained recent attention for their capacity to predict patient-specific
responses to therapeutic intervention. We investigated whether our myofibroblast
network could discern patient-specific responses to simulated drugs by predicting
changes in fibrosis-related outputs after inhibiting each of the 19 top-ranked influential
nodes identified from the network perturbation analysis above. Inhibition of each node

151

Figure 5.4. Virtual drug screen reveals stratified patient responses to inhibitor treatments. (A)
Comparison of ΔActivityinhib levels for fibrosis-related model outputs upon knockdown of top-ranked
influential nodes. Values represent average ΔActivityinhib levels across all patients for pre- and postTAVR conditions after 80% inhibition of each node relative to respective un-perturbed conditions. (BC) Example dose-response relationships between influential node inhibition and predicted output
activities for individual patients. Steady-state periostin and proCI levels were measured with Inhibition
of STAT (B) and JNK (C) respectively. Inhibitor levels represent negative modifiers applied to node
Ymax parameters, and activity levels represent mean ± SD levels measured across all estimated
parameter sets. (D-E) Network representations of influential signaling pathways and affected outputs
with inhibition, corresponding with IL6 (D) and TGFB/ET1 (E) pathway inhibition. Extracellular
inputs, signaling intermediates, signaling-mediated TFs, and model outputs are labeled as orange,
white, yellow, and green boxes, respectively.
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was performed for each patient’s pre- and post-TAVR serum profile in a dose-response
manner by limiting of the maximum activation of each node, and average changes in
activity of output nodes (ΔActivityinhib) were measured for each patient relative to unperturbed levels. Using a 5% change in mean activity as a threshold, we found that 13 of
19 influential nodes sizably altered the expression of output proteins with inhibition on
average, and 14 of 29 outputs responded to inhibition overall suggesting a selective
response of myofibroblasts towards simulated drugs (Figure 5.4A).
We found that responses to inhibitory drugs sizably varied across the patient
cohort, particularly simulated pre-TAVR conditions. Progressive inhibition of IL6
signaling species such as gp130 and STAT resulted in varying degrees of protein
suppression. For example, periostin activity decreased by as little as 19.3% or as much as
56.9% for individual patient conditions with 80% inhibition of STAT, suggesting large
differences in response to treatment (Figure 5.4B). This variance in output response was
not as apparent in post-TAVR simulations, as periostin activity was reduced in all
patients by at least 41.1%. This trend persisted across several ECM proteins in response
to IL6 pathway inhibition including P4H, CTSC and CTSL. Interestingly, patient-topatient variance in ECM protein expression persisted across pre- and post-TAVR
conditions when nodes associated with TGFB and ET1 signaling were inhibited. For
example, inhibition of JNK variably increased proCI activity across the cohort in preTAVR simulations (8.1% to 22.7% increase in activity), and similar ranges in response
were observed under post-TAVR conditions (12.2% to 24.1% increase), suggesting a
persistent stratified response towards TGFB/ET1 pathway inhibition.
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5.3. Discussion
Preventing cardiac fibrosis during AVS is crucial for long-term patient outcomes
even after surgical intervention, and although previous studies have shown that
alterations in plasma protein levels after valve replacement can deactivate
myofibroblasts10,11, the underlying mechanisms of cell activation and deactivation remain
unclear due in part to the complexities of intracellular regulatory mechanisms. In order to
aid our understanding of such mechanisms and prioritize therapeutic strategies for
slowing fibrosis-related AVS progression, we hypothesized that a computational model
of myofibroblast intracellular regulation could elucidate mechanisms-of-action mediating
myofibroblast activation by predicting fibrosis-related protein expression in response to
biochemical and biomechanical stimuli. We found that by developing a model that
encompasses signaling and epigenetic pathways and calibrating our model to multi-omic
data derived from patients undergoing surgical valve replacement, we efficiently and
accurately predicted fibrotic protein expression and used such predictions to inform
preclinical studies of anti-fibrotic therapies during AVS.
Our strategy above improved the accuracy of patient-specific predictions over
simulations based on model topology alone and resulted in a similar degree of accuracy
against experimental gene expression data compared to other fitted network models 19,20.
Correlational analyses demonstrated strong trends between both individual matrix
proteins predictions and aggregated matrix content scores with clinical measures of
disease severity and patient quality-of-life, and network-wide perturbation analyses
identified influential signaling pathways and transcriptional regulators of network activity
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and output expression such as the IL6-gp130-STAT and TGFB-ROS-JNK signaling axes,
which suggest that both axes serve as central mechanisms-of-action during myofibroblast
activation. We additionally demonstrated the capacity of the model to detect stratified
patient responses to targeted inhibition in a virtual drug screen, suggesting that select
patients may respond favorably to myofibroblast inhibitors based on plasma biomarker
profiles while the same inhibitor may not be suitable for others. Our results suggest that
our computational strategy can accelerate the development of anti-fibrotic therapies
during AVS progression by both generating insight into plausible mechanisms governing
cell behavior and by stratifying patients based on plasma biomarker levels.
Identification of Transcriptional Regulators in Myofibroblast-Mediated Fibrosis
While intracellular signaling processes remain a crucial step in transducing
environmental cues into changes in cell protein expression and phenotype, regulation on
a transcriptional level adds an additional layer of complexity and can further confound
predictions of cell behavior. Our construction and simulation of a myofibroblast
transcriptional network derived from RNA-sequencing data suggests that this layer of
regulation plays a highly influential role in myofibroblast behavior during AVS
progression. Transcriptional regulators identified here via gene regulatory network
inference have also been shown to mediate VIC and cardiac fibroblast behavior in other
cardiovascular pathologies. The transcription factor SOX9 has been identified as a
positive regulator of cardiac fibrosis and heart failure development in models of
ischemia-reperfusion injury and myocardial infarction (MI), with ischemia causing
increased SOX9 gene expression and spatial correlation with collagen gene expression
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and scar formation measured via histology 21. Fibroblast-specific deletion of SOX9 in an
MI mouse model was also shown to attenuate increases in fibroblast αSMA expression
and proliferation as well as scar formation and functional measures such as ejection
fraction and left ventricular end diastolic area, demonstrating a strong connection
between this factor and fibrotic processes. NOTCH1 and ATF3 have also been implicated
in cardiac fibrosis and myofibroblast activation, as overexpression of the NOTCH1
intracellular domain in rat cardiac fibroblasts antagonized TGFB-induced smad3
activation and in vivo overexpression after MI reduced fibrotic area in rats22, and cardiac
fibroblast-specific overexpression of ATF3 attenuated scar formation and reductions in
left ventricular internal diameter in end-systole and ejection fraction after MI 23. It should
be noted that several regulators identified by our approach play influential roles in
osteogenic differentiation such as NOTCH124–26, and although the scope of our model
does not directly reflect osteogenic phenotypes for valvular cells, this similarity in
regulatory species suggests that pathways mediating myofibroblastic and osteoblastic
phenotypes are not mutually exclusive. Our identification of these transcriptional
intermediates and connecting interactions suggests that the regulation of myofibroblast
behavior involves numerous pathways simultaneously, and that changes in expression of
SOX9, NOTCH1, and ATF3 likely mediate a number of fibrosis-related functions of
myofibroblasts during AVS progression. While the full contribution of these factors
towards fibrosis-related gene expression is unclear, modulating the expression of these
factors may be a plausible direction for new anti-fibrotic drug candidates.
Influential Signaling Axes and Regulatory Hubs Mediate Overall Myofibroblast Behavior
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Myofibroblasts respond to a variety of environmental stimuli including
inflammatory cytokines, growth factors, and hormonal peptides, all of which have been
shown to alter cell behavior individually 6,27. Within the context of AVS progression,
however, the relative contribution of each stimulant and their downstream signaling
pathways remains unclear. We performed a network-wide perturbation analysis to
identify globally influential pathways within the patient cohort during pre-TAVR and
post-TAVR scenarios, and our simulations predicted that the transduction of IL6, and
TGFB primarily influence activation levels across the network. IL6 signaling and
downstream activation of STAT has been previously linked to cardiac fibrosis across
several cardiovascular pathologies with effects across multiple pathways 28.
Dziemidowicz and colleagues found that IL6-/- mice treated with isoproterenol developed
interstitial ventricular fibrosis and increased phosphorylated levels of multiple signaling
intermediates including ERK, Raf, and p38 compared to wild-type mice 29. In a similar
finding, Hilfiker-Kleiner and colleagues found decreases in ERK and Akt
phosphorylation for mice carrying a point mutation in gp130 and subjected to MI
compared to wild-type mice. Recent evidence of IL6 as a promoter of VIC osteogenic
differentiation via the increased expression of RUNX2 and osteopontin suggest that this
pathway may serve multiple phenotypic roles11, and future targeted investigations of this
behavior may explain possible context-dependent roles of IL6 signaling during AVS
progression.
Noncanonical TGFB signaling via the activation of NADPH oxidases (NOX) and
ROS has also proved to be an effective regulator of fibrosis both in the myocardium as
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well as in valvular tissue. Inhibition of NOX4 in cardiac fibroblasts has been shown to
reduce TGFB-stimulated intracellular superoxide production, which in turn mediates
αSMA expression, CTGF and fibronectin secretion, and phosphorylation of smad2/3,
suggesting a largely pro-fibrotic role of this pathway30. The NOX-ROS signaling axis has
also been shown to mediate changes across multiple pathways to alter fibrosis in mouse
models of hypertension31, and decreases in NOX4 expression and ROS generation
following genetic knockout of SOD1 in mice mitral valves has been associated with
changes in αSMA, connective tissue growth factor (CTGF), and MMP expression in
mitral VICs32, suggesting a similar systemic effect of this noncanonical mechanism on
valvular myofibroblast behavior.
Our global analysis additionally suggests that select TFs may act as regulatory
hubs for expression of ECM-related proteins during AVS progression. We predicted that
STAT, NFKB, and Jun influence large changes in activity across the entire network, and
all three TFs have been well-studied for their roles in pathological scar formation. Our
simulations indicated that STAT primarily influenced myofibroblast behavior via the
expression of matricellular proteins, matrix proteases, and crosslinking enzymes, and
previous experimental studies have confirmed this central role of STAT in cardiac
fibrosis and systemic sclerosis. Using IL-11 as a positive regulator of STAT3 after MI in
mice, Obana and colleagues demonstrated that STAT3 activation reduced left ventricular
scar formation and improved infarct wall thicknesses compared to un-treated MI,
demonstrating a primarily anti-fibrotic effect during ischemic injury 33. However,
disruption of STAT3 phosphorylation via inhibition of EphrinB2 in a post-MI mouse
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model reduced αSMA protein expression, collagen I expression, and cell proliferation 34,
and inhibition of STAT3 during bleomycin-induced skin fibrosis reduced gene expression
of multiple ECM proteins35, suggesting that STAT may exert both pro- and anti-fibrotic
effects. In agreement with experimental evidence of IL6 signaling during AVS, the
activation of STAT3 was also associated with osteogenic de-differentiation in VICs via
downregulation of RUNX2 and BMP-236, reinforcing the need to further investigate this
intersection between fibrotic and osteogenic phenotypes. Given the experimental
evidence implicating IL6, however, our simulations make clear that targeting the IL6gp130-STAT pathway has significant therapeutic potential for AVS by modulating the
expression of ECM-crosslinking and degradation proteins.
Systems Models Relate Cell Phenotypes to Disease Severity and Predict Patient
Responses
Our model-centered approach provides unique advantages for relating cellularlevel behavior to clinical manifestations of AVS through the prediction of protein
expression based on patient-specific conditions, and our findings above indicate that
computational predictions of cell behavior correspond with multiple measures of AVS
severity including aortic valve area, LVIDS, and STS scores. Previous plasma biomarker
studies in AVS cohorts have shown individual biomarkers to be predictive of patient
outcomes such as N-terminal pro B-type natriuretic peptide (NT-proBNP) and C-reactive
protein37,38, and while useful for stratifying patient risk and informing surgical
intervention, these biomarkers alone may not connect alterations in cellular function with
overall disease progression. Our patient-specific predictions and correlation with pre-
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TAVR clinical measurements suggest that reductions in matricellular protein expression,
autocrine feedback-related cytokine expression, and collagen crosslinking enzyme
expression all corresponded with improved aortic valve areas, and aggregation of all
output proteins into a single ECM-related metric further demonstrated a strong
relationship between myofibroblast-mediated scar formation and reduced heart function.
Virtual drug screens for individual patient conditions further demonstrated the ability of
our model-based approach to discern responders versus non-responders towards
hypothetical drug candidates. Using this approach for preclinical drug development and
as a predictive tool in the clinic may improve patient responses to therapeutic
intervention, as drug discovery efforts can be directed towards patients that meet
selection criteria based on plasma biomarker levels, and treatment and/or dose decisions
for individual patients can be made in the clinic from non-invasive testing results. While
experimental validation of these trends is essential for further development and
application of this approach, the framework developed here provides opportunities to
further investigate fibrotic mechanisms-of-action for targeted patient cohorts or for other
fibrosis-related diseases.
Study Limitations and Future Directions
Our study was primarily limited by the size of patient datasets used for model
training and simulated scenarios. While this multi-omic, patient-matched design formed
an essential aspect of our model development strategy through the robust measurement of
plasma proteins and cell-specific gene expression, a lack of cohort size and diversity
limited our predictive capabilities in terms of both model training and predicted trends in
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myofibroblast behavior. Additionally, the insufficient availability of select biochemical
stimuli (e.g. estrogen), tissue biomechanical properties, and cell-secreted outputs limited
our predictions related to these stimuli and associated regulatory pathways, and further
measurement of these environmental factors will allow for the balanced predictions of
influential mechanisms-of-action while limiting bias towards measured species. While
our current parameter estimation approach using model input/output levels did improve
overall predictive capabilities compared to the model topology alone, the additional
measurement of intracellular intermediate activation via high-throughput
phosphoproteomic arrays will also improve predictive accuracy of our model through the
robust estimation of multiple reaction parameters.
Because both fibrosis and calcification processes play key roles in the
development of AVS, we acknowledge that our model of myofibroblast protein
expression alone accounts for only one component mediating overall disease progression.
Future adaptation of this modeling strategy towards osteogenic differentiation may
provide additional insight into dominating mechanisms responsible for calcification and
complement our current model of fibrosis-related gene expression for an overall picture
of cell behavior. Because several influential pathways identified here also correspond
with the expression of calcification-related proteins, implementing these same pathways
along with those known to mediate severe AVS may be valuable for investigating
differences in fibrotic versus osteogenic differentiation.
Our development of a fibroblast regulatory network and analysis of patientspecific changes in myofibroblast behavior demonstrated the translational possibilities of
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network models by identifying key mechanisms governing cell behavior within a larger
signaling context. Predicted intracellular species and pathways influencing fibrosisrelated gene expression provide targeted hypotheses for future validation, and future
experimental studies are necessary to confirm the roles of these species are necessary and
explore related signaling dynamics. Our findings of strong correlations between modelpredicted protein expression and clinical measures of disease severity additionally
suggest that simulated biological networks can relate cellular phenotypes to clinical
manifestations of AVS, and future exploration of the predictive capabilities of such
models could prove useful for clinical translation. Our virtual drug screen of individual
patient responses to pathway-inhibiting drugs further demonstrated the ability of our
model-based approach to stratify patient cohorts based on plasma biomarker profiles.
While future experimental validation is necessary to confirm these trends and improve
predictive accuracy, this strategy provides a framework for predicting cell behavior
within a complex signaling context and enables further investigation into pathways
mediating valvular fibrosis before and after surgical intervention.
5.4. Materials and Methods
Data and Code Availability
The code generated during this study is available at GitHub
(https://github.com/jdroger/Fibroblast_Gene_Regulatory_Network). The published article
includes all models generated or analyzed during this study.
Fibroblast Transcriptional Network Construction
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Gene Regulatory Network Inference. We employed a previously published
method of gene regulatory network inference to derive a network of transcription factor
(TF)-target gene interactions based on a transcriptomic dataset of VIC populations after
stimulation with patient sera. Bulk RNA-sequencing datasets recently published by our
collaborators were used as a training set for network inference, and this dataset represents
the gene expression of VIC populations stimulated with serum derived from a small
cohort of patients undergoing a TAVR procedure10. Briefly, patient blood samples were
collected at the time of surgery and at the 1-month follow up visit (n = 4 female patient
pairs and n = 4 male patient pairs, 16 samples total). The resulting serum samples were
used to treat porcine VIC cultures seeded on soft PEG hydrogels (elastic modulus of 5.8
kPa) for 48 h prior to RNA-sequencing, and counts per million (CPM) for gene
expression were used for subsequent network inference and model fitting methods.
We utilized the GRNBoost2 machine learning algorithm to infer a network of TFtarget interactions from the transcriptomic dataset above. This regression-based method is
based on the GENIE3 tree-based algorithm for predicting regulatory links between input
genes and target genes via the construction of decision tree ensembles 39. Each ensemble
of decision trees, which predicts the expression of a given target gene from the
expression of all input genes, is used to determine the relative “importance” of each input
gene in predicting the expression of the specified target gene. Decision tree ensembles are
built for all genes across the transcriptome, and input-target gene links are aggregated to
form a composite network of ranked interactions. The GENIE3 algorithm has been
shown to out-perform other methods in inferring gene regulatory networks as part of the
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DREAM4 In Silico Multifactorial challenge39, and it provides several advantages over
other common inference algorithms: (1) inference can be performed with minimal
assumptions of network topology, (2) directed interactions (i.e. gene A activates gene B)
can be inferred compared to correlation- and probability-based methods, and (3) nonlinear or combinatorial regulation can be derived compared to other regression-based
methods40. The GRNBoost2 implementation optimizes this approach using stochastic
gradient boosting, which grows decision tree ensembles on a subset of observations and
estimates the loss function on the remaining observations with each iteration. The
algorithm implements an early stopping criterion if the loss function does not improve
above a set threshold, thereby preventing unnecessary iterations of each decision tree and
reducing overall computational time41. The Arboreto library for python was used to apply
this algorithm to the RNA-sequencing data described above, and the average
computational time for network inference using a 4-core computer was approximately 10
min.
Network Pruning. Upon inference of the initial network, a 3-step workflow was
applied to filter the network for TF-target interactions that satisfy 3 requirements: (1)
interactions must be supported by experimental evidence, (2) interactions must relate to
either literature-supported TFs (primary TFs) or fibrosis-related target genes in
myofibroblasts, and (3) resulting pathways connecting primary TFs and target genes must
have relatively strong links across all individual edges as determined by interaction ranks
assigned by the GRNBoost2 algorithm (Figure 5.1A). The first step was performed by
comparing inferred TF-target interactions with databases of known TF-target interactions
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aggregated from chromatin immunoprecipitation (ChIP) studies. Curated lists of known
TF-target interactions from the ChIP-X Enrichment Analysis (CHEA) and TRANSFAC
databases were downloaded using the Harmonizome web interface 42, both of which were
chosen to maximize coverage of TFs related to myofibroblast activation. Upon filtering
the initial gene regulatory network for interactions contained in either database, the
resulting network was filtered further for interactions containing TFs or fibrosis-related
target genes in myofibroblasts. Lists of TFs and target genes were derived using our
curated network model of fibroblast signaling (see Chapter 4), which contains 11 primary
TFs and 20 target genes coding for ECM-related proteins. For TFs that consist of several
subunits (e.g. activator protein 1 [AP1] complex), both constituent genes were included
for filtering. An additional 8 target genes that were differentially expressed by patients
between pre- and post-TAVR sera were also considered: CTSC, CTSL, COL4A5,
LOXL1, P4HA1, P4HA3, LAMA4, and ELN. Proteins coded by these genes have been
shown to alter matrix degradation, collagen processing, and alter material properties of
cardiac tissue, and significant differences in expression within the RNA-sequencing
dataset provide a rationale for exploring possible regulatory pathways affecting gene
expression. After list construction, the database-filtered network above was filtered again
for interactions containing genes in either list. After filtering, interactions contained only
TF-TF interactions or TF-target interactions in which intermediate TFs not included in
the primary TF list above regulate target gene expression (i.e. primary TF A activates
secondary TF B, which activates target gene C).
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After the second stage of filtering above, the final network topology was derived
by ensuring that all resulting pathways between primary TFs and target genes contained
interactions that ranked highly among possible regulatory links according to the
GRNBoost2 algorithm. A modified depth-first-search algorithm was implemented to find
all possible pathways between each primary TF and target gene and check whether each
interaction within that pathway met this requirement using the “importance” score for the
interaction output by GRNBoost2. Individual interactions were only allowed if the
importance score of each edge was greater than either a threshold of 1 or the 75 th
percentile of all interactions stemming from the same TF. This hybrid threshold was
chosen to both limit interactions driven by noise, in which overall importance scores are
low, and to prevent premature exclusion of related interactions when all possible
regulatory links may be ranked low relative to the entire network. By implementing this
method, all interactions mediating expression of target genes were ensured to meet a
threshold of confidence relative to neighboring interactions such that one TF within a
pathway is not predictive of its downstream target. All network filtering steps were
performed in a python environment using the numpy 43 and pandas44 packages.
Composite Signaling/Transcriptional Network Implementation
Topological Integration. We combined the final transcriptional network with our
previous fibroblast signaling network describing intracellular mechanotransduction and
chemotransduction (see Chapter 4) to form a composite network capable of predicting
fibrosis-related protein expression in response to mechanical and biochemical stimuli.
New TFs (model nodes) and/or transcriptional reactions (edges) were added to the
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fibroblast signaling topology if they were not redundant to the original transcriptional
reactions described by the signaling network.
Logic-Based Ordinary Differential Equation Approach. The final network was
implemented as a system of logic-based ordinary differential equations in which activity
levels of all nodes were modeled by Hill equations. Logical NOT, AND, and OR gates
were used for complex signaling interactions by applying the respective logical
operations: 1 − 𝑓(𝑥) for NOT gates, 𝑓(𝑥)𝑓(𝑦) for AND gates, and 𝑓(𝑥) + 𝑓(𝑦) −
𝑓(𝑥)𝑓(𝑦) for OR gates. The open-source Netflux package for MATLAB was used to
build this system of differential equations 18, and all simulations were conducted using
MATLAB (Mathworks, Natwick MA). All visualizations of network topology were
constructed using Cytoscape45.
Network Parameter Estimation
Dimensionality Reduction. To improve model predictions of myofibroblast
behavior within the context of AVS before and after TAVR, we implemented a model
fitting procedure to optimize the reaction weight parameters (w) of all reactions within
the composite network. From the initial set of parameters (334 total), k-means clustering
was conducted based on a global sensitivity analysis to group reaction weights based on
changes in network-wide activity with knockdown. This method has been utilized in
previous logic-based ordinary differential equation models to identify modules with
similar functional behavior14 and provides an advantageous method for reducing model
dimensionality based on biological function. Reactions were clustered via the kmeans
MATLAB function using k = 11, which was determined to produce the highest degree of
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separation between clusters. Reactions in which the product contained a fibrosis-related
output gene were excluded from clustering to allow for additional degrees of freedom to
predict the expression of individual output proteins, and k-means clustering was repeated
1000 times for the remaining reactions using randomly chosen starting points. Clusters of
reactions occurring most frequently were assigned to final clusters and shared a weight
parameter during fitting, thus reducing the dimensionality of the final parameter set for
optimization (129 parameters total).
Multi-Omic Data Normalization. A genetic algorithm was used to fit the reduced
parameter set above to normalized model input and output concentrations extracted from
patient-specific proteomic and transcriptomic datasets recently published by our
collaborators10. In addition to the VIC RNA-sequencing data described above, relative
concentrations of 1193 proteins from the same patient serum samples were measured via
DNA aptamer array, allowing for the direct relation of changes in serum proteins before
and after TAVR to changes in myofibroblast activation. Using serum protein levels for all
patients as input concentrations and VIC gene expression levels as output concentrations,
data for each input and output node were transformed to a normalized scale useable by
the model. All input levels were normalized between activity levels of 0.1 and 0.6
(representing 10% activation and 60% activation respectively), matching previous studies
transforming biochemical cytokine and growth factor levels measured in myocardial
tissue post-MI to normalized values while maximizing network dynamic range 46. All
output levels were normalized between activity levels of 0.1 and 0.7, keeping the same
basal values as input levels while expanding the dynamic range of output expression
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beyond the default half-maximal effective concentration (EC50) to account for multiinput stimulation. All normalized input levels were implemented as initial reaction
weights within the model as representative rates of generation of each species, and all
normalized output levels were implemented as steady-state concentrations of each
species. Because not all input/output nodes were represented in the experimental datasets,
unrepresented input reaction weights were included as parameters within the fitting
parameter set, and unrepresented output activity levels were included for prediction but
not used in the final objective function.
Global Parameter Estimation. Using normalized input/output sets for each patient,
the ga MATLAB function was used for all parameter estimation. For each set of
randomly generated parameter sets within the function, steady-state output levels for each
patient were measured after 80 h given either pre-TAVR or post-TAVR levels for that
patient. Changes in steady-state output levels were calculated for each patient from preTAVR levels to post-TAVR levels (ΔActivityTAVR), and the mean squared error (MSE)
between ΔActivityTAVR values and experimental changes in normalized gene expression
between conditions (ΔExpressionTAVR) for all patients and outputs were used as the
objective function. A population of 500 was chosen to maximize intra-generational
variation while limiting computational resources, and a maximum of 100 generations
were used as minimal improvements in the objective function were found in subsequent
generations (data not shown). Program defaults were used for all other algorithm
hyperparameters, and default values for the fibroblast signaling model were used for all
other model parameters including Hill coefficient (n), EC50, maximum node activation
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(Ymax), and time constant (τ) (see Chapter 4, Materials and Methods section for full
description). Due to the stochastic nature of generating initial parameter sets for global
optimization, the model fitting procedure was repeated 50 times using random initial
parameter sets resulting in an ensemble of parameter sets. Predicted node activity levels
for all subsequent simulations reflect the mean activity levels predicted across all
estimated parameter sets.
Network Perturbation Analysis
To identify influential signaling mechanisms across pre-TAVR and post-TAVR
signaling contexts, a series of node knockdowns were simulated using normalized input
levels from each patient serum sample. For each set of normalized input levels used
during parameter estimation above, basal conditions (i.e. without any knockdown) were
applied for 80 h, followed by knockdown of individual nodes using the Y max parameter
(Ymax,KD = 0.1*Ymax,basal) for 240 h. Steady-state activity levels of all nodes were
measured with each knockdown, and changes in node activity (ΔActivity KD) were
calculated as the difference between node activity after knockdown and basal node
activity. Knockdown sensitivity of each node was calculated as the sum of absolute
ΔActivityKD levels for the node across all knockdown simulations, and knockdown
influence of each node was calculated as the sum of absolute ΔActivity KD levels for all
other nodes in the network upon knockdown.
Patient stratification analysis
Targeted simulations assessing stratified model responses to drug targets with
patient-specific conditions were conducted using a series of dose-response simulations.
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An aggregate list of top influencers was constructed from the top 10-ranked nodes in
knockdown influence for each patient condition above (19 nodes total). For each node, a
series of knockdown simulations was performed under each patient-specific condition.
Following a simulation of basal conditions using each patient’s normalized input levels
for 80 h, the Ymax parameter for each node was lowered to either 0.8, 0.6, 0.4, or 0.2
times the Ymax under basal conditions for 240 h (corresponding with 20-80% node
inhibition). Steady-state activity levels of all nodes were measured with each dose and
compared to steady-state levels prior to dosing.
Statistical analyses
Data are shown as mean levels across the ensemble of model parameter sets.
Significant differences between pre-TAVR and post-TAVR experimental groups were
determined using two-tailed Student’s t-tests MATLAB. Correlations between activity
data were determined using Pearson correlation in MATLAB, and Student’s t-tests with
Benjamini-Hochberg correction for multiple comparisons were used to assess statistical
significance. An aggregated matrix content score (MCS) was also derived for each
patient from individual output activity levels using rank-normalized values. Model
outputs were rank-normalized for each patient, and mean activity levels for all
procollagens and matricellular proteins (ActivityMatrix), mean activity levels for all matrix
proteases (ActivityProtease), and mean activity levels for all protease inhibitors were used
for aggregation: 𝑀𝐶𝑆 = 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦

− 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦

+ 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦

. Output

nodes were categorized as follows: ActivityMatrix: proCI, proCIII, fibronectin, periostin,
osteopontin, LOXL1, P4H; Activity Protease: proMMPs 1, 2, 3, 8, 9, 12, 14, CTSC, CTSL;
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ActivityInhib: TIMP1, TIMP2, PAI1. Correlations involving MCS levels were determined
using Spearman correlation in MATLAB and Student’s t-tests for statistical significance.
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CHAPTER 6
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE STUDIES
6.1. Conclusions
Cardiac fibrosis poses a central challenge in preventing heart failure for patients
who have suffered a cardiac injury, and currently prescribed therapeutics do not account
for the need to prevent scar formation when it can be detrimental to cardiac function.
Interactions between biochemical and biomechanical cues within the myocardium guide
the activation of cardiac fibroblasts during post-injury fibrosis, and while single-pathway
studies of fibroblast activation have been limited in assessing the broad effects of these
interactions, computational network models can account for this biological complexity
and identify influential mechanisms mediating cell behavior. Our investigation aimed to
identify highly influential mechanisms-of-action mediating cardiac fibroblast activation
and synthesis of matrix-related proteins through a combination of in vitro experiments
and computational simulations exploring fibroblast chemo- and mechano-transduction.
In the first aim of this investigation, we developed a high-throughput in vitro
screen for subjecting cardiac fibroblasts to combinations of canonical biochemical
agonists and cyclic mechanical tension to assess the extent of mechano-chemo
interactions in cardiac matrix synthesis. We showed that fibroblast-secreted proteins were
differentially sensitive towards biochemical stimuli, as the agonists tested primarily
altered the expression of MMPs 1, 8, 9, 12, osteopontin, and periostin over other collagen
I-associated peptides among other species. Moreover, we found that tension altered
cardiac fibroblast sensitivity towards biochemical cues by either sensitizing cells towards
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agonists that suppress matrix protease secretion such as AngII, or de-sensitizing cells
towards agonists that upregulate protease secretion such as IL-1 and TNFα. This
screening approach allowed for the discovery of significant signaling interactions guiding
matrix-related protein expression among many possible combinations, and these findings
can be used to prioritize future, targeted studies investigating fibroblast behavior.
In the second aim of this investigation, we expanded a network model of
fibroblast signaling to incorporate a robust mechanotransduction topology for predicting
cell responses in variable mechanical contexts. This model was able to reproduce
qualitative experimental findings through validation of both input-output relationships
and responses to currently prescribed drugs for MI patients. Mechano-chemo interaction
analysis identified crosstalk mechanisms by which tension amplifies, dampens, or
reverses fibroblast responses to individual biochemical stimuli compared to a low-tension
context. Global sensitivity analysis identified highly influential pathways mediating
network-wide responses as well as collagen synthesis in several mechanical contexts,
with autocrine TGFB signaling acting as a positive feedback loop to stimulate
procollagen production. We also demonstrated the utility of this signaling model in drug
discovery by screening drug combinations for the capacity to regulate matrix expression
based on the mechanical context, finding 13 mechano-adaptive therapies that promote
matrix accumulation in regions where it is needed and reduce matrix levels in regions
where it is not needed.
In the third aim of this investigation, we developed a transcriptional regulatory
network using RNA-sequencing data that improved the accuracy of modeling patient-
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specific biochemical conditions over the previous signaling network alone. When
combined with our network of fibroblast signaling and optimized for patient proteomic
and transcriptomic datasets via global parameter estimation, the model accurately
predicted changes in fibroblast activation markers and cell-secreted proteins in agreement
with in vitro and clinical outcomes. Using global sensitivity analyses, we identified
influential mechanisms mediating changes in network-wide activity and fibrosis-related
protein secretion following transcatheter aortic valve replacement, such as the IL6gp130-STAT and ET1-ROS-JNK pathways. We also demonstrated the capacity of this
composite model to predict individual patient responses to drug treatment, with simulated
knockdowns of individual nodes revealing stratified changes in fibrosis-related protein
expression across the patient pool.
While ideal anti-fibrotic therapies should act in a targeted, patient-specific manner
to only promote fibrosis when and where it is safe to do so, previous therapies have
proven ineffective due in part to complex intracellular signaling by cardiac fibroblasts.
Overall, this investigation moved our understanding of cardiac fibrosis forward by
identifying mechanisms-of-action that occur in specific mechanical contexts and in
individual patients, and model predictions can serve as new testable hypotheses for
potential treatments of maladaptive cardiac fibrosis specific to local mechanics.
6.2. Study Limitations
While this investigation generated additional insight into the complexities of
fibroblast signaling and fibrotic behavior, several limitations were apparent that should be
noted when interpreting the results of each study. One chief limitation involves the scope
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of the investigation as it relates to the clinical manifestations of fibrosis; while we studied
fibroblast secretion of pro- and anti-fibrotic proteins as a cause of pathological tissue
remodeling, protein secretion is one of several factors affecting overall tissue mechanics
and performance during heart failure progression. Other factors such as the orientation of
insoluble collagen fibers and the generation of local traction forces by fibroblasts must
also be considered when translating cellular-level changes to differences in tissue
properties, and therefore our findings should be considered in conjunction with the larger
fibroblast mechanosensing and mechanotransduction body of literature.
Within the experimental aim of our investigation, we acknowledge several
limitations when comparing our in vitro platform to in vivo myocardial conditions:


High variance in our treatment conditions were likely due in part to contamination
of other cell types during fibroblast isolation such as cardiomyocytes and
macrophages. Because we did not specifically assess for the purity of primary cell
cultures, the extent of this factor is unknown, and future studies should apply
additional methods for cell purification.



The fibrin matrix chosen for our study differs in several aspects from native
myocardium including material properties such as elastic modulus as well as
motifs for cell-matrix adhesion. While this choice of material allowed us to
measure collagen synthesis without excessive inhibition by a pure collagen
matrix, combinations of fibrin and collagen may be substituted in future studies
for a closer approximation of myocardial ECM.
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The stretch regimen applied during our study additionally differed from
conditions experienced in vivo, as the axial strain applied (6.5%) is lower than
reports of in vivo circumferential strains in several animal models. Additionally,
the strain frequency of 1 Hz, while applicable to human resting heart rates (~60
bpm), is substantially lower than resting heart rates for mice (~450 bpm). While
these differences suggest that our platform did not fully model in vivo
physiological and pathological conditions, the study revealed changes in
fundamental fibroblast behavior with disease-relevant biochemical and
biomechanical signals, and future studies should consider closer approximations
to myocardial biomechanics.

Within the computational aims of our investigation, we acknowledge several
additional limitations when comparing our models to fibroblast signaling in vivo:


While our models of intracellular signaling and transcriptional regulation
incorporate topological information and inferred dynamics from many different
biological pathways, our semi-mechanistic approach does not include quantitative
kinetic information such as reaction rates, absolute concentrations, and
pharmacokinetic parameters. Additionally, our models assume similar Hill
kinetics between all signaling species which may not hold true for several
reactions such as those involving inside-out mechanotransduction. Further
translation of these models into therapeutic development will require additional
mechanistic detail and integration into pharmacokinetic models for the accurate
prediction of safety and efficacy.
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Our inference of the transcriptional regulatory model and fitting of the composite
signaling-transcription model in Chapter 5 rely on a limited dataset of 16 patient
conditions which may not reflect the larger population of severe aortic valve
stenosis patients. While this patient-matched dataset provided a powerful basis for
investigating mechanisms-of-action in response to plasma protein signatures,
further validation against larger trial populations is necessary to extrapolate
predicted trends. Furthermore, these datasets generated from in vitro experiments
do not fully reflect VIC phenotypes in the native aortic valve, and preclinical
animal studies would be essential for future validation and therapeutic
development.

6.3. Recommendations for Future Studies
The model-centered approach used in this investigation presents a variety of
opportunities to both improve our understanding of mechanisms underlying cardiac
fibrosis and to predict fibrosis-related development for individual patients. While the
work presented here furthers the groundwork for these efforts by developing the
underlying signaling and transcriptional topologies in cardiac fibroblasts, future efforts to
expand model topology, optimize model fit, and validate findings are essential to using
this approach for translational applications to improve patient care.
Model Topology Expansion
While the current investigation focused on cardiac fibrosis development in
fibroblasts via well-studied transduction pathways such as β-integrin, TRP, and syndecan
mechanosensing as well as TGFβ, AngII, and interleukin chemosensing, fibroblasts
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respond to a wide variety of mechanical and biochemical stimuli in vivo, and
incorporation of these various modes of signaling into future models may further answer
questions related to fibroblast responses within specific disease contexts. For mechanical
signaling, future delineation of various modes of cell deformation (i.e. stretch vs. stiffness
vs. pressure) would provide a more accurate representation of the mechanical
microenvironments as well as a link to specific disease states such as hypertensioninduced pressure overload. This delineation was not included in this investigation due to
the lack of specific literature evidence linking these individual modes to mechanosensing
receptors, and targeted experiments measuring the relative activation of receptors such as
integrins and stretch-activated ion channels with individual mechanical stimuli in cardiac
fibroblasts are necessary for both model implementation and for improving mechanistic
understanding. For biochemical signaling, future integration of additional agonists known
to alter fibroblast activation such as epidermal growth factor (EGF), interferon-γ (IFNγ) 1,
or additional interleukins such as IL-112 would provide a more robust topology for
predicting fibroblast behavior given the diversity of the cardiac proteome. Because these
and other species may only be differentially expressed after certain initial pathologies,
tailoring the current signaling network to particular disease scenarios through the addition
of differentially-expressed signaling proteins and removal of others could provide further
insight into fibroblast-mediated remodeling within particular disease states.
While we successfully constructed an initial network describing transcriptional
regulation in myofibroblasts, the accuracy of this topology is highly dependent on the
relatively limited RNA-sequencing dataset used for inference, and future integration of
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transcriptomic datasets of larger sample sizes are essential for improving the accuracy of
this network. Ideally, large scale RNA-sequencing of patient-derived fibroblasts or
fibroblasts treated in a patient-specific manner like the dataset employed here would
provide further confidence in inferred TF-target interactions, but practical considerations
make this ideal a long-term effort. Single cell transcriptomics has gained traction in
recent years its ability to generate detailed insight of the transcriptional landscape for
thousands of cells simultaneously, and many bioinformatic tools have been developed to
infer gene regulatory networks using relatively fewer samples 3. Additionally, several
recent studies have used single cell “omics” methods to investigate cardiac stromal cell
behavior post-MI4–6, and so using these single-cell datasets to infer fibroblast
transcriptional regulation could complement the transcriptional network presented here
by revealing additional influential mechanisms mediating fibrosis-related gene
expression. While several drawbacks in single cell sequencing limit the usefulness of
these datasets such as relatively low number of genes and counts detected, they may be a
useful tool for discovering influential mechanisms in lieu of large-scale bulk RNAsequencing experiments.
One additional direction that could improve predictive capabilities of both
signaling and transcriptional models is the investigation of non-coding RNAs such as
microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). A growing body of
research has identified miRNAs as highly influential mediators of cardiac fibrosis and
overall function for their role in cell signaling7–9, and the inhibition of the lncRNA Meg3
has been shown to inhibit MMP-2 gene expression in cardiac fibroblasts and collagen
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deposition after transverse aortic constriction in mice10. These signaling-related
transcripts have also been incorporated into networks via the inference of miRNA-TF
interactions11, demonstrating that applying network biology methods to signaling-related
transcripts can generate insight into additional modes of signaling and transcriptional
regulation. The incorporation of well-known miRNA and lncRNA species within the
current signaling network via a curated literature search could serve as an initial step for
incorporating this type of signaling, and future experiments measuring changes in
miRNA or lncRNA via microarray or long-read sequencing could identify new
transcripts for further incorporation.
High-Throughput Phosphoproteomics for Parameter Optimization
A critical area for bridging the gap between our current suite of models and
potential translational applications is the improvement of robust parameter optimization.
While our normalized signaling model presented in Chapter 4 was able to reproduce
qualitative changes in fibroblast-secreted ECM proteins and proteases compared to
independent experimental studies, accurate quantitative predictions of signaling
intermediate activity and protein expression are necessary to reliably predict cell
responses to potential drug treatments. While our optimization of reaction weight
parameters based on a small sample of patient-derived proteomic and transcriptomic data
in Chapter 5 proved useful for predicting relative patient responses to simulated drugs, a
robust dataset measuring activity changes in intracellular signaling intermediates would
provide a basis for extensively training model parameters. This dataset could be
generated using controlled in vitro conditions such as isolated cardiac fibroblasts
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stimulated with individual biochemical and/or biomechanical stimuli, as well as
fibroblasts isolated from mice subjected to MI or AVS. High throughput
phosphoproteomic assays such as reverse phase protein array (RPPA) or Luminex
phosphoprotein arrays provide quantitative methods for measuring intracellular protein
activation and inhibition across many signaling species and have been used for robust
fitting of network models12,13. To optimally fit the dynamics of signaling pathways,
experiments should be conducted in either a dose-response manner (in the case of in vitro
experimental conditions) or at multiple time points for pairing with changes in
biochemical concentrations (in the case of in vivo experimental conditions).
Validation of Model Predictions
The validation of model predictions remains an essential step for translating
model-based findings into therapeutic solutions for cardiac fibrosis. Our simulations
throughout this investigation suggested that several key pathways highly influence
fibroblast secretion of ECM-related proteins in various contexts, such as the NOX-ROSAP1 signaling axis under high levels of mechanical stimulation or the IL6-gp130-STAT
axis in post-TAVR biochemical conditions. While these findings show some agreement
in the literature, testing the hypotheses that these signaling pathways mediate ECMrelated protein expression should be conducted in vitro in a targeted manner. These
predictions can be tested using pharmacological inhibition or RNA interference for
intracellular signaling species, and the use of variable-stiffness substrates can be used as a
positive mechanical stimulus alone, in combination with individual biochemical stimuli,
or in combination with patient sera samples. Fibrosis-regulating drug candidates from our

186

comprehensive in silico drug screen in Chapter 4 can also be validated using a similar
experimental design, and future experimental efforts will focus on testing the hypothesis
that combinatory perturbation of the PI3K-Akt and IL6-gp130 pathways can lead to
mechano-adaptive changes in fibrosis-related protein expression in cardiac fibroblasts.
Additional Directions for Cardiac Network Models
While our model-based approach of cardiac fibroblast behavior was able to
identify intracellular pathways regulating protein expression related to fibrosis, it is
important to note that cardiac fibrosis is regulated by many cellular and extracellular
systems working in tandem. While fibroblasts play a large role in synthesizing matrix
proteins and proteases in response to environmental cues, other cell types such as
cardiomyocytes, macrophages, and neutrophils play highly influential roles through
intercellular communication and cell-ECM interactions. Other groups have constructed
models of these other cell types with similar rates of success as our investigation, and
integrating these systems together could aid our understanding of how the larger
multicellular system mediates pathological collagen accumulation. While simply
combining many large-scale networks together may be computationally challenging,
developing specific, mechanistic models of highly influential pathways guiding the
behavior of each cell type may reduce complexity while generating new insight into
intercellular communication. Such mechanistic models would also be more amenable to
translational applications such as drug development, thus further bridging the gap
between model-based discovery and patient care.
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One final application of our current modeling approach is in the development of
multiscale models in which molecular-level changes in signaling, cellular-level changes
in matrix secretion and local mechanical stresses, and tissue-level changes in mechanical
properties and function are modeled simultaneously. These models show promise in
directly translating molecular-level changes into clinically-relevant changes in tissue
function, and the application of our fibroblast model suite to cellular-level changes via
agent-based models and to tissue-level changes via finite element models could allow for
a complete solution to treating cardiac fibrosis both in terms of therapeutic development
for the general population as well as in precision medicine via the use of individual
patient tissue geometries and plasma biomarkers.
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Appendix A
Aim 1 Supplemental Figures

Figure A-1: Validation of strain for PDMS wells and fibroblast-seeded gels during cyclic uniaxial tension.
(A) Average strains of individual PDMS wells subjected to uniaxial tensile deformation. Green strain
tensors were derived from the deformation of well sidewalls in the axial (11) and transverse (22) directions
(N=4 technical replicates). (B) Average strain of individual fibroblast-seeded fibrin gels subjected to
uniaxial tension. Green strain tensors were derived using similar directional conventions as in A-1A (N=4
technical replicates).

Figure A-2: Viability of fibroblast populations across all experimental groups and biological replicates.
Viability was determined using a live/dead fluorescent double staining kit after the duration of each
treatment regimen and is shown as the proportion of calcein-positive cells to total cells for images taken of
each gel (400.2±183.9 cells per image, N=7 biological replicates).

192

Figure A-3: Fibroblasts maintain alignment along the axis of stretch in fibrin gels. Fluorescent images for
fibroblast-seeded fibrin gels across all experimental groups were collected after conducting cell viability
analysis for each sample (Fig. A-2). The orientations of calcein-positive cells for one image per gel
(400.2±183.9 cells per image, N=7 biological replicates) were calculated using CellProfiler software.
Orientations are expressed as the angle in degrees from the axis of stretch, with 0° denoting cell alignment
parallel to the direction of stretch, and ±90° denoting cell alignment perpendicular to the direction of
stretch.
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Figure A-4: Immunocytochemistry and imaging analysis for fibroblast-seeded fibrin gels. (A) Fibrin gels
probed for αSMA and DAPI were analyzed for fluorescence intensity and cell count per image using
CellProfiler software. Cell counts per image, as determined by DAPI-labeled nuclei, were extrapolated to
measured areas of each gel in order to estimate total cell counts per gel. (B) Comparison of bulk gel
compaction from before treatment to after treatment for high-dose agonist treatments and agonist-stretch
combinations. (C) Comparison of fluorescence intensity for αSMA across high-dose agonist treatments and
agonist-stretch combinations. Gel-averaged intensities were determined by averaging the integrated
intensity of each cell across all cells in each image (N=8 biological replicates). (D) Comparison of
extrapolated cell counts across high-dose agonist treatments and agonist-stretch combinations.
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Figure A-5: Statistical significance of individual agonists compared to un-stretched or stretched controls
shown in Fig. 3.3. P-values of Dunnett’s post-hoc tests are displayed for agonist treatments only versus unstretched controls (A), agonist-stretch combinations versus un-stretched controls (B), and agonist-stretch
combinations versus stretched controls (C).
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Appendix B
Aim 2 Supplemental Figures

Figure B-1: Schematic of fibroblast chemo-/mechano-transduction network modifications for current study.
Added nodes relating to mechanotransduction mechanisms, mechano-chemo crosstalk mechanisms, and
additional secreted outputs are highlighted in blue.
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Figure B-2: Optimization of reaction parameters for maximizing accuracy of qualitative predictions.
Parameter sweeps of half-maximal effective concentration (EC50) and Hill coefficients (n) were conducted
by simulating changes in output node expression (A) and intermediate node activity (B) in response to
single input stimuli (see Materials and Methods, Model Validation section for full description). Shading of
parameter combinations represents the total proportion of correct qualitative predictions compared to each
independent experimental validation set used in Figure 4.2.
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Figure B-3: Comparison of mechano-chemo interaction trends across individual biochemical stimuli. (A)
Probability density distributions of changes in area under normalized dose response curves (∆AUC) with
incremental levels of tension. Distributions were estimated from data using a kernel density smoothing
function with a bandwidth of 0.01, and dashed lines represent a ±5% threshold used to identify nodes that
exhibited amplified or dampened responses towards biochemical stimuli with added tension. (B)
Comparison of topological measures of centrality for biochemical inputs. Topological analysis of the full
network was conducted using the NetworkAnalyzer plugin for Cytoscape.
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Figure B-4: Results of Kolmogorov-Smirnov tests with Benjamini-Hochberg correction comparing ΔAUC
distributions for biochemical inputs between levels of tension.
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Figure B-5: Full network perturbation analaysis results. Changes in activity for all nodes in the network
were measured following comprehensive knockdown of individual nodes (Ymax = 0.1) under given levels
of tension. Values reflect changes in node activity between perturbed and un-perturbed conditions at each
tension level. Refer to the model logic file available on GitHub for the order of nodes perturbed/measured.
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Figure B-6: Comparisons of model-predicted and experimentally-measured changes in procollagen
expression and signaling intermediate activity. (A) Simulated and experimental measurements of
procollagen I/collagen synthesis in response to increasing doses of neprilysin inhibitor LBQ657 (LBQ).
Simulated concentrations of NEPi represent positive modifiers added to Ymax parameters, and
experimental concentrations represent concentrations of LBQ657 in μM. (B) Simulated and experimental
measurements of procollagen I/collagen synthesis in response to increasing doses of angiotensin receptor
blocker valsartan (VAL). Simulated concentrations represent negative modifiers subtracted from Ymax
parameters, and experimental concentrations represent concentrations of valsartan in μM. (C) Simulated
and experimental measurements of PKG activity in response to valsartan and/or neprilysin inhibitor
sacubitril (SAC). Experimental values reflect phorphorylation of PKG analog VASP (vasodilatorstimulated phosphoprotein). (D) Simulated and experimental measurements of Rho activity in response to
valsartan and/or sacubitril. All experimental data represent mean levels ± SEM.
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Figure B-7: Screen of individual drug targets for mechano-adaptive matrix expression. Changes in matrix
content as a function of output node expression were measured following comprehensive knockdown and
overexpression of individual nodes in low or high tension contexts. Perturbations were scored for mechanoadaptive behavior based on matrix content change values as described in Materials and Methods, MechanoAdaptive Drug Screen section. Overlapping low- and high-tension values indicate perturbations that
equally altered matrix content regardless of the tensional context.
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Appendix C
Aim 3 Supplemental Figures

Figure C-1: Schematic of inferred transcriptional network for current study. Signaling-activated TFs
(yellow boxes), secondary TFs (white hexagons), and model outputs associated with fibrosis or autocrine
feedback (green/orange boxes) are connected by directed activation and inhibition reactions (red and blue
arrows, respectively). Edge widths and transparency represent relative “importance” scores of each TFtarget interaction as measured via the GRNBoost2 algorithm.
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Figure C-2: Full network perturbation analaysis results. (A) Changes in activity for all nodes in the network
were measured following comprehensive knockdown of individual nodes (Ymax = 0.1) under individual
patient pre- and post-TAVR conditions. Values reflect average changes in node activity between perturbed
and un-perturbed conditions with each patient condition. Refer to the model logic file available on GitHub
for the order of nodes perturbed/measured. (B) Coefficients of variation (CV) across patient cohort for node
influence and sensitivity values.
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